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Small	heat	shock	proteins	are	chaperones	with	variable	mechanisms	of	action.	The	function	 of	 cardiac	 family	member	Hspb7	 is	 unknown,	 despite	 being	 identified	through	GWAS	as	a	potential	cardiomyopathy	risk	gene.	I	discovered	that	zebrafish	
hspb7	 mutants	 develop	 cardiomegaly	 with	 mild	 focal	 cardiac	 fibrosis	 and	sarcomeric	abnormalities.	Strikingly,	significant	mortality	was	observed	in	hspb7	mutants	subjected	to	exercise	stress,	demonstrating	a	genetic	and	environmental	interaction	that	determines	disease	outcome.	I	identified	large	sarcomeric	proteins	FilaminC	and	Titin	as	Hspb7	binding	partners.	In	the	absence	of	Hspb7,	FilaminC	was	prone	to	aggregate	formation,	which	arises	following	protein	damage	and	is	detrimental	 to	 cardiac	 function.	 Damaged	 FilaminC	 undergoes	 autophagic	processing	to	maintain	sarcomeric	homeostasis.	I	discovered	that	loss	of	Hspb7	in	zebrafish	 or	 human	 cardiomyocytes	 stimulated	 autophagic	 pathways	 and	expression	of	the	sister	gene	encoding	Hspb5.	Finally,	inhibiting	autophagy	caused	FilaminC	aggregation	in	HSPB7	mutant	human	cardiomyocytes	and	developmental	cardiomyopathy	 in	 hspb7	 mutant	 zebrafish	 embryos,	 demonstrating	 enhanced	reliance	 on	 autophagy	 in	 the	 absence	 of	 Hspb7.	 These	 studies	 highlight	 the	importance	of	damage-processing	networks	in	cardiomyocytes,	and	a	previously	unrecognized	role	in	this	context	for	Hspb7.	Additionally,	hspb7	mutant	zebrafish	are	a	model	system	of	cardiomyopathy	 in	which	additional	 insults	precipitate	a	severe	phenotype,	mimicking	human	cardiac	disease.	Thus,	it	provides	a	novel	tool	for	finding	modifier	genes	or	pathways	that	impact	severity	of	cardiomyopathy.		
	Previous	work	suggested	that	hspb7	is	regulated	by	the	Gata4	transcription	factor.	In	a	separate	but	complementary	project,	 I	generated	novel	zebrafish	lines	with	mutations	 in	 gata4,	 gata5,	 and	 gata6.	 I	 characterized	 defects	 in	 cardiac	development	 that	 arise	 in	 embryos	 null	 for	 gata6,	 including	 a	 previously	undiscovered	alteration	in	ventricular	myocyte	identity.	Additionally,	I	observed	failure	in	pancreas	and	liver	development.	Surprisingly,	I	discovered	that	gata4	is	dispensable	 for	 zebrafish	 development.	 However,	 gata4	 mutants	 have	 a	developmental	 delay,	 suggesting	 a	 role	 for	 Gata4	 in	 regulating	 early	 epiboly.	Finally,	I	documented	compensation	between	gata4	and	gata6	in	the	developing	zebrafish,	including	a	novel	role	in	the	establishment	of	left-right	asymmetry.	This	work	provides	tools	for	further	elucidation	of	the	unique	and	overlapping	roles	of	GATA	factors	during	zebrafish	development.	
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CHAPTER	1: INTRODUCTION	
Cardiac	development,	function	and	disease.	
Introduction	to	cardiac	disease	Cardiovascular	disease	(CVD)	accounts	for	1	in	3	deaths	in	the	United	States1	and	1	in	4	in	the	United	Kingdom2.	Heart	pathologies	can	be	broadly	subdivided	into	diseases	of	cardiac	morphogenesis,	which	affect	around	8	in	1000	live	births1,	and	cardiomyopathies	of	the	adult	cardiovascular	system.	Adult	cardiomyopathies	can	either	be	attributed	to	inheritance	of	a	particular	gene	variant,	or	can	be	a	complex	disease	with	 various	 smaller	 genetic	 or	 environmental	 influences	 presumed	 to	have	a	combinatorial	deleterious	effect.	Despite	causing	problems	to	a	common	organ,	the	mechanisms	by	which	these	separate	pathologies	arise	are	remarkably	diverse.		
The	 leading	 cause	 of	 CVD	 in	 the	Western	world	 is	 ischemic	 heart	 disease	 (also	known	as	coronary	artery	disease,	CAD),	although	the	margin	between	mortality	caused	by	CAD	and	 that	 caused	by	 other	 forms	of	 CVD	 is	 narrowing3.	 CAD	 is	 a	complication	of	atherosclerosis,	a	disease	caused	by	the	buildup	of	fatty	deposits,	known	as	plaque,	in	the	blood	vessels.	The	presence	of	plaque	leads	to	progressive	dysfunction	and	remodeling	of	the	walls	of	the	blood	vessels	as	well	as	pathological	activation	 of	 inflammatory	 signaling	 pathways.	 Narrowing	 of	 the	 blood	 vessels	supplying	 the	 heart	 to	 the	 extent	 that	 the	 supply	 of	 oxygen	 to	 the	 heart	 is	compromised	 leads	 to	 chest	 paid	 known	 as	 angina.	 However,	 the	most	 severe	consequence	 of	 CAD	 is	 a	 heart	 attack,	 where	 a	 blood	 clot	 occurs	 following	rupturing	of	an	atherosclerotic	plaque	and	blocks	the	cardiac	oxygen	supply.	The	original	plaque	rupture	may	occur	anywhere	in	the	body.	CAD	has	been	a	focus	of	
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many	 studies	 that	 have	 linked	 its	 increased	 prevalence	 to	 unhealthy	 lifestyle	choices;	plaque	buildup	is	increased	with	high-fat,	high-sugar	diet,	lack	of	regular	exercise	and	smoking.	Lifetime	risk	of	CAD	 is	 increased	10-	 to	20-fold	with	 the	addition	 of	 these	 environmental	 risk	 factors*.	 There	 are	 known	 genetic	contributors,	and	even	causal	mutations,	for	CHD,	and	it	is	important	to	note	that	CAD	and	its	associated	risk	factors	will	likely	have	an	impact	on	the	progression	and	outcome	of	any	adult	cardiac	pathology.	However,	this	thesis	will	now	focus	exclusively	on	congenital	and	complex	genetic-based	cardiomyopathies.	
Inherited	 cardiomyopathies	 can	 manifest	 during	 development	 in	 the	 form	 of	congenital	 heart	 defects.	 These	 defects	 in	 cardiac	 development	 are	 a	 result	 of	errors	in	the	migration,	patterning	or	morphogenesis	of	cardiac	precursors	as	they	mature	into	adult	cardiomyocytes	and	can	often	be	mapped	to	mutations	in	key	regulators	 of	 cardiogenesis,	 including	 transcription	 factors.	 Alternatively,	inherited	cardiomyopathies	may	only	become	apparent	 later	 in	 life.	Such	adult-onset	pathologies	are	often	attributable	to	mutations	in	structural	components	of	the	sarcomere,	the	contractile	unit	of	the	cardiomyocyte,	including	myosin,	actin	and	myosin	binding	proteins4,5,	cardiac	troponins6	and	filamin	C7,8.	
Often,	the	development	of	cardiovascular	disease	in	adults	is	not	associated	with	a	mutation	in	one	particular	risk	gene.	Instead,	a	number	of	factors	are	presumed	to	contribute	en	masse	 to	 the	prevention	or	promotion	of	 ‘complex’	heart	disease.	These	 can	 include	 external	 contributions	 from	 the	 lifestyle	 and	 environmental	influences	discussed	above.	Over	the	past	decades,	large	genome-wide	association	
																																																								
*	 Lifetime	 risk	 with	 an	 optimal	 risk	 factor	 profile	 is	 <1%(females),	 3.6%(males)	 but	 rises	 to	18.3%(females),	37.3%(males)	with	2	or	more	major	risk	factors3.	Risk	factors	include	smoking,	high	chlolesterol,	low	HDL,	high	blood	pressure	and	diabetes.	
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studies	 (GWAS)	 have	 sought	 to	 identify	 genetic	 contributors	 to	 complex	 heart	disease.	To	date,	candidate	genes	from	the	structural	sarcomeric	components	as	well	 as	 regulators	 of	 calcium	 signaling,	 contraction	 and	 growth	 have	 all	 been	implicated4.	One	problem	 in	 this	 field	 is	 the	 lack	of	 reproducibility	of	candidate	genes,	highlighting	the	importance	of	delineating	the	role	and	mechanism	of	action	of	such	candidates	in	the	heart.		
Inherited	 and	 complex	 cardiomyopathies	 can	 lead	 to	 different	 types	 of	cardiomyopathy:	 hypertrophic,	 dilated	 and	 restrictive.	 Hypertrophic	cardiomyopathy	 (HCM)	 is	 characterized	 by	 the	 thickening	 and	 stiffening	 of	 the	cardiac	 walls.	 Conversely,	 in	 dilated	 cardiomyopathy	 (DCM)	 the	 cardiac	 walls	become	thinner	and	weaker,	leading	to	enlargement	of	the	ventricles.	Restrictive	cardiomyopathy	is	the	least	common	of	the	three	types	and	is	characterized	by	wall	stiffening	 without	 the	 thickening	 found	 in	 typical	 HCM.	 Unlike	 other	cardiomyopathies,	 HCM	 is	 often	 asymptomatic	 in	 patients	 until	 sudden	 cardiac	arrest.	
Heart	 failure	 is	 the	 final	 common	 outcome	 of	 CAD,	 DCM	 and	 restrictive	cardiomyopathies	and	occurs	when	the	heart	is	no	longer	strong	enough	to	pump	sufficient	blood	around	the	body,	 leading	to	fatigue,	generalized	and	pulmonary	edema	 and	 shortness	 of	 breath.	 The	 pathways	 that	 lead	 to	 the	 development	 of	heart	 failure	 are	 complex,	 for	 as	 the	 heart	 becomes	 progressively	 more	dysfunctional,	the	increased	load	on	the	myocytes	activates	various	compensatory	systems	 are	 activated	which	 lead	 to	 remodeling	 of	 the	 cardiac	 tissue.	 Although	these	 pathways	 are	 intended	 to	 offset	 initial	 dysfunction,	 they	 are	 ultimately	damaging	and	lead	to	pathological	alteration	in	heart	structure	and	function.		
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The	stepwise	progression	to	heart	failure	is	incompletely	elucidated,	but	is	thought	to	 arise	 following	 dysregulation	 of	 adrenergic	 activation	 and	 calcium	 signaling	following	 alteration	 in	 cardiac	 load.	 This	 could	 be	 chronic,	 following	 slow	progression	 of	 a	 congenital	 cardiomyopathy,	 or	 acute	 in	 response	 to	 a	 heart	attack4.		
The	prevention	and	treatment	of	controllable	risk	factors	for	cardiac	disease,	e.g.	recognition	of	the	influence	of	diet	on	heart	health,	and	the	treatment	of	high	blood	pressure	with	 statins,	 has	 gone	 a	 considerable	way	 to	 improve	 heart	 health	 in	many	individuals	predisposed	to	heart	disease9.	However,	 the	treatment	for	the	end-stage	of	these	diseases,	heart	failure,	remains	either	palliative	care	or	heart	transplant.	Mortality	rates	for	heart	failure	are	documented	to	be	falling,	but	the	5-year	 survival	 rate	 remains	 around	 50%1.	 This	 high	 mortality	 rate	 for	 patients	suffering	from	end-stage	heart	disease	is	indicative	of	a	bottleneck	in	our	progress	in	the	development	of	effective	therapeutics.	Additionally,	studies	indicate	that	the	overall	population	with	heart	failure	will	grow	in	the	coming	years	as	a	result	of	a	growing	and	aging	population1.	
The	huge	threat	and	enormous	complexity	of	cardiovascular	disease	necessitate	considerable	 further	 investigation	 in	 order	 to	 better	 understand	 both	 the	pathogenic	processes,	and	how	best	to	treat	these	patients.	One	strategy	to	better	understand	cardiac	disease	is	to	study	cardiac	development.	 In	this	manner,	we	can	 gain	 a	 fundamental	 understanding	 of	 the	 physiological	 roles	 of	 genes	 and	pathways	 that	 are	 important	 for	 the	 genesis	 and	maintenance	 of	 a	 functioning	heart,	and	learn	more	about	what	can	go	wrong	when	these	genes	and	pathways	are	compromised.	Ultimately,	we	might	hope	to	be	able	to	take	these	discoveries	
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and	translate	them	into	treatments	or	tools	to	prevent,	correct	or	ameliorate	the	human	pathologies.		
An	Overview	of	Cardiac	Development	The	early	stages	of	cardiogenesis	are	relatively	well	conserved,	and,	given	the	focus	of	much	 of	 the	 studies	 detailed	 in	 this	 thesis,	 the	 zebrafish	 is	 here	 used	 as	 an	example	system.		
The	 embryo	 starts	 out	 as	 a	 single	 fertilized	 egg,	 which	 undergoes	 a	 series	 of	divisions	to	form	a	multicellular	blastocyst	(Figure	1-1A).	Prior	to	the	specification	of	particular	organs,	the	cells	of	the	developing	embryo	first	become	one	of	three	primitive	germ	layers:	endoderm,	ectoderm,	or	mesoderm,	from	which	the	heart	is	derived	(Figure	1-1B).	
Figure	1-1:	Initial	embryogenesis	leads	to	the	formation	of	germ	layers.	
(A)	Progression	 of	 zebrafish	 egg	 from	 fertilized	 single	 cell	 through	numerous	 cell	
divisions	until	the	cells	begin	to	envelop	the	yolk.	Adapted	from	Kimmel	et	al	(1995)10.	
(B)	Schematic	detailing	the	germ	layers	in	the	developing	zebrafish	at	50%	epiboly.		
At	 50%	 epiboly,	 the	 earliest	 stages	 of	 zebrafish	 cardiac	 development	 occur,	including	the	specification	of	progenitors	(Figure	1-2A).	The	myocardium	is	 the	product	 of	 two	 waves	 of	 cellular	 influx	 from	 distinct	 progenitor	 populations,	referred	to	as	the	first	and	second	heart	field	(FHF/SHF).	Early	specification	stages	
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are	controlled	by	morphogen	signaling	gradients	that	relate	positional	information	to	cells	in	the	developing	embryo.		
	
Figure	1-2	Stages	of	zebrafish	cardiogenesis.	
Schematic	detailing	the	stages	of	zebrafish	cardiac	specification	and	morphogenesis,	
occurring	in	the	first	48	hours	post	fertilization.	For	more	details	see	text.	Adapted	
from	Bakkers	(2011)11.		
At	the	15	somite	stage	(Figure	1-2B),	the	FHF	myocardial	progenitors	are	situated	in	the	anterior	lateral	plate	mesoderm	(ALPM)	of	the	developing	embryo	and	begin	to	undergo	instructional	interactions	with	the	developing	endoderm	(Figure	1-2C).	The	importance	of	this	interaction	is	highlighted	by	the	phenotype	of	incomplete	migration	and	resultant	cardia	bifida	in	animals	with	defects	in	genes	important	for	 endoderm	 specification12,13,	 as	 well	 as	 in	 endoderm-derived	 signaling	molecules	such	as	sphingosine-1-phosphate14.	Reciprocally,	the	cardiac	mesoderm	is	known	to	modulate	the	migration	of	endocardial	precursors.		
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FHF	cells	migrate	to	the	midline	of	the	embryo	(Figure	1-2B,C)	and	form	a	circular	population	called	the	cardiac	cone	(Figure	1-2D).	Following	the	specification	and	migration	 of	 cardiac	 progenitors,	 the	 developing	 heart	 begins	 a	 complex	morphogenetic	process.	The	cardiac	cone	periscopes	to	form	a	linear	heart	tube	(Figure	1-2E),	which	begins	to	beat	in	a	peristaltic	motion.	The	heart	tube	extends	out	 and	 jogs	 to	 the	 left	 (Figure	 1-2F).	 During	 the	 extension	 process,	 the	cardiomyocytes	of	the	developing	heart	tube	have	very	low	levels	of	proliferation,	and	instead	growth	is	mediated	by	the	migration	of	SHF-derived	cells	that	add	to	the	poles	of	the	heart15.		
The	 heart	 tube	 subsequently	 undergoes	 a	 process	 known	 as	 ‘looping’	 to	 bring	presumptive	 atrial	 and	 ventricular	 sections	 of	 the	 heart	 tube	 to	 a	 side-by-side	position	(Figure	1-2G,Figure	1-3).	The	genetic	regulators	and	signaling	pathways	that	control	the	looping	process	are	poorly	understood.	Intriguingly,	the	processes	of	looping	and	jogging	appear	to	be	linked,	since	the	low	percentage	of	hearts	that	jog	 to	 the	 right	 usually	 ultimately	 form	 a	 ‘D-loop’	 mirror	 image	 of	 the	 normal	morphology.		
During	 looping,	 the	 cardiac	 chambers	 also	 become	 visually	 distinct	 through	 a	process	 known	 as	 ‘ballooning’,	 in	 which	 both	 the	 presumptive	 atrial	 and	ventricular	 portions	 of	 the	 heart	 tube	 take	 on	 separate	 curvatures,	 which	 are	separated	by	a	constricting	region,	the	atrio-ventricular	(AV)	canal	(Figure	1-3A,	see	 below).	 Changes	 in	 overall	 cardiac	 morphology	 are	 also	 associated	 with	chamber-specific	 changes	 in	 the	 cytoskeletal	 structure	 of	 individual	 myocytes.	Work	from	the	Stainier	lab	has	capitalized	on	the	zebrafish’s	visual	accessibility	during	 development	 to	 observe	 actin	 rearrangements	 in	 developing	 atrial	 and	
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ventricular	 myocytes16.	 The	 cytoskeletal	 structure	 of	 myocytes	 is	 essential	 for	their	function,	and	in	turn	myocyte	function	drives	changes	in	cardiac	morphology.	
	
Mutants	in	sarcomeric	genes	such	as	myh617	and	vmhc18,	which	alter	sarcomeric	development	 in	 the	 atrium	 or	 ventricle	 respectively,	 have	 defective	cardiomorphogenesis,	secondary	to	alteration	in	signaling	pathways	stimulated	by	blood	flow	and	myocardial	stretch.	Likewise,	loss	of	or	abnormalities	in	the	cardiac	conduction	system	lead	to	alterations	in	the	size	and	shape	of	both	the	individual	myocytes	and	the	overall	chambers19.		
Figure	1-3	Structure	of	the	developing	zebrafish	heart.	
Cross-section	 through	 the	developing	zebrafish	heart	at	 (A)	48hpf	and	 (B)120hpf,	
detailing	 the	 endo-,	 myo-	 and	 epicardial	 layers.	 Taken	 from	 Staudt	 and	 Stainier	
(2012)19.	
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As	 the	 chambers	 specify,	 there	 is	 concurrent	 specialization	of	 the	 endocardium	that	lines	them.	Endocardial	cells	in	the	AV	canal	region	thicken	into	endocardial	cushions	 which	 will	 ultimately	 become	 the	 AV	 valve,	 important	 for	 ensuring	unidirectional	blood	flow.	Key	developmental	signals	BMP,	Notch	and	Wnt	become	restricted	to	the	AV	region	between	36	and	48hpf.	The	AV	endocardium	undergoes	progressive	changes	 in	cell	shape	over	the	following	3	days	which	result	 in	two	valve	leaflets	through	invagination†.	The	process	of	endocardial	cushion	formation	and	 subsequent	 division	 of	 the	 heart	 into	 separate	 chambers	 is	 recapitulated	during	the	process	of	septation	in	the	four-chambered	mammalian	heart20.		As	seen	for	 chamber	 morphogenesis,	 valve	 formation	 is	 affected	 by	 fluid	 forces,	 and	mutations	 that	 affect	 myocyte	 contraction	 lead	 indirectly	 to	 errors	 in	valvulogenesis21.		
The	cardiomyocytes	that	form	the	two	chambers	must	also	specialize	to	become	either	an	atrial	or	a	ventricular	myocyte.	The	restriction	of	the	expression	of	some	genes	to	either	the	atria	or	the	ventricle	has	been	long	established,	however	the	external	cues	and	transcription	factor	programs	that	result	in	these	differences	are	less	well	elucidated.	Recent	studies	have	identified	nkx2-5	and	2-7	as	essential	for	the	 repression	 of	 atrial	 genes	 in	 zebrafish	 ventricular	myocytes22,	 and	 the	 Tbx	family	of	transcription	factors	are	known	to	be	differentially	expressed	in	human	cardiac	 chambers20.	 Studies	 from	 our	 own	 laboratory	 are	 making	 progress	 in	understanding	 how	 the	 GATA	 transcription	 factor	 family	 (see	 page	 24)	 are	involved	in	myocyte	identity	(Unpublished	data	E.J.M.	see	Chapter	6,	and	Tang	and	Evans).	 The	 utilization	 of	 novel	 sequencing	 techniques	 to	 understand	 the	
																																																								
†	 In	 amniotes	 this	 process	 occurs	 via	 endothelial-mesenchymal	 transition	 and	 subsequent	delamination	rather	than	invagination.	
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transcriptomes	 of	 specific	 cell	 types	 in	 development23,	 and	 in	 the	 adult24	 and	regenerating25	heart,	will	certainly	lead	to	discoveries	in	this	field.	
The	 period	 between	 48hpf	 and	 6dpf	 is	 also	 characterized	 by	 marked	cardiomyocyte	proliferation	leading	to	overall	growth	of	the	heart	and	thickening	of	the	myocyte	wall.	The	Tgfb,	Igf	and	Hedgehog	pathways	have	been	identified	as	regulators	of	cardiomyocyte	proliferation	during	development26‡.	Fibroblasts	and	endocardial	 tissues	 are	 known	 to	 be	 the	 originators	 of	 these	 signals,	 and	 thus	crucial	 drivers	 of	 myocardial	 proliferation.	 In	 the	 absence	 of	 adequate	proliferation,	hearts	become	pathologically	enlarged	and	thin-walled,	a	phenotype	reminiscent	 of	 dilated	 cardiomyopathy.	 Proliferating	 ventricular	myocytes	may	also	 undergo	 an	 identity	 change	 and	 delaminate	 from	 the	 ventricular	 wall,	migrating	inwards	to	form	the	network	of	internal	muscle	called	trabeculae.		
For	a	more	detailed	review	of	cardiogenesis	in	the	zebrafish,	see	Bakkers	(2011)11	or	Staudt	and	Stainier	(2012)19.		
A	network	of	evolutionarily	conserved	core	transcription	factors,	some	of	which	have	 already	 been	 mentioned	 above,	 coordinates	 these	 complex	 cardiac	specification	 and	morphogenetic	 events27–29	 (Figure	 1-4).	 These	 factors	 include	
NKX2-5,	 TBX5	 and	 GATA4.	 Our	 lab	 has	 focused	 considerable	 effort	 toward	understanding	the	roles	of	the	GATA	factors,	including	GATA4,	in	development.	The	GATA	proteins	and	their	roles	in	embryogenesis	are	explored	further	on	page	24.		
																																																								
‡	And	were	subsequently	shown	to	also	be	important	for	the	proliferation	of	cardiomyocytes	in	the	regenerating	zebrafish	heart26.		
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Figure	1-4:	Core	network	of	key	transcription	factors	for	cardiac	development.	
The	 transcription	 factor	 GATA4	 works	 in	 cooperation	 with	 other	 cardiac	
transcription	 factors	 including	Nkx2-5	and	Tbx5	 to	 regulate	 cardiac	 specification	
and	morphogenesis.	Figure	from	McCulley	and	Black	(2012)30	
An	introduction	to	the	functioning	cardiomyocyte	The	heart	is	the	earliest	organ	to	form	and	function.	As	discussed	above,	myocytes	initiate	a	lifelong	contractile	routine	as	soon	as	the	initial	heart	tube	is	formed,	and	continue	to	beat	as	morphogenesis	occurs.	
Contractile	Units	of	the	heart	The	minimal	force-generating	unit	in	a	muscle	cell	is	the	subunit	of	the	myofibril;	the	sarcomere	 (Figure	1-5).	Sarcomeric	 structure	 is	based	around	 thin-filament	chains	 of	 polymerized	 actin,	 which	 overlap	 with	 thick	 filaments	 composed	 of	myosin.	By	hydrolyzing	ATP,	myosin	heads	are	able	to	move	along	the	thin	actin	filaments	and	pull	the	surrounding	structure	together	to	contract.	The	thick	and	thin	filaments	are	framed	by	larger,	structural	proteins	that	form	scaffolds	around	them.		
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Figure	1-5:	Structure	of	a	sarcomere.	
Basic	schematic	detailing	the	components	of	a	sarcomere.		Myosin	makes	up	the	thick	
filament	(A	band),	which	slides	along	the	thin	filament	(I	band,	predominantly	actin)	
during	contraction.	The	Z-disc	is	composed	of	structural	proteins,	including	Filamin	
C,	 and	 is	 also	attached	 to	 the	 sarcolemma.	 Integrins	and	other	 signaling	proteins	
localized	 on	 the	 sarcolemma	 facilitate	 transduction	 of	 external	 signals,	 including	
changes	in	the	tension	on	the	cell	or	the	force	of	surrounding	contraction.	Adapted	
from	Hwang	and	Sykes	(2015)31.	
These	scaffolding	proteins	include	titin,	which	acts	as	a	molecular	spring,	and	runs	half	the	length	of	a	sarcomere.	Titin	limits	the	amount	of	stretch	that	can	occur	to	the	sarcomere,	helping	maintain	tension	in	a	muscle.	Filamin-C	(FLNC)	is	another	of	the	scaffolding	proteins	that	help	to	structure	the	sarcomere.	The	filamin	family	are	known	to	be	involved	in	the	cross-linking	of	actin	in	all	cell	types,	and	FLNC	is	the	isoform	specifically	expressed	in	striated	muscle.	FLNC	is	usually	localized	to	Z-discs;	 multiprotein	 complexes	 involved	 in	 sensing	 and	 communicating	biomechanical	stress.	Sarcomeric	structures	are	coupled	to	the	plasma	membrane	at	 various	 foci,	 which	 facilitate	 signal	 transduction,	 and	 FLNC	 has	 been	hypothesized	 to	 have	 a	 conduit	 role,	 allowing	 communication	 from	 the	extracellular	 space	 to	 the	 sarcomere.	 This	 signal	 transduction	 allows	 the	
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contraction	 of	 the	 sarcomere	 to	 be	 coupled	 to	 external	 stimuli	 including	mechanical	stressors,	adrenergic	signals	and	surrounding	myocyte	contraction.		
Multiple	 overlapping	models	 exist	 of	myofibrillogenesis	 (the	 assembly	of	 initial	sarcomeres	and	their	subsequent	coalescence	into	myofibrils).	Recent	advances	in	imaging	 technologies	 have	 facilitated	 more	 detailed	 studies	 of	 cardiac	myofibrillogenesis	 in	 the	zebrafish.	Huang	et	al.	describe	a	multistep	process	 in	which	an	initial	non-striated	network	of	actin	stress	fiber-like	structure	develops	in	developing	cardiomyocytes32(Figure	1-6A).	This	network	is	similar	to	that	found	in	many	cell	types.		
Figure	1-6:	Stages	of	myofibril	assembly.	
Diagram	detailing	the	basic	stages	of	myofibril	assembly.	For	details	see	text.		
Z-bodies	 composed	 of	a-actinin	 assemble	 along	 the	 actin	 stress	 fibers	 (Figure	1-6B).	 Subsequently,	 sarcomeric	 protein	 expression	 is	 upregulated	 and	muscle	myosin	and	troponin	t	begin	to	assemble	into	thick	and	thin	‘rodlet’	pre-myofibrils	respectively	(Figure	1-6C).	As	a-actinin	begins	to	localize	in	regular	nuclei	along	the	 stress	 fiber-like	 actin	 structure,	 the	 pre-myofibrils	 begin	 to	 assemble	 in	striations	 along	 with	 it	 (Figure	 1-6D).	 Finally,	 the	 overall	 distance	 between	adjacent	striations	increases,	and	the	heart	begins	to	beat.	Sarcomeric	maturation	
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after	this	point	includes	increases	in	size,	positional	alignment	and	synchronous	contraction.	
The	importance	of	the	sarcomeric	proteins	is	highlighted	by	what	happens	when	they	 do	 not	 function	 correctly.	 Mutations	 in	 sarcomeric	 component	 proteins	including	 titin,	 FLNC,	 	 g-sarcoglycan	 and	 a-actinin	 are	 among	 those	 most	commonly	identified	in	cardiac	disease.	Sarcomeric	dysfunction	is	central	to	the	pathologies	of	hypertrophic	and	dilated	cardiomyopathies.		
Whilst	 the	 sarcomere	 appears	 a	 stable	 mechanical	 structure,	 it	 has	 become	increasingly	apparent	 that	 it	 is	highly	dynamic.	Studies	have	shown	turnover	of	even	large	sarcomeric	proteins,	including	actin33,	titin34	and	FLNC35,	which	occur	even	while	the	sarcomere	continues	to	contract.	A	recent	study	has	also	suggested	that	FLNC	actually	plays	a	functional	role	in	sarcomeric	turnover,	facilitating	repair	of	 damaged	 myofibrils35.	 Following	 removal	 from	 the	 sarcomere,	 damaged	proteins	 must	 then	 be	 degraded	 to	 prevent	 their	 forming	 into	 pathological	aggregates.	 	Though	somewhat	unexpected,	 it	 is	evident	 that	 the	processes	 that	allow	 for	 removal	 of	 damaged	 proteins	 from	 the	 sarcomere	 are	 extremely	important	 for	 continued	 cardiac	 function	 because	 mutations	 in	 many	 genes	involved	in	this	process	lead	to	cardiac	disease.	This	is	striking	because	in	some	cases,	such	as	for	mutations	of	cardiac	Troponin	T6	and	FilaminC7,	the	protein	in	question	is	broadly	expressed	in	striated	muscle,	but	disease	can	be	localized	to	the	heart5.	
Proteostasis	in	the	heart.	
Protein	turnover	is	very	important	in	the	heart.	The	 cardiomyocyte	 represents	 a	 relatively	 unique	 cell	 type	 for	 a	 number	 of	reasons.	First,	it	has	to	continuously	contract	and	relax	in	order	to	maintain	blood	
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flow,	 exposing	 the	 cytoskeletal	 components	 to	 continuous	 mechanical	 strain.	Second,	the	mammalian	cardiomyocyte	has	been	shown	to	be	post-mitotic,	with	low	 levels	 of	 cytokinesis	 following	 the	 first	 few	 days	 of	 life36–38.	 It	 is	 generally	believed	that	following	the	loss	of	proliferative	ability,	growth	in	the	overall	size	of	the	 mammalian	 heart	 is	 achieved	 through	 hypertrophy	 of	 the	 cardiomyocyte	rather	than	division§.	Dilution	of	protein	aggregates	through	cytokinesis	is	thus	a	response	mechanism	that	is	not	available	in	this	instance.		
Although	the	post-mitotic	state	of	mammalian	cardiomyocytes	is	well	accepted,	it	is	not	true	in	all	organisms.	For	example,	the	zebrafish	retains	a	significant	amount	of	plasticity	 in	 its	heart	and	cardiomyocytes	are	able	to	partially	dedifferentiate	and	proliferate	following	traumatic	damage	or	cardiomyocyte	death26,39,	resulting	in	complete	healing	of	 the	damaged	portion	of	 the	heart	with	minimal	scarring.	Additionally,	 recent	studies	have	suggested	 that	 there	may	be	 transient	periods	during	the	life	of	an	organism	in	which	the	cardiomyocytes	re-enter	the	cell	cycle.	Work	 from	 the	 Husain	 and	 Graham	 labs	 recently	 identified	 a	 pre-adolescent	cardiomyocyte	 proliferative	 burst	 in	 mice40	 that	 interestingly	 falls	 in	 a	 similar	period	 of	 development	 to	 the	 juvenile	 expansion	 stage	 of	 the	 cardiac	 wall	 in	zebrafish,	a	process	that	is	known	to	be	reliant	on	Gata441.		
																																																								
§Newer	studies	suggest	that	some	cytokinesis	is	retained	in	young	human	hearts38,	but	this	falls	to	below	1	in	10,000	after	the	first	decade	of	life.	Therefore,	this	is	unlikely	to	be	a	relevant	source	of	cardiac	growth,	or	a	useful	strategy	to	deal	with	protein	aggregates.	
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General	mechanisms	of	protein	turnover.	The	 lack	 of	 cell	 division	 and	 requirement	 for	 continuous	 movement	 in	 a	cardiomyocyte	put	 it	at	particular	risk	for	the	formation	of	aggregates,	and	so	a	functional	adult	cardiomyocyte	employs	a	number	of	strategies	for	the	removal	of	damaged	 proteins.	 One	 of	 the	most	 comprehensively	 applicable	 of	 these	 is	 the	process	of	autophagy,	outlined	in	Figure	1-7.	
Figure	1-7:	Autophagy	is	a	mechanism	for	degrading	damaged	proteins	
Schematic:	(A-B)	Damage	can	occur	to	normal	proteins	or	protein	complexes	that	
may	 then	 be	 processed	 by	 (C-F)	 macroautophagy,	 (C’-D’)	 chaperone-assisted	
autophagy	or	(C’’)	microautophagy.	For	more	details	see	text.		
Depletion	 of	 energy	 or	 nutrients	 activates	 autophagic	 genes	 (Atg	 family)	 and	inhibits	 negative	 regulators	 of	 autophagy.	 Initially,	 an	 isolation	 membrane	 is	formed.	It	subsequently	elongates,	a	process	that	requires	sequential	activation	of	various	 Atg	 family	 members	 including	 Atg8/LC3,	 which	 is	 processed	 from	 a	soluble	precursor	 (LC3-I)	 to	an	autophagic-membrane	associated	 form	(LC3-II).	The	 growing	 membrane	 sequesters	 proteins	 and	 organelles	 targeted	 for	autophagic	degradation.	Following	completion	of	the	autophagosome,	it	fuses	with	
	 	17	
a	lysosome;	lysosomal	proteases	catabolize	the	contents,	making	their	component	parts	available	for	reuse.	Finally,	the	autophagolysosome	is	degraded42.		
It	is	increasingly	recognized	that	the	process	of	macroautophagy,	described	above,	is	a	simplified	view	of	the	situation.	In	addition	to	macroautophagic	generalized	degradation	 of	 cellular	materials,	 two	 additional	 pathways	 have	 been	 detailed:	microautophagy	(Figure	1-7C’’)	and	chaperone-assisted	autophagy	(Figure	1-7C’-F’).		
Non-canonical	forms	of	autophagy	Like	macroautophagy,	the	process	of		microautophagy	can	mediate	the	engulfment	and	 degradation	 of	 	 larger	 structures	 such	 as	 entire	 organelles,	 or	 of	 protein	aggregates.	 In	 contrast	 to	macroautophagy,	microautophagy	 involves	 the	direct	invagination	 of	 the	 lysosomal	 membrane	 (Figure	 1-7C’’)	 to	 engulf	 the	 nearby	cytoplasm.	 The	 regulation	 of	 microautophagy	 is	 not	 well	 understood,	 but	 it	 is	increased	by	nutrient-low	conditions43.	
Chaperone-assisted	 autophagy	 can	 mediate	 the	 degradation	 only	 of	 soluble	proteins,	and	is	thus	inherently	more	limited	than	macro-	or	microautophagy	in	terms	of	 its	 targets.	However,	an	 important	consideration	 is	 that	 indiscriminate	self-eating	 may	 ultimately	 be	 detrimental	 to	 the	 cell.	 Chaperone-mediated	autophagy	is	able	to	specifically	select	proteins	for	recycling	through	the	protein-protein	 interactions	 of	 the	 chaperone	 proteins.	 Therefore,	 for	 particularly	aggregate-prone	proteins	or	those	that	need	to	be	closely	regulated,	chaperone-mediated	autophagy	 is	a	 targeted	strategy.	 	The	process	can	actually	be	 further	divided	 into	 two	 pathways:	 chaperone-mediated	 autophagy	 (CMA)	 and	chaperone-assisted	selective	autophagy	(CASA).		
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Proteins	targeted	for	the	CMA	pathway	contain	a	characteristic	pentapeptide	motif	that	can	be	recognized	by	the	chaperone	protein	Hsc70	(Figure	1-7C’),	which	binds	the	substrate	protein	and	translocates	to	the	lysosomal	membrane	(Figure	1-7D’).	The	hsc70:substrate	complex	interacts	with	LAMP2-A	protein	on	the	target	of	the	lysosome,	whereby	the	substrate	 is	unfolded	and,	assisted	by	LAMP2-A,	crosses	the	 lysosomal	 membrane	 (Figure	 1-7E’).	 Within	 the	 lysosome,	 the	 substrate	protein	is	degraded.	As	is	evident,	the	key	determinant	of	CMA	degradation	is	the	pentapeptide	motif,	 which	 is	 composed	 of	 a	 sequence	 of	 amino	 acids	 carrying	specific	charges**.	Around	30%	of	proteins	carry	such	a	motif44,	and	so	it	has	been	proposed	 that	 these	 proteins	 can	 avoid	 degradation	 through	 burying	 the	pentapeptide	 motif	 in	 hydrophobic	 domains,	 or	 through	 post-translational	modifications	that	mask	or	alter	the	charge	sequence.	Conversely,	proteins	that	do	not	naturally	have	a	pentapeptide	motif	can	acquire	one	through	post-translational	modifications	that	add	charge.	A	key	example	protein	of	therapeutic	interest	that	is	regulated	in	this	manner	is	huntingtin,	acetylation	of	which	has	been	shown	to	target	it	for	CMA-mediated	degradation45.		
An	alternate	form	of	autophagy	in	which	chaperones	play	a	pivotal	role,	CASA,	was	recently	described	in	a	series	of	papers	from	the	Höhfeld	laboratory46–48.	In	this	paradigm,	 the	 substrate	 protein	 is	 bound	 by	 a	 complex	 of	 chaperone	 proteins	including	 Hsc70,	 BAG3	 and	 HSPB8.	 In	 contrast	 with	 the	 direct	 delivery	 to	lysosomal	LAMP2	seen	in	CMA,	CASA	substrates	and	their	associated	chaperone	protein	 BAG3	 are	 subsequently	 ubiquitylated.	 Ubiquitin	 is	 a	 regulatory	 protein																																																									
**	The	canonical	hsc70	recognition	sequence	is	KFERQ,	which	carries	positive	charges	on	lysine	and	arginine,	a	central	hydrophobic	phenylalanine	and	a	negatively	charged	glutamatic	acid	followed	by	a	glutamine.	Studies	have	shown	that	the	overall	pattern	of	charges	and	hydrophobicity	is	more	important	than	the	specific	amino	acids,	although	a	glutamine	is	always	found	at	the	beginning	or	end	of	the	motif.		
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that	 is	 ligated	 onto	 proteins	 that	 are	 usually	 targeted	 for	 degradation	 by	 the	proteasomal	system.	In	the	case	of	CASA,	ubiquitylated	substrate	and	its	associated	chaperone	 complex	 recruit	 a	 ubiquitin-autophagy	 adaptor	 which	 subsequently	induces	 the	 formation	 of	 the	 autophagosome	 to	 engulf	 the	 complex.	 The	 CASA	pathway	 has	 been	 shown	 to	 be	 active	 in	 muscles,	 where	 it	 is	 integrated	 with	tension	 sensing	 and	 upregulation	 of	 substrate	 proteins48,	 ensuring	 the	stoichiometric	ratios	of	myoskeletal	components	is	maintained.	
Further	complicating	the	overall	picture,	the	forms	of	autophagy	presented	above	are	not	mutually	exclusive	and	can	interact	with	each	other	to	form	combination	pathways	under	certain	circumstances.	In	addition,	other	auxillary	pathways	exist	that	 mediate	 degradation	 of	 specific	 cellular	 components,	 including	 direct	degradation	of	phagocytosed	material.	These	pathways,	 their	regulation,	 targets	and	interactions	are	currently	a	field	of	active	research	with	many	unknowns	and	controversies.	 As	 such,	 they	 are	 not	 discussed	 further	 herein,	 but	 the	 reader	 is	referred	to	recent	reviews	on	the	topic43,49–51.	
Autophagy	in	the	heart	Autophagy	occurs	constitutively	 in	cardiac	 tissue,	and	genetic	or	pharmacologic	inhibition	 of	 autophagy	 can	 induce	 heart	 failure52.	 In	 addition,	 upregulation	 of	autophagy	 in	 response	 to	 cardiomyopathy	 is	 long	 established53,	 and	 has	 been	illustrated	 following	 various	 insults,	 including	 ischemia-reperfusion,	anthracycline-mediated	 cardiotoxicity	 and	 heart	 failure.	 In	 some	 situations	induction	 of	 autophagy	 exacerbates	 pathology54;	 however,	 upregulation	 of	autophagy	has	been	shown	to	be	protective	in	some	models	of	heart	failure55–58.	Thus,	 physiological	 function	 requires	 autophagic	 processes	 to	 be	 carefully	regulated	and	operating	at	appropriate	levels.	
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Model	systems	for	studying	cardiac	development	and	
function	In	order	to	study	the	development	of	organ	systems,	including	the	heart,	a	number	of	 different	model	 systems	 are	 routinely	 employed.	 These	 include,	 but	 are	 not	limited	to,	the	zebrafish,	and	human	embryonic	stem	cell-derived	cardiomyocytes	(hESC-CMs).	 Whilst	 hESC-CMs	 may	 seem	 the	 logical	 choice	 for	 the	 study	 of	pathways	 and	 genes	 relevant	 to	 human	 disease,	 current	 research	 techniques	cannot	 generate	 fully	differentiated,	 adult	 cardiomyocytes	or	 entire	 functioning	hearts.	Conversely,	in	the	zebrafish	one	can	rapidly	gain	a	mature,	complete	organ	but	 are	 compromised	by	differences	 from	 the	human	system	and	 limitations	 in	available	 biochemical	 tools.	 Thus,	 the	 use	 of	 a	 combination	 of	 model	 systems	confers	complimentary	benefits.	
The	Zebrafish	Model	System	The	zebrafish	has	a	number	of	distinct	characteristics	that	recommend	it	for	the	study	 of	 development.	 Zebrafish	 embryos	 develop	 externally	 and	 can	 be	 easily	maintained	in	a	transparent	state	for	the	entirety	of	embryogenesis,	either	through	the	 use	 of	 small	 molecules	 or	 of	 pigment-free	 Casper	 line59.	 The	 process	 of	zebrafish	embryogenesis	is	substantially	progressed	by	72	hours	post	fertilization	(hpf),	commencing	with	the	laying	of	several	hundred	eggs	by	a	single	adult	female.	An	 important	 consideration	here	 is	 that	 in	 the	 zebrafish	we	 can	 easily	 observe	stages	of	 the	developmental	process	 that	occur	post-implantation	 in	 the	mouse,	and	are	thus	near	impossible	to	track	in	mammals	with	any	accuracy.	A	beautiful	depiction	of	 the	stages	and	accurate	 timing	has	been	 in	existence	 for	decades10,	allowing	 consistent	 comparison	of	 zebrafish	mutants	 between	 strains,	 research	groups	and	generations.			
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Importantly,	genetics	of	the	zebrafish	are	well	conserved	with	that	of	the	human	and	 mutagenesis	 screens	 in	 zebrafish	 have	 resulted	 in	 the	 identification	 of	 a	number	of	key	genes	that	control	developmental	pathways	in	higher	vertebrates.	The	study	of	genetic	pathways	in	the	zebrafish	has	been	aided	by	the	technique	of	microinjection,	 in	 which	 macromolecules	 including	 DNA,	 RNA,	 proteins	 and	modified	oligonucleotides	such	as	morpholinos	can	be	injected	directly	into	the	1-2	cell	stage	embryo.	This	allows	researchers	to	easily	modulate	levels	and	locations	of	gene	expression	during	early	embryogenesis.	Additionally,	the	aquatic	abode	of	the	zebrafish	enables	easy	exposure	to	soluble	small	molecules.	Most	recently,	the	advent	of	genome	editing	 technologies	 such	as	TALEN	and	CRISPR	has	enabled	targeted,	rapid	and	specified	mutation	of	genes	of	interest	in	the	zebrafish	system	for	the	first	time60–62.		
Embryonic	Stem	Cell	Model	System	ESCs	are	derived	from	the	inner	cell	mass	of	developing	blastocysts63.	These	cells	maintain	a	pluripotent	state;	they	are	able	to	both	renew	themselves	indefinitely	and	to	differentiate	to	form	any	of	the	tissue	types	that	are	found	in	the	adult	body.	This	system	is	complemented	by	induced	pluripotent	stem	cells	(iPSCs),	which	are	derived	by	the	transfection	of	adult	somatic	cells	with	factors	that	drive	them	to	dedifferentiate	back	to	pluripotency64.	iPSCs	offer	the	advantage	of	the	production	of	stem	cell	 lines	with	disease-associated	genotypes,	 facilitating	identification	of	abnormalities	in	the	development	and	function	of	specified	cell	types,	and	are	now	routinely	used	in	laboratories	all	over	the	world.	
Many	 groups	 have	 contributed	 to	 the	 development	 of	 robust	 protocols	 for	 the	derivation	 of	 various	 tissues,	 including	 the	 heart,	 from	 these	 stem	 cells,	 often	
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recapitulating	 the	 signaling	 events	 that	 are	 known	 to	 play	 key	 roles	 in	 in	 vivo	organogenesis.		
Human	embryonic	stem	cell-derived	cardiomyocytes.		Human	 ESC-derived	 cardiomyocytes	 (hESC-CMs)	 arise	 spontaneously,	 if	sporadically,	 when	 ESCs	 are	 allowed	 to	 differentiate	 into	 aggregated	 clusters,	known	 as	 embryoid	 bodies65.	 Following	 initial	 observations	 of	 spontaneous	myogenesis,	 decades	 of	 work	 have	 defined	 and	 refined	 protocols	 for	cardiomyocyte	derivation	from	ESCs66.		
ESC/iPSC-CMs	 represent	 a	 desirable	 system	 for	 the	 study	 of	 cardiac	 genes	 and	processes	 for	 several	key	 reasons.	First,	 they	provide	a	model	 in	which	we	 can	directly	study	the	differentiation	and	 function	of	human	cardiomyocytes,	 rather	than	 representatives	 from	 other	 animals.	 This	 is	 particularly	 useful	 for	 the	exploration	 of	 the	 effects	 of	 specific	 genetic	 inconsistencies	 that	 have	 been	associated	with	 disease,	 by	making	 iPSCs	 from	 patients	 who	 exhibit	 particular	symptoms.	Second,	the	hope	remains	that	one	day	we	may	be	able	to	derive	enough	numbers	of	functionally	mature	iPSC-CMs	to	use	in	the	treatment	of	human	heart	disease	–	through	the	replacement	of	damaged	heart	tissue	or	valves,	or	even	by	growing	entire	functioning	hearts	in	the	lab	for	organ	transplant.		
The	 excitement	 of	 being	 able	 to	 generate	 hESC-CMs	 is	 tempered	 by	 important	caveats.	 First,	 the	 cardiomyocytes	 generated	 by	 this	 method	 are	 functionally	immature:	 displaying	 morphology,	 cytoskeletal	 arrangements	 and	electrophysiological	profiles	more	closely	matched	to	human	fetal	cardiomyocytes	than	to	adult	cells.	Although	these	phenotypes	can	be	partially	mitigated	through	engineered	 maturation	 methods,	 including	 extended	 culture	 periods,	 enforced	
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synchronization	 of	 contraction,	 mechanical	 loading	 and	 tissue	 engineering,	 the	discrepancies	between	the	model	system	and	the	real	human	heart	remain67.	
HL-1	cells	as	a	model	system	Finally,	 the	murine	atrial	cell	 line,	HL-1,	has	been	routinely	used	in	the	study	of	cardiac	proteins	and	functions.	This	cell	line	was	developed	by	the	Claycomb	lab	through	 optimization	 of	 conditions	 for	 cell	 culture	 passage	 of	 the	 AT-1	differentiated	cardiomyocyte	tumor,	a	line	derived	through	targeting	the	Simian	Virus	40	large	T	antigen	under	the	atrial	natriuretic	factor	promoter68.	It	is	the	only	spontaneously	beating,	passageable	cardiac	cell	line	to	date	and	has	been	a	huge	asset	for	research	in	this	field,	providing	adequate	numbers	of	manipulatable	cells	for	 biochemical	 experimentation	 and	 imaging.	 However,	 in	 contrast	 with	 early	reports,	research	using	this	model	system	has	been	compromised	by	heterogeneity	in	 phenotype	 and	 proteome	 within	 the	 population	 of	 HL-1	 cells	 (69	 and	 E.J.M.	observations).		
Summary:	Cardiac	Development,	Function	and	Disease	There	is	a	large	literature	exploring	the	heart	and	its	physiological	and	pathological	development	and	function.	In	this	section,	the	basic	stages	of	cardiac	development	have	 been	 explored.	 In	 addition,	 various	 model	 systems	 used	 to	 study	 heart	development	and	 function	were	outlined	and	their	relative	merits	discussed.	Of	particular	note,	recent	advancements	 in	the	field	of	human	embryonic	stem	cell	research	 are	 the	 cause	of	 excitement	 as	 they	 enable	 the	 examination	of	 human	cardiac	differentiation	in	vitro.	In	addition,	such	protocols	facilitate	the	comparison	of	differentiation	and	function	in	lines	derived	from	patients	with	various	genetic	alterations	that	lead	to	cardiac	disease.	When	combined	with	novel	genome	editing	technologies,	 the	 true	 contribution	of	 single	mutations	 in	 isogenic	backgrounds	
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can	 be	 elucidated,	 raising	 hopes	 that	more	 intricate	mechanisms	 of	 action	 and	possible	treatment	avenues	for	these	diseases	may	be	revealed.	
However,	 despite	 centuries	 of	 research,	 there	 is	 still	much	 to	be	uncovered.	As	discussed	above,	 the	numerous	contributors	 to	adult-onset	cardiomyopathy	are	more	difficult	to	unravel.	There	is	an	ongoing	requirement	for	model	systems	that	more	 closely	 resemble	 human	disease	 and	 its	 complex	nature,	 and	 for	 a	 better	understanding	of	the	various	contributors	to	and	stages	of	cardiomyopathy.		
Particular	attention	has	been	paid	to	discussing	the	process(es)	of	autophagy,	and	its	role	in	the	heart.	As	a	generally	applicable	strategy	for	disposing	of	problematic	unfolded,	faulty	or	excess	proteins	or	aggregates,	autophagy	is	uniquely	poised	to	play	a	protective	role	in	the	cardiomyocyte.	A	better	understanding	of	autophagic	processes	 and	 their	 compensatory	 role	 in	 the	heart	might	 facilitate	 therapeutic	interventions	that	can	accurately	titrate	this	pathway	to	optimal	efficacy.		
An	introduction	to	GATA	Transcription	Factors	
GATA	proteins	are	transcription	factors	The	GATA	proteins	are	a	family	of	zinc	finger	transcription	factors	that	recognize	and	 bind	 to	 an	 WGATAR	 motif	 in	 genomic	 DNA70.	 The	 zinc	 finger	 domain	 is	comprised	 of	 a	 C-X-X-C-X17-C-X-X-C	motif	which	 coordinates	 zinc	 ions	with	 the	cysteine	residues,	and	is	required	for	DNA-binding	activity71.		
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The	GATA	family	members	have	been	shown	to	have	roles	as	regulators	of	tissue-specific	developmental	programs.	GATA	proteins	can	be	divided	into	GATA-1,	-2	and	-3,	which	have	important	roles	in	hematopoiesis,	and	GATA-4,	-5	and	-6	which	are	 important	 in	endoderm	and	mesoderm	development,	 including	 in	the	heart,	liver	and	gut	(Figure	1-8).		
Figure	1-8:	The	GATA	factors	play	roles	in	the	development	of	many	different	
organs.	
Schematic	depicting	 the	relative	expression	patterns	and	roles	of	 the	GATA	 factor	
family	members	in	each	tissue	type.	Adapted	from	Lentjes	et	al.	(2016)72	
In	contrast	to	the	two	zinc-finger	DNA-binding	domains	detailed	above,	the	roles	of	the	remaining	domains	of	the	GATA	proteins	are	not	well	described.	A	nuclear	localization	 sequence	 has	 been	 identified	 in	 GATA4,	 -5	 and	 -6	 and	 presumably	exists	in	the	other	family	members,	which	are	routinely	localized	to	the	nucleus.	The	N-	and	C-	terminal	regions	of	the	proteins	are	more	variable	and	are	believed	to	play	transactivation	roles	through	interactions	with	other	transcription	factors,	co-activators	and	co-repressors.	The	tissue	specificity-based	bisection	of	the	GATA	family	is	recapitulated	by	increased	similarity	between	the	proteins	within	each	
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subgroup	(Figure	1-9).		The	GATA4,	-5,	-6	family	are	of	particular	interest	to	the	research	detailed	herein.		
Figure	1-9:	Structure	and	homology	of	the	GATA	factor	proteins.	
The	GATA	factors	have	high	homology	specifically	in	the	DNA	binding	domain	(dark	
blue)	with	relatively	unconserved	N	and	C	terminals.	They	can	be	divided	into	two	
separate	familes.	Adapted	from	Chlon	and	Crispino	(2012)73.	Zinc	finger	domains	in	
red	(N	and	C	terminal).	Nuclear	localization	sequence	in	black.		
An	introduction	to	GATA4		One	 of	 the	 earliest	 roles	 of	 GATA	 factors	 is	 in	 the	 development	 of	 the	 extra-embryonic	tissues.	Mouse	embryos	null	for	GATA4	die	around	E8.5	due	to	defects	in	the	extra-embryonic	visceral	endoderm	that	precipitate	abnormalities	in	folding	of	 the	 embryonic	 tissues74,75.	When	 the	 early	 defects	 are	 rescued	 by	 tetraploid	complementation,	cardiac	defects	(discussed	below)	are	 lethal	at	E9.5,	however	subsequent	 studies	 have	 utilized	 tissue-specific	 and/or	 conditional	 knockout	systems	to	determine	later	roles	for	GATA4	in	various	organs.		Loss	of	GATA4	in	the	intestine	leads	to	changes	in	the	gut	epithelial	barrier,	changing	resorption	of	
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bile	 acid	 and	 suggesting	 a	 role	 for	 GATA4	 in	 gut	 repair	 following	 injury76,77.	Conditional	 knockout	 in	 the	 osteoblasts	 leads	 to	 perinatal	 death	 secondary	 to	defects	in	bone	formation78,	and	loss	of	GATA4	in	the	hepatic	endoderm	or	septum	transversum	mesenchyme	(STM††)	promotes	liver	fibrosis79.	GATA4	has	also	been	shown	to	play	a	role	in	gonadal	development80,81.			
These	studies	are	complemented	by	work	from	our	laboratory	conducted	in	the	zebrafish82.	 Knockdown	 of	 gata4	 with	 a	 morpholino	 leads	 to	 defects	 in	 the	development	of	the	heart,	gut,	pancreas,	 liver	and	swim	bladder.	The	overlap	of	organ	systems	affected	by	depletion	of	GATA4	in	the	zebrafish	and	in	the	mouse	suggests	 that	 its	 role	 is	 conserved	 through	 evolution.	 In	 humans,	mutations	 in	GATA4	 are	 predominantly	 associated	 with	 a	 spectrum	 of	 congenital	 heart	malformations,	with	some	concomitant	testicular	abnormalities83.		
GATA4	in	cardiac	development	and	function	
Gata4	is	expressed	in	the	early	cardiac	progenitor	populations	on	either	side	of	the	midline	in	the	developing	embryo,	and	expression	is	retained	in	the	differentiating	cardiomyocyte.	 In	contrast	with	the	drosophila	pannier	mutant,	cardiomyocytes	are	 still	 specified	 following	 loss	 (mouse)	 or	 knockdown	 (zebrafish)	 of	 GATA4.	Following	rescue	of	early	embryogenesis	by	tetraploid	complementation,	GATA4	null	 embryos	 have	 subsequent	 problems	 in	 cardiac	 morphogenesis,	 namely	disruption	 to	 the	 looping	process,	 septation	defects	and	hypoplastic	ventricular	myocardium84.	The	pro-epicardium	is	missing	in	GATA4	null	embryos84.	
																																																								
††	The	STM	is	a	transient	structure	in	the	developing	embryo	that	gives	rise	to	the	diaphragm,	and	is	an	important	source	of	signals	that	conduct	liver	development.		
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GATA4	has	been	shown	to	be	required	following	initial	heart	tube	formation,	with	zebrafish	gata4	morphants	and	Gata4	null	mice	both	exhibiting	failure	of	jogging	of	 the	 presumptive	 atrial	 portion	 of	 the	 tube	 and	 failure	 of	 the	 chambers	 to	expand82,84,85.	Deletion	of	Gata4	 later	in	mouse	embryonic	development	leads	to	decreased	myocardial	wall	thickness	and	decrease	in	cardiomyocyte	proliferation,	illustrating	that	Gata4	has	a	continued	role	following	initial	morphogenesis85.	In	humans,	mutation	of	GATA4	leading	to	hemizygosity	is	associated	with	a	variety	of	congenital	 heart	 defects,	 demonstrating	 that	 its	 function	 during	cardiomorphogenesis	is	conserved.		However,	there	is	considerable	variation	even	between	 family	members	 carrying	 the	 same	GATA4	mutation.	Thus,	 loss	of	 one	allele	 of	 GATA4	 is	 in	 itself	 insufficient	 to	 determine	 disease	 phenotype.	Haploinsufficiency	 of	 Gata4	 has	 been	 further	 investigated	 in	 mice.	 Mice	heterozygous	 for	 a	GATA4	mutation	 that	 truncates	 the	protein	express	half	 the	wildtype	protein	level.	In	mice	of	mixed	genetic	background,	cardiac	development	is	 normal.	 However,	 in	 inbred	 C57	mice	 the	 same	 genotype	 leads	 to	 defects	 in	cardiac	development,	including	septal	and	endocardial	cushion	defects	similar	to	those	 seem	 in	 human	 disease86.	 These	 studies	 lead	 to	 the	 insight	 that	 GATA4	haploinsufficiency	 is	 paradigmatic	 of	 haploinsufficiency	 in	 a	 developmental	regulator	 and	 highlights	 the	 importance	 of	modifier	 genes	 for	 determining	 the	ultimate	outcome	of	such	heterozygous	mutations	for	congenital	birth	defects.	
GATA4	in	the	adult	heart.	Genes	 that	 are	 important	 during	 the	 development	 of	 the	 heart	 often	 have	 a	continued	role	in	the	adult	cardiomyocyte	in	physiological	or	pathological	states.		
In	 the	adult	 zebrafish	 cardiomyocyte,	gata4	expression	 is	normally	very	 low	or	absent,	 but	 is	 upregulated	 upon	 injury,	 and	 required	 for	 successful	 repair	 of	
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ventricular	 injury87.	 Inducible	 knockout	 of	Gata4	 from	 the	 hearts	 of	 adult	mice	leads	to	progressive	cardiac	enlargement	and	dysfunction,	which	appears	to	occur	downstream	of	dysregulation	of	a	network	of	genes	required	for	cardiomyocyte	survival88.	In	humans,	null	mutations	in	GATA4	have	not	been	identified	in	patients	with	late-onset	cardiomyopathies,	however	it	seems	likely	that	severe	phenotypes	occurring	early	in	the	GATA4-deficient	heart	obscure	the	later	requirement.		
Conditional	knockout	of	Gata4	from	mouse	cardiomyocytes	(CM)	demonstrated	an	ongoing	 role	 for	 GATA4	 in	 developing	myocardium,	with	 these	mice	 exhibiting	myocardial	 thinning,	abnormal	ventricular	morphogenesis	and	CM	proliferation	defects85.	Although	re-expression	of	GATA4-regulated	fetal	genes	in	an	adult	has	been	considered	to	be	pathological89–91,	other	groups	have	shown	that	GATA4	is	required	 to	maintain	normal	homeostatic	heart	 function	 throughout	 life88.	Mice	heterozygous	 for	 Gata4	 exhibit	 mild	 cardiac	 dysfunction	 with	 decreased	 CM	number,	 and	 are	 hypersensitive	 to	 pressure	 overload92.	 Moreover,	 it	 is	 well	established	 that	 GATA4	 expression	 is	 cardioprotective	 in	 a	 variety	 of	 stress	conditions	including	hyperglycemia93,	anthracyclin-induced	cardiotoxicity94,95	and	ischemia-reperfusion96.		
Thus,	 GATA4	 is	 essential	 for	 cardiac	 morphogenesis,	 is	 required	 for	 the	maintenance	of	post-natal	cardiac	function,	and	is	of	particular	importance	under	conditions	of	increased	cardiac	stress.	Some	progress	has	been	made	to	identify	targets	of	GATA4	that	might	facilitate	its	cardioprotective	activity.	These	include	anti-apoptotic	BCL2	family	members94,97,	as	well	as	 less	predictable	targets.	For	example,	the	muscle	transcription	factor	CARP	is	regulated	by	GATA4,	and	CARP	depletion	mimics	a	doxorubicin	(dox)-mediated	sarcomeric	disarray	phenotype98.	However,	 CARP	 overexpression	 is	 insufficient	 to	 rescue	 CM	 treated	 with	 dox,	
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consistent	with	multiple	mechanisms	 acting	 downstream	 of	 GATA4	 to	mediate	cardioprotection.	 This	 example	 highlights	 a	 major	 gap	 in	 our	 knowledge	concerning	 the	 molecular	 mechanisms	 contributing	 to	 both	 physiological	 and	pathological	response	to	stress	in	the	heart.		
In	 summary,	 although	many	previous	 studies	 have	 carefully	 outlined	 a	 role	 for	GATA4	throughout	the	life	of	the	heart,	and	in	particular	during	stress	response,	the	 mechanistic	 basis	 of	 GATA4	 function	 is	 incompletely	 understood.	 A	 better	understanding	 of	 cardioprotective	 pathways	 is	 key	 for	 the	 development	 of	effective	 therapies.	 Mutations	 in	 cardiac	 stress	 response	 genes	 have	 been	associated	 with	 cardiomyopathy99–101,	 suggesting	 that	 loss	 of	 protective	mechanisms	that	counteract	cardiac	stress	contributes	to	the	enormous	burden	of	heart	failure.	
As	a	master	regulator	transcription	factor,	GATA4	has	myriad	targets	within	the	genome	and	controls	 the	expression	of	hundreds	of	genes28,102.	 It	 is	 therefore	a	strong	hypothesis	that	multiple	mechanisms	downstream	of	GATA4	coordinate	to	control	tissue	migration,	differentiation	and	identity.		
An	introduction	to	GATA6	Similar	to	GATA4,	embryos	in	which	GATA6	has	been	knocked	out	die	around	E5.5	due	to	defects	in	the	extra-embryonic	endoderm.	This	early	lethality	was	recently	demonstrated	 to	 be	 due	 to	 a	 requirement	 for	 GATA6	 in	 the	 specification	 of	primitive	endoderm	through	inhibition	of	Nanog	signaling103.	Following	rescue	by	tetraploid	complementation,	GATA6	null	embryos	can	develop	to	E10.5,	although	they	 are	 smaller	 than	 sibling	 controls104.	 Analyses	 of	 the	 embryos	 at	 E10.5	indicated	that	up	until	this	point	GATA6	is	dispensable	for	formation	of	the	heart,	vasculature	and	STM,	but	that	there	are	defects	in	liver	formation.	The	hepatic	bud	
	 	31	
specifies	 but	 fails	 to	 expand	 in	 GATA6	 null	 embryos,	 indicating	 that	 GATA6	 is	required	 for	 hepatic	 outgrowth.	 The	 cause	 of	 death	 in	 GATA6	 null	 embryos	remains	unknown.		
The	exploration	of	conditional	GATA6	knockout	in	various	tissue	types	has	been	less	 thorough	 than	 for	 GATA4.	 Knockout	 of	 GATA6	 in	 the	 neural	 crest-derived	vascular	smooth	muscle	cells	(SMCs)	led	to	malformations	of	the	cardiac	outflow	tract	and	aortic	arch105.	The	neural	crest-derived	SMCs	are	known	to	be	a	source	of	 patterning	 cues	 for	 the	 developing	 heart,	 but	 appeared	 to	 have	 developed	normally	 in	 these	 animals,	 suggesting	 that	 the	 role	 of	 GATA6	 is	 specifically	 to	regulate	 expression	 of	 SMC-derived	 signaling	molecules.	 Mice	 with	 conditional	deletion	 of	 GATA6	 in	 endothelial	 cells	 still	 develop	 normally	 but	 develop	spontaneous	hypertension,	suggesting	that	GATA6	plays	a	role	in	blood	vessel	tone	or	function106.		
Zebrafish	 embryos	 with	 gata6	 knockdown	 develop	 early	 defects	 in	 cardiac	development,	with	abnormalities	in	cardiac	precursor	migration.	These	defects	are	earlier	 than	 those	 observed	 in	 the	 mouse,	 suggesting	 a	 species-specific	requirement	 for	 GATA6	 at	 different	 stages	 of	 heart	 development.	 In	 humans,	mutation	 in	 GATA6	 is	 associated	 with	 congenital	 cardiac	 malformations107.	 In	addition,	 some	 patients	 present	with	 pancreatic	 agenesis,	 suggesting	 a	 role	 for	GATA6	 in	pancreatic	development	 that	 is	not	 revealed	by	Gata6	 gene	knockout	studies	in	the	mouse.		
Redundancy	between	GATA	factors	during	cardiac	development.	Although	the	single	knockout	and	single	conditional	knockout	studies	have	been	informative,	 combination	 knockout/down	 studies	 by	 our	 lab	 and	 others	 has	demonstrated	 that	 GATA	 factors	 are	 able	 to	 compensate	 for	 each	 other	 during	
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development.	Xin	et	al.	(2006)	showed	that	whilst	mice	heterozygous	for	Gata4	or	Gata6	 can	 develop	 normally,	 compound	 heterozygosity	 resulted	 in	 a	 range	 of	defects	 in	 cardiogenesis	 with	 early	 embryonic	 lethality,	 illustrating	 that	 GATA	dosage	 is	 an	 important	 factor	 in	 cardiogenesis108.	Work	 from	 our	 own	 lab	 has	demonstrated	 that	 Gata5	 and	 Gata6	 are	 redundant	 for	 cardiac	 development109.	Redundancy	between	GATA	factors	appears	 to	vary	according	to	species	and	to	tissue	type.	
In	 mouse,	 compound	 heterozygosity	 of	 GATA4	 and	 GATA6	 leads	 to	 defects	 in	cardiovascular	development	including	thinning	of	the	myocardium108.	Strikingly,	a	 similar	 phenotype	 is	 observed	 in	GATA4/GATA5	 compound	heterozygotes110,	suggesting	 that	 overall	 GATA	 load	 is	 potentially	 more	 important	 in	 heart	development	than	the	contributions	of	specific	GATA	factors.	 In	zebrafish,	work	from	our	laboratory	has	demonstrated	that	gata5	and	gata6	are	redundant	for	the	specification	 of	 cardiomyocytes	 but	 that	 cardiomyocytes	 are	 lost	 following	 the	knockdown	by	morpholino	of	both	genes109.	Combined	knockdown	of	gata4	and	
gata5	or	gata6	did	not	lead	to	the	same	phenotype,	suggesting	that	in	the	zebrafish	
gata4	is	less	important	than	the	other	family	members	for	cardiac	specification.		
Combinatorial	conditional	deletion	of	murine	GATA4	and	GATA6	has	also	revealed	that	they	play	a	role	in	pancreatic	development111.	Here,	again,	overall	GATA	load	appears	 to	 play	 a	 role,	 since	 deletion	 of	 one	 GATA6	 allele	 in	 a	 GATA4	 null	background	led	to	a	substantial	loss	of	pancreatic	mass.	The	same	was	not	true	for	loss	of	one	GATA4	allele	 in	a	GATA6	null	background,	suggesting	that	GATA6	is	better	able	to	compensate	for	GATA4	than	vice	versa,	at	least	in	the	pancreas.		
Questioning	whether	the	differential	expression	pattern	or	inherent	differences	in	the	protein	prevented	complete	redundancy,	a	recent	study	replaced	the	murine	
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GATA4	 gene	 with	 the	 GATA6	 cDNA	 and	 demonstrated	 that	 GATA6	 is	 able	 to	recapitulate	the	role	of	GATA4	in	extraembryonic	tissues,	but	not	in	the	developing	heart112.	 	Such	replacement	studies	will	be	of	particular	use	to	help	deconvolute	the	 various	 contributions	 of	 each	 GATA	 family	 member	 to	 developmental	processes.	
Regulation	and	modification	of	GATA	activity	When	considering	different	model	systems,	there	are	some	differences	in	the	roles	of	and	redundancies	between	GATA-4,	-5	and	-6.	The	factors	that	control	binding	of	GATA4	rather	than	GATA5	or	GATA6	are	not	well	understood,	although	there	is	evidence	 that	 they	 do	 not	 have	 entirely	 overlapping	 binding	 sites.	 Potential	explanations	 for	 the	 differences	 in	 target	 genes	 include	 the	 contribution	 of	cofactors	 to	 binding	 location	 and	 activity	 upon	 binding,	 as	 well	 as	 post-translational	modifications.		
Key	candidate	cofactors	for	mediating	some	of	these	redundancies	and	differences	are	the	friend	of	GATA	(FOG)	proteins.	These	proteins	contain	a	series	of	zinc	finger	domains,	as	well	as	domains	known	to	recruit	corepressors73.	In	humans	there	are	two	FOG	proteins,	 FOG1	and	FOG2,	which	 can	be	 generally	 associated	with	 the	hematopoietic	 and	 cardiac	 GATA	 factor	 families,	 respectively.	 This	 is	 based	 on	expression	pattern	during	development.	FOG2	has	predominantly	been	studied	in	terms	of	its	relationship	with	GATA4.	Although	knockout	of	FOG2	in	mice	leads	to	lethal	 cardiac	defects	during	embryogenesis,	 they	arise	 later	 than	 those	seen	 in	GATA4	null	embryos113,	indicating	that	GATA4	has	FOG2-independent	roles.	FOG2	has	 also	 been	 shown	 to	 cooperate	 with	 GATA4	 in	 other	 tissues,	 including	 the	liver114	 and	 lung73.	 Interestingly,	 there	 is	 evidence	 that	 FOG1	 cooperates	 with	
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GATA4	 in	 the	 small	 intestine115,	 highlighting	 how	 co-factors	 can	 regulate	 the	specificity	and	activity	of	GATA	factors.		
In	addition	to	dedicated	co-factors,	improvements	in	ChIP	and	chromatin	mapping	technologies	 have	 allowed	 researchers	 to	 identify	 complexes	 of	 transcription	factors	within	which	the	GATA	factors	reside.	A	recent	study	of	differences	in	the	expression	patterns	of	cardiomyocytes	harboring	a	mutation	 in	another	cardiac	transcription	 factor,	 TBX5,	 demonstrated	 that	 the	 relationship	 between	 GATA4	and	TBX5	was	altered,	driving	a	loss	of	identity	for	the	cardiomyocyte	through	a	genome-wide	alteration	in	the	binding	sites	of	transcription	factor	complexes116.	Studies	such	as	this	highlight	how	master	transcription	factors	can	work	in	concert	to	 conduct	 genome-wide	alterations	 in	 transcription	 to	define	 cell	 identity,	 and	serve	as	a	reminder	that	the	activity	of	each	GATA	factor	is	highly	regulated	by	a	plethora	of	binding	partners.		
The	relationship	between	the	GATA	factor	and	its	binding	partners,	as	well	as	with	DNA,	can	be	regulated	by	post-translational	modifications.	A	conserved	stretch	of	basic	amino	acid	residues	is	known	to	be	an	important	site	of	post-translational	modifications	that	control	DNA	binding	and	the	ability	of	the	GATA	factor	to	initiate	transcription.	Phosphorylation	and	acetylation	sites	have	been	 identified	within	and	 surrounding	 the	 zinc	 finger	 domains,	 and	 such	 post-translational	modifications	 have	 been	 demonstrated	 to	 be	 important	 for	 the	 activity	 of	GATA4117,118,	 illustrating	 how	 signaling	 pathways	 can	 act	 on	 kinases	 or	 acetyl	transferases	to	rapidly	act	to	alter	GATA	function.	
GATA	 factors	 are	 also	 thought	 to	 heterodimerize119,	 which	 may	 contribute	 to	redundancy,	 particularly	 in	mutants	 in	which	 the	 protein	 is	 partially	 truncated	rather	than	completely	deleted.	
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In	 summary,	 the	 mechanisms	 by	 which	 GATA	 activity	 can	 be	 modulated	 and	regulated	are	myriad,	and	are	still	under	investigation.	By	appreciating	the	abilities	of	GATA	factors	to	compensate	for	each	other	under	defined	circumstances,	and	what	those	circumstances	are,	we	will	be	better	able	to	understand	their	roles	in	development	and	disease.		
Gata4	regulates	expression	of	hspb7	With	a	view	to	identifying	cardioprotective	targets	of	GATA4,	a	previous	graduate	student	 in	 our	 laboratory	 performed	 an	 RNA-sequencing	 experiment.	 Using	injected	morpholinos	 (MOs),	 he	 depleted	 Gata4	 in	 zebrafish	 embryos	 from	 the	
tg(myl7:gfp)	strain,	which	expresses	GFP	in	CMs.	GFP+	CMs	were	purified	by	FACS	from	stage-matched	morphants	and	controls,	and	RNA	was	deep-sequenced	using	the	 Illumina	 Hi-Seq	 platform.	 Using	 this	 platform,	 he	 discovered	 that	 Gata4	regulates	the	expression	of	small	heat	shock	protein	beta	7	(Hspb7)120.		ChIP-seq	data	from	murine	HL-1	cells	indicates	that	Hspb7	is	a	conserved	and	direct	target	gene	of	Gata4	in	mammalian	CMs102,120.		
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The	small	heat	shock	proteins	
Introduction	to	the	small	heat	shock	proteins.	The	 small	 heat	 shock	 proteins	 (sHSPs)	 are	 a	 family	 of	 15-30kDa	 chaperone	proteins	that,	unlike	their	higher-molecular-weight	counterparts,	do	not	depend	on	 ATP	 for	 their	 cytoprotective	 actions.	 The	 family	 is	 conserved	 down	 to	invertebrates,	 with	 demonstrated	 roles	 for	 sHSP	 family	 members	 in	 the	development	 of	 Drosophila121.	 sHSPs	 are	 characterized	 by	 a	 C-terminal	 alpha-crystallin	domain	composed	of	eight	b-strands	that	interact	to	form	a	b-sheet,	and	has	 been	 demonstrated	 to	 play	 a	 role	 in	 homo-	 and	 hetero-oligomerization	 of	various	 sHSP	 family	members.	The	human	 sHSP	 family	 is	 composed	of	10	 core	members	and	one	associated	protein122,	whereas	the	zebrafish	has	14	predicted	sHSPs123	(Table	1-1).		
Table	1-1:	Summary	of	the	small	heat	shock	protein	family	
Detailing	 the	members	of	 the	 small	 heat	 shock	protein	 family	and	 their	alternate	
names.	Conservation	in	human	(H),	mouse	(M)	and	zebrafish	(Z)	is	indicated.	Human	
disease	in	which	specific	mutations	in	an	HSPB	family	member	has	been	identified	
are	 detailed	 in	 the	 right-hand	 column.	 *Considered	 to	 be	 ‘HSPB-like’	 based	 on	
sequence	similarity.	†Expression	 identified	by	blast	query	and	confirmed	at	mRNA	
level	only.		
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Alignment	of	 the	HSPB	familes	 from	human,	mouse	and	zebrafish	demonstrates	that	most	members	are	more	closely	related	between	species	than	to	each	other	(Figure	1-10).		
	Figure	1-10:	Phylogenetic	tree	of	the	HSPB	family.	
Phylogenetic	 tree	 of	 the	 human,	 mouse	 and	 zebrafish	 (danre)	 small	 heat	 shock	
proteins	generated	with	ClustalX.	Zebrafish	small	heat	shock	proteins	cluster	more	
closely	with	their	human	or	mouse	orthologs	than	with	other	zebrafish	paralogs.		
sHSP	 have	 varied	 expression	 patterns	 during	 development124	 and	 in	 the	 adult	(Table	1-1),	and	the	molecular	mechanisms	of	action	of	the	sHSP,	where	they	are	known,	 are	 heterogeneous.	 For	 these	 reasons,	 it	 is	 difficult	 to	 extrapolate	 the	function	 of	 one	 sHSP	 from	 another,	 and	 for	 several	 family	 members	 the	physiological	role	and	mechanism	of	action	is	as-yet	unknown.	Indeed,	a	number	of	studies	evaluating	the	activity	of	each	of	the	human	sHSP	proteins	 in	specific	stress	scenarios	clearly	demonstrate	variety	in	both	their	function	and	mechanism	of	action125–128.	
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Small	heat	shock	proteins	and	protein	aggregation	There	 are	 an	 increasing	 number	 of	 discoveries	 linking	 the	 sHSP	 to	 protein	aggregation.	Sequencing	data	from	patients	with	protein	aggregate	disorders	has	unearthed	 mutations	 in	 HSPB5	 (also	 known	 as	 CRYAB).	 These	 mutations	 are	associated	 with	 myofibrillar	 myopathies,	 in	 which	 electrical	 or	 clinical	cardiomyopathy	is	also	a	symptom129.		
The	presumed	role	of	sHSPs	in	preventing	protein	aggregation	has	been	explored	by	various	groups	through	testing	the	ability	of	overexpression	of	a	specific	sHSP	to	prevent	aggregation	of	an	overexpressed	aggregate-prone	protein	or	protein	fragment.	 Experimental	 aggregate	 proteins	 include	 polyglutamate-containing	polypeptides	such	as	mutated	huntingtin	and	mutated	ataxin-3127,	as	well	as	non-polyglutamate	 pre-aggregates	 such	 as	 mutated	 amyloid-beta	 protein.	 In	 most	studies,	 the	 full	 panel	 of	 sHSPs	 were	 screened	 for	 their	 ability	 to	 prevent	aggregation	of	the	mutant	protein	in	question.	
Small	heat	shock	proteins	in	the	heart	A	subset	of	the	sHSP,	HSPB1-3	and	HSPB5-8,	are	expressed	in	the	human	heart.	Interestingly,	 there	 is	 not	 complete	 agreement	 across	 all	 species	 regarding	 the	expression	 pattern	 of	 particular	 sHSP	 family	 members,	 suggesting	 that	 their	relative	contributions	to	cardiac	function	may	vary	between	species.	Knockout	of	HSPB1,	 a	 highly	 expressed	 cardiac	 sHSP,	 did	 not	 result	 in	 any	 cardiac	abnormalities130,	however	high	 levels	of	over-expression	of	HSPB1	appeared	 to	result	in	a	decrease	in	reductive	stress.	This	is	attributed	to	contributions	of	HSPB1	(and	also	HSPB8)	to	the	modulation	of	the	redox	state	of	glutathione131.		
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Small	heat	shock	protein	beta	7	HSPB7	is	among	the	least	characterized	sHSPs,	except	that	its	expression	is	known	to	be	highly	restricted	to	the	developing	and	adult	heart124,132,	and	at	lower	levels	in	 skeletal	 muscle.	 The	 structural	 and	 functional	 diversity	 of	 the	 sHSP	 family	precludes	inference	of	HSPB7	function	from	findings	concerning	other	sHSP	family	members,	and	so	much	was	left	to	uncover	when	I	started	this	project.	
Early	work	characterizing	HSPB7	identified	an	interaction	partner	in	the	human	heart,	a-filamin	(FLNA)132,	which	crosslinks	actin	 filaments	and	 links	actin	with	membrane	 glycoproteins.	 FLNA	 is	 involved	 in	 remodeling	 the	 cytoskeleton	 to	facilitate	 changes	 in	 cellular	 morphology,	 migration	 and	 mechanosensory	transduction133,134.	However,	a	functional	relationship	between	HSPB7	and	FLNA	was	never	characterized.	HSPB7	has	also	been	shown	to	prevent	aggregation	of	poly-glutamate	 tract-containing	 proteins,	 albeit	 in	 an	 ectopic	 overexpression	system127.	 The	 authors	 conducted	 a	 series	 experiments	 which	 eliminated	activation	of	the	general	cell	stress	response;	active	refolding	of	unfolded	proteins;	targeting	of	aggregates	to	the	proteasome;	and	upregulation	of	other	small	heat	shock	proteins	as	the	molecular	mechanism	underlying	this	activity.	However,	the	authors	did	demonstrate	that	the	anti-aggregate	activity	of	HPSB7	was	attenuated	by	 loss	 of	 a	 key	 autophagic	 protein,	 Atg5.	 Interestingly,	 this	 study	 also	demonstrated	that,	unlike	other	HSPB	family	members,	HPSB7	does	not	form	large	oligomers.	
Work	 from	 the	Brundel	 lab	 reported	 that	HSPB7	co-localizes	with	 tachypacing-induced	F-actin	stress	 fibers,	and	 is	protective	against	both	their	 formation	and	tachypacing-induced	calcium	transient	reductions	in	cultured	murine	CM	(HL-1)	cells126.	In	keeping	with	the	preceding	studies,	the	anti-aggregate	activity	of	HSPB7	
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has	been	shown	to	operate	exclusively	by	preventing	aggregate	formation	rather	than	through	promoting	clearance	of	pre-formed	aggregates135.		
A	recent	conditional	knockout	study	in	mice	demonstrated	that	skeletal	muscles	undergo	 progressive	 myopathy	 in	 the	 absence	 of	 HSPB7136.	 This	 study	 also	identified	dimerized	FLNC	as	a	binding	partner	of	HSPB7	in	skeletal	muscle,	and	showed	that	FLNC	aggregates	form	in	HSPB7-/-	myofibers.		
Thesis	objectives	
Having	identified	HSPB7	as	a	GATA4	target	gene	in	the	developing	heart,	we	were	interested	 in	 uncovering	 its	 physiological	 role	 in	 the	 cardiomyocyte.	 Taken	together,	 the	 literature	suggests	 that	HSPB7	does	have	an	 important	role	 in	 the	heart.	Restriction	of	HSPB7	expression	to	striated	muscle	suggests	that	this	role	may	be	muscle	specific.		
I	hypothesized	that	HSPB7	binds	to	potentially	problematic	cardiac	proteins	and	prevents	their	unfolding	and/or	aggregation.	I	hypothesized	that	in	the	absence	of	HSPB7,	 cardiomyocytes	 would	 develop	 pathological	 aggregates	 that	 interfered	with	their	function,	potentially	to	the	point	of	causing	cardiomyopathies	in	HSPB7	null	animals.	My	thesis	studies	were	designed	to	test	these	hypotheses.		 	
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CHAPTER	2: MATERIALS	AND	METHODS	
Basic	Zebrafish	Methodologies	
Zebrafish	Husbandry	All	 zebrafish	 strains	were	maintained	at	28.5°C	 in	our	zebrafish	 facility,	 and	all	procedures	carried	out	as	approved	by	the	WCMC	IACUC.	Embryos	were	staged	as	described137.		
Zebrafish	Lines	The	tg(myl7:gfp)	 strain	was	originally	obtained	 from	H.J.	Tsai	 (Taiwan)	and	has	expression	 of	 GFP	 in	 the	 myocardium.	 The	 tg(lfabf:dsRed;elaA:EGFP)(LiPan)	strain138	was	originally	obtained	from	Z.	Gong	(Singapore)	and	expresses	GFP	in	the	 pancreas	 and	 dsRed	 in	 the	 liver.	 The	 tg(fli:gfp)	 line	was	 obtained	 from	 the	Zebrafish	 International	 Research	 Center	 (ZIRC)	 and	 expresses	 GFP	 in	 the	endothelium.	 The	 tg(gata1:rfp)	 line	 was	 a	 kind	 gift	 of	 Leonard	 Zon	 (Harvard	Medical	 School)	 and	 expresses	 RFP	 in	 the	 erythrocytes.	 The	 tg(fli:gfp)	 and	
tg(gata1:rfp)	 lines	 were	 crossed	 in	 our	 laboratory	 to	 generate	 the	 double	transgenic	tg(fli:gfp;	gata1:rfp)	line.		
Preparation	of	fertilized	embryos	The	day	before	injection,	adult	animals	were	set	up	in	individual	breeding	tanks	males	and	females	separated	by	a	divided	to	prevent	premature	egg	release	and	allow	accurate	embryo	staging.	Up	to	two	males	and	two	females	were	housed	in	one	individual	breeding	tank.	The	following	morning,	the	fish	were	transferred	to	fresh	system	water.	The	divider	was	removed	to	allow	breeding	to	commence.	A	perforated	screen	separated	adult	fish	from	the	fertilized	eggs,	which	sank	through	
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the	screen	to	the	bottom	of	the	tank	and	were	collected	around	20	minutes	after	adult	release.		
Microinjection	Needles	for	microinjection	are	made	as	needed	from	3.5”	capillary	tubes	(VWR)	that	have	been	prepared	with	a	Model-97	micropipette	puller	(Sutter).	Needles	are	cut	with	a	razor	blade	to	a	tip	diameter	of	0.14-0.18	µm.		
Exercise	of	adult	zebrafish	Equal	 numbers	 of	 hspb7	mutant	 zebrafish	 and	 wildtype	 sibling	 controls	 were	placed	in	a	swim	tunnel	(Loligo	Systems,	Denmark)	and	subjected	to	water	flow	of	50	cms-1	for	30	minutes,	once	a	day.	Zebrafish	mortality	was	tracked	by	physical	daily	count,	and	fish	locations	tracked	with	an	iPhone	camera.	Zebrafish	location	during	swim	challenge	was	tracked	with	MTrackJ	for	ImageJ139.	
Monitoring	oxygen	consumption	of	adult	zebrafish	during	exercise	Following	placement	of	equal	numbers	(10	each)	of	hspb7	mutant	zebrafish	and	wildtype	 controls	 in	 a	 swim	 tunnel,	 the	 apparatus	 was	 sealed.	 The	 respirator,	which	measures	oxygen	concentration	(Witrox4,	Loligo	Systems,	Denmark)	was	calibrated	 to	 minimum	 and	 maximum	 levels	 by	 bubbling	 nitrogen	 or	 air,	respectively,	through	breeding	tanks	of	system	water	for	10	minutes	before	taking	measurements.	Oxygen	concentration	in	the	water	was	recorded	every	1	second	throughout	 the	 period	 of	 exercise	 using	 the	 Witrox	 CTRL	 software	 (Loligo	Systems).	Oxygen	saturation	(%)	was	calculated	using	the	Witrox	CTRL	software.	Overall	change	in	oxygen	saturation	from	the	beginning	to	the	end	of	the	swim	was	used	 to	 determine	 oxygen	 consumption	 during	 the	 swim.	 Oxygen	 levels	 in	 the	swim	 tunnel	were	 restored	 to	maximum	by	 replacement	of	water	 and	aeration	before	a	new	school	of	fish	was	exercised.	
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Small	molecule	treatment	of	embryonic	zebrafish	Zebrafish	 embryos	 were	 manually	 dechorionated	 with	 forceps	 at	 24	 hpf	 and	exposed	to	increasing	concentrations	of	bafilomycin	A1,	chloroquine	diphosphate	or	 3-methyladenine	 (all	 from	 Sigma)	 in	 a	 solution	 of	 E3	medium	 (5.0mM	NaCl,	0.17mM	 KCl,	 0.33mM	 CaCl,	 0.33mM	MgSO4)	 with	 1%	 DMSO	 (all	 Sigma).	 Small	molecule	compounds	were	refreshed	every	24	hours.		
Microdissection	of	complete	hearts	from	embryonic	zebrafish	Hearts	were	dissected	from	3-5dpf	zebrafish	larvae	as	described140.	This	protocol	is	 suitable	 for	 the	 isolation	 of	 larval	 zebrafish	 hearts	 for	 immunostaining	 or	generation	of	RNA:	
• Zebrafish	 larvae	 were	 anesthetized	 in	 1X	 Tricaine	 in	 E3	 until	 touch	response	was	lost.		
• Transfer	one	larva	and	a	pool	of	E3	with	1X	Tricaine	to	the	well	of	a	concave	microscope	slide,	positioned	under	a	light	microscope.		
• Taking	two	X-gauge	needles,	use	one	to	spear	the	zebrafish	larva	dorsal	to	the	 heart,	 trying	 to	 avoid	 piercing	 the	 yolk.	 Insert	 the	 second	 needle	immediately	ventral	to	the	first	needle	and	pull	forward	swiftly.	The	heart	will	detach	from	the	embryo	at	the	inflow	and	outflow	tracts	and	float	into	the	liquid	surrounding	the	fish.	
• Use	a	cut-off	20µl	pipette	set	to	2µl	to	capture	the	dissected	heart.	Transfer	to	buffer	of	your	choice	for	further	processing	
Dissection	of	hearts	from	adult	zebrafish	Hearts	were	dissected	from	adult	zebrafish	as	described141.		
• Aesthetize	adult	(3-18	month)	zebrafish	on	ice	for	20	minutes.		
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• Immobilized	fish	by	inserting	one	half	of	a	pair	of	forceps	into	the	mouth	and	pinching	the	head.		
• Bisected	 the	 fish	with	 a	 clean	 razor	 blade	 immediately	 posterior	 to	 the	pectoral	fins.		
• Use	 forceps	 to	cut	 the	ventral	attachment	of	 the	operculum	to	 the	body,	exposing	the	dorsal	aorta.	Use	forceps	to	bisect	the	dorsal	aorta.		
• Hold	the	fish	head	in	place	with	one	set	of	forceps,	and	use	a	second	set	of	forceps	to	grasp	the	pectoral	fins	and	attached	body	cartilage,	and	lift	them	away	from	the	main	torso.		
• The	heart	will	either	have	come	away	with	the	pectoral	fins,	or	remains	in	the	torso,	but	is	easily	visible.	In	many	cases	the	heart	will	still	be	beating	slowly.		
• Release	the	fish	head	and	use	both	pairs	of	forceps	to	tease	the	heart	away	from	the	torso	and	remove	the	pericardium.	
• Grip	the	heart	by	the	remainder	of	the	dorsal	aorta	and	place	onto	a	clean	microscope	 slide	 for	 imaging,	 or	 transfer	 to	 a	 buffer	 of	 your	 choice	 for	extraction	of	nucleic	acids	or	protein.		
Measuring	zebrafish	heart	size.	Following	dissection,	adult	zebrafish	hearts	were	placed	on	a	microscope	slide	and	imaged	on	a	dissection	microscope	(Nikon)	with	top-lighting.	Hearts	were	rotated	to	present	maximal	ventricular	area	and	images	were	captured	with	Spot	Imaging	Software.	Ventricular	area	was	calculated	with	FIJI	software,	as	described56.		
Prior	to	dissection,	anesthetized	zebrafish	were	partially	dried	with	paper	towels	and	weighed.	Zebrafish	mass	was	used	as	a	normalizing	factor	for	heart	size	index	(VA/BW)	since	it	is	a	greater	variable	than	body	length	in	adult	fish56.		
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Generation	of	mutant	zebrafish	lines		Sequences	of	TALEN	and	CRISPRs	used	in	this	thesis	are	provided	in	Table	2-2.		
Generation	of	TALENs	and	TALEN-derived	mutant	lines	TALENs	were	 designed	 using	 the	 Cornell	 TAL	 Effector	 Nucleotide	 Targeter	 2.0	website142	 and	 plasmids	 encoding	 specific	 TALENs	 were	 generated	 with	 the	TALEN	Golden	Gate	2.0	kit	 (Addgene)	as	previously	described143.	Generation	of	correct	sequences	was	confirmed	through	digestion	with	BspEI,	which	generates	a	 characteristic	 fingerprint.	 Resultant	 vectors	 were	 linearized	 with	 SmaI	 and	mRNA	 encoding	 TALENs	 was	 synthesized	 with	 the	 mMessage	 mMachine	 kit	(Thermo	Fisher).	mRNA	was	quantified	with	a	Nanodrop	machine	and	run	out	on	a	 1%	 agarose	 gel	 with	 ethidium	 bromide	 in	 order	 to	 verify	 that	 there	 was	 no	degradation.	100-400	pg	of	mRNA	was	injected	into	zebrafish	embryos	at	the	1-2	cell	stage.		
Generation	of	CRISPRs	and	CRISPR-derived	mutant	lines	Guide	RNAs	(gRNAs)	for	CRISPR-Cas9	mediated	mutagenesis	were	designed	with	the	CHOPCHOP	website144	and	ordered	as	double	stranded	oligo	cassettes	with	a	T7	 promoter	 at	 the	 5’	 end	 from	 IDT.	 The	 gRNA	 was	 generated	 with	 the	MEGAshortscript	 kit	 (Thermo	 Fisher)	 and	 purified	 through	 ammonium	 acetate	precipitation	as	per	the	manufacturers	instructions.	mRNA	was	quantified	with	a	Nanodrop	machine	and	 run	out	on	a	1%	agarose	gel	with	ethidium	bromide	 in	order	to	verify	that	there	was	no	degradation.	250	ng/µl	gRNA	was	combined	with	500	ng/µl	recombinant	Cas9	protein	(PNA	BIO)	and	0.2M	KCl,	and	incubated	at	room	temperature	for	15	minutes	to	allow	RNA-protein	complexes	to	form.		1nl	of	the	 gRNA-Cas9	 complexes	was	 injected	 into	 embryos	 at	 the	 1-2	 cell	 stage.	 Cell	injections	were	performed	in	this	case	but	it	is	worth	noting	that	yolk	injections	
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have	subsequently	been	shown	to	lead	to	equivalent	mutation	rates	by	members	of	the	community	and	may	be	more	efficient	for	future	experiments.		
Identification	of	mutant	lines	by	genotyping	of	pools	of	embryos	DNA	was	generated	from	2-3	pools	of	5-10	individuals	from	clutches	of	F0-injected	embryos	 using	 the	DNEasy	 kit	 (Qiagen).	 DNA	was	 quantified	 by	 nanodrop	 and	stored	at	4°C.	For	HSPB7,	carriers	of	mutations	were	identified	through	PCR	across	the	target	locus	followed	by	RFLP	analysis	with	HpyCH4V	(NEB).	Primers	for	each	target	 locus	 are	 listed	 in	 Table	 2-3.	 For	 all	 other	 genes	 targeted,	 carriers	 of	mutations	 were	 identified	 through	 re-naturation	 of	 PCR	 products	 followed	 by	digestion	with	T7	endonuclease	I	(NEB)	as	described145.	PCR	products	were	cloned	into	a	TOPO	vector	(Invitrogen)	and	sequenced	to	identify	mutant	alleles.	Clutches	of	 embryos	 containing	 mutations	 were	 raised	 to	 adulthood	 and	 outcrossed	 to	wildtype	animals.	Pools	of	F1	embryos	were	screened	for	mutations	as	described	above,	 and	 clutches	 of	 embryos	 from	 F0	 fish	 that	were	 transmitting	mutations	were	raised	to	adulthood.		
gDNA	collection	from	larval	zebrafish	by	tail	biopsy	DNA	was	extracted	from	3dpf	embryos	for	genotyping	as	previously	described146:	
Figure	2-1:	Detailing	the	desired	dissection	for	tail	biopsy	of	3dpf	zebrafish	
Brightfield	image	of	3dpf	zebrafish	embryo,	showing	pigment	gap	in	the	tail.	Desired	
cut	for	tail	biopsy	(dashed	line)	is	immediately	posterior	to	the	looping	caudal	vein.	
• Before	 commencing,	 dechorionate	 all	 zebrafish	 and	 remove	 discarded	chorions.	
• To	a	24	well	plate,	add	1ml	E3/well.		
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• To	a	96	well	plate,	add	35µl	50mM	NaOH/well.		
• To	a	petri	dish,	add	15µl	20%	Tween	in	1X	Tricaine	in	E3.	Move	embryos	to	be	genotyped	to	1X	Tricaine	in	E3+Tween	in	batches	of	~4.		
• Transfer	single	embryos	to	the	upturned	lid	of	a	petri	dish.	Minimize	the	amount	of	liquid	transferred.	
• Under	a	microscope,	use	a	microscalpel	to	dissect	off	tail	fin	in	pigment	gap	posterior	to	blood	stream	(Figure	2-1)	
• Use	20µl	tip	to	suck	up	dissected	tail	and	add	to	1	well	of	96	well	plate.		
• Move	embryo	to	numbered	well	of	24	well	plate	in	1ml	E3	medium.	
• Following	dissection	of	 tails	 for	all	embryos	to	be	genotypes,	 transfer	24	well	plate	to	incubator	at	28°C.	
• Seal	96	well	plate	with	foil.	
• Heat	to	98°C	for	2-5	minutes	and	spin	down	for	10	seconds	at	500g.		
• Add	10%	(3µl)	1M	Tris-HCL,	pH8	and	spin	down	for	10	seconds	at	500g.		
• Use	 2µl	 of	 gDNA	 immediately	 in	 PCR	 reaction.	 gDNA	 generated	 in	 this	manner	is	prone	to	degradation	and	should	be	used	within	48	hours.		
gDNA	extraction	from	adult	zebrafish	DNA	was	extracted	from	adult	animals	for	genotyping	as	follows:	
• Anesthetize	adult	fish	in	0.16mg/ml	Tricaine	in	system	water	for	5	minutes.	
• Use	a	clean	razor	blade	to	slice	off	a	small	section	of	the	anal	or	the	ventral	caudal	fin.	
• Return	the	animal	to	system	water	in	a	labeled	isolation	tank		
• Place	fin	in	50µl	gDNA	extraction	buffer	(10mM	Tris-HCl	pH8.4,	50mM	KCl,	1.5mM	MgCl2,	0.3%	Tween-20,	0.3%	NP-40)	in	a	PCR	tube	
• Heat	at	95°C	for	15	minutes	then	cool	to	55°C	
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• Add	3µl	Proteinase	K	(20mg/ml	stock,	Roche),	incubate	at	55°C	for	1	hour	
• Heat	at	95°C	for	20	minutes	
• Use	2µl	of	gDNA	in	PCR	reaction	and	store	the	remainder	at	4°C	Identification	of	F1	animals	carrying	mutations	was	performed	by	RFLP	analysis	or	T7	assay	as	described	below.	PCR	products	from	heterozygous	mutant	animals	were	 cloned	 into	 the	 pCR-BluntII-TOPO	 vector	 (Thermo)	 according	 to	 the	manufacturer’s	 instructions.	 Vectors	 were	 sequenced	 from	 the	 M13Reverse	primer	at	the	Cornell	Institute	of	Biotechnology	Resource	Center,	or	by	GeneWiz,	New	Jersey.	Primers	for	genotyping	of	zebrafish	are	provided	in	Table	2-3.	Primers	for	sequencing	of	mutant	alleles	are	provided	in	Table	2-5.	
T7Endonuclease	1	(T7E1)	assay:	The	T7E1	 assay	 allows	 identification	 of	mutants	within	pools	 of	 embryos	 or	 of	heterozygosity	 within	 a	 particular	 region.	 The	 T7E1	 enzyme	 will	 cleave	 at	mismatched	base	pairs,	generating	digestion	products.			
• To	10µl	PCR	product	add	1.5µl	NEB	Buffer	2	and	3.5µl	ddH2O	
• Hybridize	 PCR	 products	 on	 the	 thermocycler	 (95°C	 5	min,	 95-85°C	 at	 -2C/sec,	85-25°C	at	-0.1C/sec,	hold	at	4°C).	
• Remove	from	thermocycler.	To	each	reaction	add	0.5µl	NEB	Buffer	2,	4.3µl	ddH2O	and	0.2µl	T7E1.	
• Incubate	 the	20µl	 reaction	 at	 37°C	 for	 20	minutes.	 Run	on	 gel	 or	 freeze	immediately	to	prevent	star	activity	of	T7E1.	
A	novel	PCR-based	strategy	for	screening	for	known	mutations	For	identification	of	some	mutations	the	published	RFLP	analysis	and	T7E1	assay	strategies	are	insufficient.	The	T7E1	assay	is	not	useful	for	distinguishing	between	homozygous	mutants	and	wildtype	individuals,	since	neither	of	these	animals	will	
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have	 mismatched	 base	 pairs	 following	 PCR	 and	 hybridization.	 RFLP	 analysis	requires	the	convenient	gain	or	loss	of	a	relatively	uncommon	restriction	site.	As	an	alternative	screening	tool,	I	devised	a	PCR-based	strategy	in	which	two	forward	primers	 are	 combined	with	 one	 reverse	 primer	 in	 the	 same	 PCR	 reaction.	 The	outside	 forward	primer	 (F)	binds	 to	a	 section	of	gDNA	unaltered	 in	 the	mutant	animal.	The	internal	forward	primer	(F’)	is	designed	so	that	the	3’	terminus	falls	directly	onto	the	base(s)	that	are	altered	in	the	mutant	allele	(Figure	2-2A).	In	a	heterozygous	genome,	both	primer	pairs	(F-R	and	F’-R)	are	equally	able	to	bind	and	amplify,	resulting	in	a	long	amplicon	(derived	from	F-R)	and	a	short	amplicon	(derived	from	F’-R).	In	the	mutant	genome,	F’	is	totally	unable	to	bind,	resulting	in	the	production	of	only	 the	 long	amplicon.	 In	 the	wildtype	genome,	both	primer	pairs	 are	 theoretically	 able	 to	 bind	 and	 one	 might	 initially	 anticipate	 the	production	 of	 both	 the	 long	 and	 short	 amplicon	 from	 wildtype.	 However,	 we	observe	near-exclusive	generation	of	the	short	amplicon	(derived	from	F’-R).	Since	F’	is	able	to	bind	to	both	amplicons,	but	F	only	to	the	long	amplicon,	we	find	that	F’-R	pairing	outcompetes	F-R	pairing,	resulting	in	visible	production	of	the	short	amplicon	only	from	wildtype	genomes	(Figure	2-2B,C).		
Sequences	of	genotyping	primers	are	provided	in	Table	2-3.	 	
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Figure	2-2:	A	novel	PCR-based	screening	method	for	known	mutations.	
(A)	Schematic	to	show	locations	of	primers	F,	F’	and	R	on	wildtype	(WT)	and	Mutant	
alleles.	(B)	Schematic	illustrating	predicted	PCR	readout	of	wildtype,	heterozygous	
and	mutant	genomes	using	a	combination	of	primers	F,	F’	and	R.	(C)	Genotyping	of	
offspring	 from	a	heterozygous	 incross	using	a	combination	of	primers	F,	F’	and	R.	
Derived	genotypes	wildtype	(W),	heterozygote	(H)	or	homozygous	mutant	(M)	are	
written	 below	 each	 lane.	 (D)	 Confirmation	 of	 identification	 of	 mutants	 using	
individual	primer	pairs	F-R	and	F’-R,	in	which	F’-R	is	unable	to	amplify	the	mutant	
genome.		
Generation	of	inducible	cardiac	CRISPR	mutant	line	The	tg(myl7:Cas9;U6:hspb5b-gRNA)	(EM02)	line	was	generated	as	follows.	gRNAs	against	hspb5b	were	designed	as	described	above	and	cloned	into	a	tissue	specific	expression	 system	 adapted	 from	 Ablain	 et	 al147.	 Briefly,	 complimentary	 single	stranded	DNA	oligos	with	3’	–GT	overhangs	were	ordered	from	IDT	and	hybridized	together	by	heating	a	1:1	ratio	to	95°C	and	lowering	the	temperature	down	to	4°C	over	the	course	of	20	minutes.	The	resultant	double	stranded	oligonucleotide	was	
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ligated	into	the	pDest	Tol2pA2	U6:gRNA	(a	kind	gift	from	J.	Ablain,	Zon	laboratory,	Harvard)	vector	which	had	been	digested	with	BseRI.	The	Gateway	LR	II	Clonase	enzyme	was	incubated	overnight	at	room	temperature	with	150ng	of	the	resultant	pDest	Tol2pA2	U6:hspb5b-gRNA,	100ng	pME-Cas9T2AGFP	(also	from	J.	Ablain),	100ng	p5’cmlc2	and	100ng	p3’polyA.	1-2	cell	stage	embryos	were	injected	with	25	pg	of	the	final	vector	(pEM02)	combined	with	25pg	Tol2	mRNA.	F0	embryos	were	screened	for	GFP	signal	in	the	hearts.	Successful	generation	of	mutations	in	hspb5b	were	 identified	 in	pools	of	F1	embryos	as	described	above.	Since	mutations	are	isolated	to	the	heart,	fin	clip	genotyping	was	not	performed.		
Cell	Culture	Methodologies	Formulations	of	media	described	below	are	described	in	Table	2-1.	
Culture	of	HL-1	cells.	HL-1	 cells	 (a	 kind	 gift	 from	 Dr.	 W.	 Claycomb,	 LSU)	 were	 maintained	 in	Supplemented	 Claycomb	 medium	 (Sigma)	 according	 to	 manufacturer’s	instructions.	
Coating	Plates	
• Coat	 tissue	 culture	 flasks	 with	 5µg/ml	 fibronectin	 in	 0.02%	 gelatin.	Incubate	at	37°C	for	one	hour.		
• Remove	excess	gelatin/fibronectin	by	aspiration	just	before	adding	cells.		
Thawing	Cells	
• Transfer	10ml	Wash	Media	into	15ml	tube	and	put	in	37°C	water	bath.	
• Thaw	cells	in	water	bath	at	37°C	(~2min)	
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• Transfer	cells	to	15ml	tube	containing	wash	medium	and	centrifuge	for	5	minutes	at	500g.	
• Aspirate	 wash	 medium	 and	 resuspend	 pellet	 in	 6ml	 Supplemented	Claycomb.	Add	to	3	wells	of	6-well	plate	(2ml/well).	
• Replace	 the	 medium	 with	 fresh	 Supplemented	 Claycomb	 Media	 after	 4	hours	and	every	24-48	hours	thereafter.	
Splitting	Cells	Note	that	HL-1	cells	are	happiest	at	high	confluency	(>60%).		
• Aspirate	spent	medium.		
• Rinse	with	sterile	PBS	warmed	to	37°C.	Aspirate	PBS.	
• Add	1ml	trypsin/EDTA	(Gibco)	and	incubate	at	37°C	for	~3	minutes	until	cells	are	detached.		
• Add	 1ml	 wash	 medium,	 pipette	 to	 capture	 all	 detached	 cells.	 Transfer	trypsinized	cells	to	15ml	tube	in	5ml	wash	medium.	
• Centrifuge	at	500g	for	5	minutes.	
• Aspirate	 wash	 medium	 from	 15ml	 tube	 and	 resuspend	 cells	 in	 2ml	Supplemented	Claycomb.	
• Plate	2E5	cells	per	well	of	6-well	plate	for	around	50%	confluence.	
Freezing	Cells	
• Label	cryovials.	Make	5%	DMSO	in	FBS.	Place	at	-20°C.		
• Aspirate	 spent	 media.	 Rinse	 with	 pre-warmed	 PBS	 and	 add	 1ml	Trypsin/EDTA.	
• Incubate	at	37°C	for	3	minutes	or	until	cells	dislodge.	
• Add	 1ml	 wash	 medium,	 pipette	 to	 capture	 all	 detached	 cells.	 Transfer	trypsinized	cells	to	15ml	tube	in	5ml	Wash	Medium.	
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• Centrifuge	at	500g	for	5	minutes		
• Remove	Wash	Medium	by	aspiration	and	resuspend	pellet	in	1.5ml	of	5%	DMSO	in	FBS.		
• Pipette	 1ml	 of	 freezing	 media	 into	 each	 cryovial.	 Place	 cryovials	 in	polystyrene	at	-80°C.	
• Transfer	after	12	hours	to	liquid	nitrogen.		
Culture	of	hESCs	Human	 embryonic	 stem	 cells	 (hESCs)	 containing	 inducible	 Cas9148	 (generously	provided	 by	 Dr.	 Danwei	 Huangfu,	 MSKCC)	 were	 maintained	 as	 described145	 in	hESC	 Media,	 or	 in	 mTESR	 media	 or	 TESR-E8	 media	 (both	 from	 STEMCELL	technologies)	on	Matrigel	(VWR).	
Generation	of	HSPB7	and	HSPB5	mutant	lines	The	hESC	clonal	lines	carrying	mutations	in	HSPB7	were	generated	as	described145.	Briefly,	 gRNAs	 targeting	HSPB7	and	HSPB5	 (Table	2-2)	were	designed	with	 the	CHOPCHOP	website144.	Guide	sequences	were	flanked	with	the	T7	promoter	and	the	constant	chimeric	sgRNA	sequence,	and	ordered	as	gBlocks	from	IDT	(Figure	2-3).		
Figure	2-3:	Standard	sequence	for	gRNA	gBlock.	
gBlocks	 for	 the	 synthesis	of	gRNAs	are	ordered	as	 shown.	Black	nucleotides	are	a	
spacer	 region	 to	 facilitate	T7	binding	and	achieve	 the	minimum	 sequence	 length.	
Blue	nucleotides	are	the	T7	promoter.	Green	nucleotides	denote	the	location	of	the	
gene-specific	 gRNA	 targeting	 sequence	 (20bp).	 Red	 nucleotides	 are	 the	 constant	
chimeric	sgRNA	sequence.		
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gBlocks	were	diluted	to	5ng/µl	in	RNAse-free	water	and	10-20ng	was	used	as	the	template	 for	 short	 RNA	 synthesis	 with	 the	 MegaShortScript	 T7	 kit	 (Thermo	Fisher).	Resultant	sgRNA	was	purified	with	the	MegaClear	kit	(Thermo	Fisher)	or	diluted	to	150µl	in	0.5M	Ammonium	Acetate,	10mM	EDTA	and	then	precipitated	with	2	volumes	ethanol	at	-20°C	for	60	minutes.	sgRNA	was	eluted	or	resuspended	in	RNAse-free	water.	
• Day	 0:	 When	 hESCs	 are	 60%	 confluent,	 pretreat	 cells	 with	 doxycycline	(2ug/ml)	for	24	hours	before	transfection.		
• Day	 1:	 Dissociate	 cells	 with	 TrypLE	 and	 replate	 with	 0.2,	 0.4	 and	 1E6	cells/ml	in	hESC	Media	with	5μM	Rock	inhibitor	and	2μg/ml	doxycycline.	
• Plate	0.5ml/well	into	a	24-well	plate.	Plate	in	duplicate	for	transfection	plus	one	 well	 for	 each	 dilution	 to	 serve	 as	 a	 non-transfected	 control	 for	 T7	assays.	
• For	each	well	prepare:	
o Mix	1:	25µl	Opti-MEM	+	0.5µg	sgRNA	(160ng	total).		
o Mix	2:	25µl	Opti-MEM	+	1.5µl	RNAiMAX	
• Combine	Mix	1	and	Mix	2,	incubate	for	5	minutes	at	room	temperature,	then	add	50µl/well	dropwise	to	dissociated	hPSCs.	
• Day	 2:	 Refresh	 hPSC	 medium	 with	 2µg/ml	 doxycycline	 and	 repeat	transfection	with	sgRNA	as	above.		
• Day	3:	Aspirate	media	and	replace	with	Supplemented	DMEM/F12	without	doxycycline.	
• Day	4:	Take	one	well	from	each	pair,	and	extract	gDNA	from	transfected	and	nontransfected	 control	 cells	 with	 DNeasy	 columns.	 Adjust	 final	concentration	to	50ng/µl.	
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Mutation	efficiency	was	assessed	by	PCR	across	the	CRISPR	target	locus	followed	by	 analysis	 with	 the	 T7E1	 assay,	 as	 described	 above.	 Indel	 percentage	 was	determined	by	the	formula	100•(1-(1-(b+c)/	(a+b+c))1/2)	where	a	is	the	intensity	of	 the	undigested	PCR	product	 and	b	 and	c	 are	 the	 intensities	of	 each	 cleavage	product.	Transfected	cells	with	an	 indel	percentage	>20%	were	replated	3	days	after	final	gRNA	transfection.		
Isolation	of	clonal	hESC	lines.	
• The	 day	 before	 replating,	 seed	 irradiated	 mouse	 embryonic	 fibroblasts	(MEFs)	in	Feeder	Media	into	a	10cm	dish	precoated	with	gelatin.	
• Dissociate	to	single	cells	with	TrypLE	Express	followed	by	passing	through	a	40µm	cell	strainer.	
• Plate	2000	cells	into	10cm	dish	on	MEFs	in	hESC	Mediawith	5µM	Rocki.	
• Change	media	 3	 days	 after	 plating	 and	 remove	Rocki.	 Change	 every	 2-3	days.	
• 10	days	after	replating	single	cells,	manually	pick	around	48	colonies	and	pipette	into	an	uncoated	96	well	plate	in	100µl	hESC	Media	with	5µM	Rocki.	
• Clone	is	mechanically	disaggregated	by	pipetting	up	and	down	five	times	and	 immediately	 re-plated:	 twice	 50µl	 into	 duplicate	wells	 of	 2	 96	well	plates,	on	MEFs	in	hESC	Media	with	5µM	Rocki.	3	days	after	replating	into	duplicate	96	well	plates,	gDNA	was	extracted:		
• To	each	well	of	one	96	well	plate	add	50µl	gDNA	extraction	buffer	(10mM	Tris-HCl	pH8.4,	50mM	KCl,	1.5mM	MgCl2,	0.3%	Tween-20,	0.3%	NP-40).	
• Heat	at	95°C	for	15	minutes	then	cool	to	55°C	
• Add	3µl	Proteinase	K	(20mg/ml	stock,	Roche),	incubate	at	55°C	for	1	hour	
• Heat	at	95°C	for	20	minutes	
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• Use	2µl	of	gDNA	in	PCR	reaction	and	store	the	remainder	at	4°C	Clones	carrying	mutant	alleles	were	 identified	by	PCR	across	 the	CRISPR	target	locus	followed	by	TOPO	cloning	and	Sanger	sequencing	of	5	clones.		
Differentiation	of	hESC-CMs	The	following	protocol	(Figure	2-4)	was	modified	from	the	method	described	by	Lian	et	al.149,	and	used	to	generate	beating	cardiomyocytes	from	hESC	lines.		
Figure	2-4:	Protocol	for	differentiation	of	cardiomyocytes	from	hESCs.		
Schematic	 of	 protocol	 for	 derivation	 of	 cardiomyocytes.	 Alterations	 from	 the	
referenced	 method149	 are	 number	 of	 hESCs	 initially	 plated	 and	 length	 and	
concentration	 of	 CHIR99021	 treatment.	 DMEM/F12	 media	 is	 supplemented	 (see	
Table	2-1)	and	we	routinely	include	1X	Pen/Strep	in	RPMI	1640	to	prevent	growth	of	
contaminants.		 	
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Dissociation	of	hESC-CMs	for	replating	or	flow	cytometry.	At	day	10,	cells	were	processed	for	further	analysis	as	described150.		
• Wash	well	3X	with	sterile	PBS	to	remove	extracellular	calcium	and	inhibit	beating.		
• Add	0.5ml/well	TrypLE	Express	and	incubate	for	5	minutes	at	37°C.	Pipette	up	and	down	to	disaggregate	cells	and	repeat	incubation	and	pipetting.		
• 	Transfer	 cells	 to	 a	 15ml	 Falcon	 tube	 in	 Cardiomyocyte	 Media	 and	centrifuge	at	400g	for	5	minutes.		
• Resuspend	 in	 2ml	 Cardiomyocyte	 Media	 and	 pass	 through	 100µm	 cell	strainer	to	ensure	single	cells.		
• Dilute	to	1e6	cells/ml.	To	replate	for	IF	staining,	plate	5e5	cells/well	onto	4	well	microscope	slide	on	Matrigel	or	5µg/ml	fibronectin	in	0.02%	gelatin.	Alternatively,	process	single	cells	for	flow	cytometry.		
Flow	cytometry	of	cardiomyocytes.		Day	10	or	higher	hESC-CMs	were	dissociated	into	single	cells	as	described	above.	
• Transfer	 1.5e6	 cells	 for	 each	 required	 sample	 at	 400g	 for	 5	 minutes.	Resuspend	 in	 100µl	 feeder	 media.	 Note	 that	 additional	 samples	 are	required	for	unstained	and	single	stained	controls.		
• Add	100µl	4%	PFA	to	give	a	final	concentration	of	2%	PFA.	Incubate	at	room	temperature	for	30	minutes.	
• Transfer	cells	to	a	U-bottom	96	well	plate.	Spin	down	at	950g	for	2	minutes.	Resuspend	in	200µl	FACs	buffer	(10%	FBS	in	PBS).	Incubate	for	5	minutes	at	room	temperature.	Repeat	this	step	once.		
• Spin	down	at	950g	for	2	minutes.	Resuspend	in	200µl	FACs	buffer	+	0.5%	Saponin	with	desired	primary	antibodies.	Incubate	for	1	hour	at	room	temp.	
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o Mouse	anti-cardiac	troponin	(13-11,	1:500,	Thermo)	
o Rabbit	anti-HSPB7	(ab150390,	1:250,	Abcam)	
• Spin	down	at	950g	for	2	minutes.	Resuspend	in	200µl	FACs	buffer.	Incubate	for	5	minutes	at	room	temperature.	Repeat	this	step	once.	
• Spin	down	at	950g	for	2	minutes.	Resuspend	in	200µl	FACs	buffer	+	0.5%	Saponin	with	desired	secondary	antibodies.	 Incubate	 for	1	hour	at	 room	temp.	
o AlexaFluor	647	goat	anti-mouse	IgG	(Thermo)	at	1:400		
o AlexaFluor	488	goat	anti-rabbit	IgG	(Thermo)	at	1:400	
• Spin	down	at	950g	for	2	minutes.	Resuspend	in	200µl	FACs	buffer.	Incubate	for	5	minutes	at	room	temperature.	Repeat	this	step	once.	
• Resuspend	 in	 200µl	 FACs	 buffer	 and	 pipette	 through	 mesh-top	 flow	cytometry	tubes.	Add	800µl	additional	FACs	buffer/tube.	
• Run	samples	on	Accuri	CFlow.			 	
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Table	2-1:	Cell	Culture	Media	Composition	
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Table	2-1:	Cell	Culture	Media	Composition	continued	
*Add	FGFb	to	aliquots	of	hESC	media	(2µl/ml)	as	required.		 	
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Microscopy	and	Imaging	
Anatomical	analysis	of	adult	zebrafish	Adult	male	zebrafish	were	submitted	for	histopathological	processing	and	blinded	analysis	by	the	pathology	core	at	Memorial	Sloan	Kettering	Cancer	Center.	The	fish	was	 fixed	 in	 Bouin’s	 solution	 for	 24	 hours,	 cut	 parasagitally,	 processed	 via	automated	 tissue	 processor,	 embedded	 in	 paraffin,	 and	 two	 4	micron	 sections	were	taken	100	microns	apart.	Sections	were	then	stained	with	hematoxylin	and	eosin	and	Masson’s	trichrome	using	standard	methods.		
Adult	 zebrafish	 hearts	 were	 dissected	 as	 described151	 and	 fixed	 in	 2.5%	glutaraldehyde,	 4%	 paraformaldehyde,	 0.02%	 picric	 acid	 (all	 Sigma).	 Samples	were	 submitted	 to	 the	 imaging	 core	 at	Weill	 Cornell	Medicine.	 Following	 post-fixation	processing,	as	described152,	samples	were	contrasted	with	lead	citrate	and	viewed	 on	 a	 JEM	 1400	 electron	 microscope	 	 (JEOL,	 USA,	 Inc.	 Peabody,	 MA)	operated	at	100kV.	Digital	images	were	captured	on	a	Veleta	2K	x	2K	CCD	camera	(Olympus-SIS,	Germany).	
Immunofluorescence	techniques	Immunostaining	 on	 cultured	 cells	 was	 performed	 after	 fixing	 cells	 with	 4%	paraformaldehyde	 (VWR)	 and	 permeabilizing	 with	 0.1%	 Triton	 X-100	 (MP	Biomedicals)	at	room	temperature	or	50	µg/ml	digitonin	(Sigma)	in	PBS	at	37°C.	Digitonin	permeabilization	was	followed	by	quenching	with	40mM	NH4Cl	(Sigma).	Cells	were	blocked	with	2%	IgG-free	bovine	serum	albumin	(Jackson),	5%	lamb	serum	(Invitrogen)	and	incubated	overnight	at	4°C	with	the	appropriate	primary	antibodies:	anti-cardiac	 troponin	T	 (13-11,	1:500,	Thermo	Fischer);	anti-HSPB7	(ab150390,	 1:250,	 Abcam);	 anti-LC3B	 (ab51520,	 1:250,	 Abcam);	 anti-FLNC	
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(sc48496,	 1:100,	 Santa	 Cruz).	 Cells	 were	 counterstained	 with	 DAPI	 (1:10000,	Invitrogen)	and	imaged	on	an	Axio	Observer.Z1,	or	LSM	510/880	Confocal	(Zeiss).		
Quantification	of	puncta	in	immunofluorescence	images	Number	 and	 size	 of	 puncta	 were	 quantified	 as	 described153.	 For	 easier	visualization,	the	process	is	summarized	in	Figure	2-5.		Some	modifications	were	made	to	the	parameters	used	for	identification	of	puncta:	
• Image	 was	 converted	 to	 RGB	 and	 despeckled	 in	 FIJI	 prior	 to	 further	processing.	
• Threshold	was	set	to	0-150	to	filter	out	additional	background.	
• An	individual	cell	was	outlined	with	a	freeform	shape	in	FIJI,	and	the	area	of	the	cell	was	measured	for	normalization	of	puncta.		
• The	selected	cell	was	processed	using	a	published	macro	for	the	counting	of	puncta	in	FIJI153.	
• Required	 particle	 size	was	 set	 to	 1-300µm2	 to	 filter	 out	 any	 large	 auto-fluorescent	areas.		
• Resultant	data	 (individual	 particle	 sizes,	 shapes	 and	overall	 counts)	was	exported	 into	 Microsoft	 Excel.	 Average	 particle	 number/10µm2	 and	average	 particle	 size	were	 calculated	 for	 each	 cell.	 An	 average	 of	 3	 cells	were	 taken	per	 image	 from	an	average	of	7	 images	 for	each	genotype	of	hESC-CM	examined.			 	
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Figure	2-5:	Quantification	of	LC3-B	or	FLNC	puncta.	
Schematic	detailing	the	stages	of	puncta	quantification	in	the	method	adapted	from	
Dagda	et	al.153		
Molecular	Biology	
Isolation	of	gDNA		Methods	 for	extraction	of	gDNA	from	embryonic	and	adult	zebrafish	 is	detailed	above.	gDNA	from	cultured	cells	was	isolated	with	DNEasy	Kit	(Qiagen).		
Isolation	of	RNA	and	generation	of	cDNA	RNA	was	isolated	with	Trizol	Reagent	(Thermo)	according	to	the	manufacturer’s	instructions.	cDNA	was	generated	using	0.5µg	RNA	and	the	SuperScript	VILO	Kit	(Thermo	Fisher),	according	to	manufacturer’s	instructions	except	that	incubation	at	42°C	was	increased	from	60	to	120	minutes.	
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Quantitative	RT-PCR	(qPCR)	analysis	of	gene	expression	in	zebrafish	Zebrafish	embryos	or	adult	tissues	were	homogenized	in	Trizol	(Invitrogen)	and	RNA	was	extracted	according	to	manufacturer’s	instructions.		The	qPCR	analysis	was	performed	on	a	LightCycler	480	II	(Roche)	using	LightCycler	480	Sybr	Green	master	mix	(Roche).	Primer	sequences	are	provided	 in	Table	2-4.	Relative	gene	expression	was	determined	as	described154.		
Immunoprecipitation	of	HSPB7		HL-1	cells	were	lysed	on	ice	in	a	modified	RIPA	buffer	(20mM	Tris	pH7.5,	150mM	NaCl,	 1%	 NP-40)	 with	 cOmplete	 mini	 protease	 inhibitor	 (Roche).	 Debris	 was	cleared	from	lysed	cells	by	centrifugation	(21,000g,	10	minutes,	4°C)	and	protein	concentration	was	calculated	with	QuickStart	Bradford	Protein	Assay	kit	(BioRad).	Lysates	were	precleared	by	incubation	with	1:10	dilution	of	Protein	G	Dynabeads	(Invitrogen,	30	minutes,	4°C)	and	then	incubated	overnight	with	1:100	anti-HSPB7	(ab150390,	Abcam)	or	 control	 rabbit	 IgG	whole	molecule	 (Jackson).	Complexes	were	precipitated	with	1:10	Protein	G	Dynabeads	(120	minutes,	4°C)	and	eluted	into	 Western	 buffer	 (65%	 modified	 RIPA,	 25%	 NuPAGE	 Sample	 Buffer,	 10%	NuPAGE	Reducing	Agent	(both	Invitrogen)	by	incubation	at	95°C	for	10	minutes.	Residual	Protein	G	Dynabeads	were	removed	with	DynaMag	2.0	(Thermo).	
Western	Blotting	Samples	 for	western	blotting	were	 initially	 lysed	 as	described	 above.	Resultant	lysates	were	diluted	with	25%	NuPAGE	Sample	Buffer	and	10%	NuPAGE	Reducing	Agent	and	incubated	at	95°C	for	10	minutes.	20µl	per	sample	was	loaded	onto	a	10%,	12%	or	a	4-12%	Bis-Tris	Acetate	Gel‡‡	(Thermo)	and	run	in	800ml	1X	MOPS																																																									
‡‡	Gel	density	 is	 altered	according	 to	 the	 size	of	 the	protein	one	 is	blotting	 for.	10%	gel	 for	30-150kDa,	12%	gel	for	<30kDa,	4-12%	gel	for	>150kDa.		
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buffer	with	500µl	NuPAGE	Antioxidant	(100V	for	1-2	hours).	For	transfer	of	large	proteins,	 post-elecrophoresis	 gels	 were	 incubated	 for	 30	 mintues	 in	 an	Equilibration	buffer	(10%	Methanol,	2X	MOPS	and	1:1000	NuPAGE	Anti-oxidant).	Westerns	were	transferred	using	the	iBlot	Dry	Blotting	System	(P3,	5-8	minutes§§).	Following	transfer	membranes	were	processed	as	follows:	
• Rinse	with	PBST	
• Block	with	3%	IgG-free	BSA	in	PBST	for	30	minutes	at	room	temp,	rocking		
• Wash	once	in	TBST	
• Cut	off	irrelevant	areas	of	gel	and	discard	
• Incubate	overnight	in	heat-sealed	bag	at	4°C,	rocking	in	primary	antibody	in	3%	IgG-free	BSA	in	PBST		
o Mouse	anti-cardiac	troponin	(13-11,	1:500,	Thermo)	
o Rabbit	anti-HSPB7	(ab150390,	1:250,	Abcam)	for	mouse/human		
o Rabbit	anti-HSPB7	(15700-1-AP,	1:200,	ProteinTech)	for	zebrafish		
o Mouse	anti-b-Actin	(A1978,	1:2000-1:3000,	Sigma)	
o Rabbit	anti-cofilin-1	(ab11062,	1:500,	AbCam)	
o Rabbit	anti-GAPDH	(ab9484,	1:5000,	AbCam)	
o Mouse	anti-FLNC	(HPA006135,	1:200,	Sigma)		
• Wash	3X	5	minutes	in	TBST	
• Apply	secondary	1:2000	 in	5%	milk	 in	TBST***	 for	1	hour	at	 room	temp,	rocking.		
o Goat	anti-mouse	IgG	HRP	conjugate	(170-6516,	1:2000,	BioRad)	
o Goat	anti-rabbit	IgG	HRP	conjugate	(170-6515,	1:2000,	BioRad)	
• Wash	3X	5	minutes	in	TBST	
• Incubate	protein	side	up	5	min	in	plastic	box	with	~1ml	Pierce	West	pico	pipetted	directly	onto	membrane.		
																																																								
§§	Transfer	timing	was	altered	according	to	protein	size.	7	minutes	for	30-150kDa,	5	minutes	for	<30kDa	and	8	minutes	for	>150kDa.	***	Change	from	milk	to	3%	IgG-free	BSA	in	TBST	for	anti-goat	secondaries.		
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• Image	 with	 c-DiGit	 Western	 Blot	 Scanner	 (Licor)	 for	 12	 minutes	 (high	sensitivity).	Densitometry	analysis	of	Western	blots	was	performed	with	ImageJ	software.		
In	gel	trypsinolysis	and	mass	spectrometry.	Samples	for	in	gel	trypsinolysis	were	initially	processed	as	described	for	Western	Blot.	Following	electrophoresis,	gels	were	incubated	with	1X	Coomassie	Brilliant	Blue	 (Thermo)	 for	 15	minutes,	 and	 then	 rinsed	with	 distilled	water	 to	 remove	background	staining.	Visible	bands	of	 interest	were	excised	with	a	clean	scalpel	and	 processed	 with	 In-Gel	 Tryptic	 Digestion	 Kit	 (Sigma)	 according	 to	manufacturer’s	 instructions.	Reduction	 and	 alkylation	 steps	were	performed	as	recommended	to	optimize	sequence	recovery.	
Peptide	samples	were	eluted	with	1%	TFA	and	subsequently	vacuum-centrifuged	at	60°C	to	near-dryness	in	a	SpeedVac.	Remaining	sample	was	diluted	to	30µl	with	0.1%	TFA	for	analysis	by	liquid	chromatography-tandem	mass	spectrometry.		
Mass	 spectrometry	 and	 subsequent	 peptide	 identification	 was	 performed	 as	described155.	 Briefly,	 peptides	 were	 analyzed	 using	 a	 6520	 accurate-mass	quadrupole-time	of	flight	(Q-TOF)	mass	spectrometer	coupled	to	a	chip	cube	with	an	on-chip	C18	column	(Agilent	Technologies,	Santa	Clara,	CA).	The	mobile	phases	were	 0.1%	 formic	 acid	 in	 water	 (solvent	 A)	 and	 0.1%	 formic	 acid	 in	 90%	acetonitrile	(solvent	B).	Peptide	elution	utilized	solvent	gradient	3–40%	solvent	B	for	 52	min.	 Non-eluting	 peptides	 were	 then	 displaced	 by	 treatment	 with	 90%	solvent	B	for	2–5	min.		
Mass	 spectra	were	 acquired	 in	 automated	 data-dependent	 acquisition	mode	 at	0.5s	intervals,	and	MS/MS	scans	were	performed	on	the	four	most	intense	ions	for	
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each	 MS	 scan.	 Peptides	 were	 identified	 using	 Spectrum	 Mill	 software	 version	A.03.03	(Agilent).	Peptide	files	were	searched	against	a	regularly	updated	Swiss-Prot	database,	with	a	peak	intensity	threshold	of	50%,	precursor	mass	tolerance	of	 20	 ppm	 and	 a	 product	 mass	 tolerance	 of	 50	 ppm.	 In	 each	 search,	 a	 fixed	modification	 was	 set	 for	 dimethylated	 N-terminal	 residues	 and	 variable	modifications	for	carbamidomethylated	Cys	residues,	oxidized	Met	residues	and	dimethylated	Lys	residues.	For	all	searches,	peptides	with	a	Spectrum	Mill	score	of	9	or	higher	were	considered	valid.	
Filter	Trap	Assay	The	filter	trap	assay	was	performed	as	described127.	In	brief,	cells	were	counted	and	 a	 fixed	 number	 were	 lysed	 in	 200µl	 FTA	 buffer	 (10mM	 Tris-HCl,	 pH8.0,	150mM	NaCl)	containing	2%	SDS.	Samples	were	boiled	for	10	minutes	and	loaded	onto	a	pre-washed	(FTA,	0.1%	SDS)	0.2µm	cellulose	acetate	filter	(GE	Healthcare)	with	supporting	filter	paper	(Bio-Rad)	in	Bio-Dot	96	well	 filtration	system	(Bio-Rad).	Suction	was	applied	to	filtrate	the	samples.	Following	loading,	membranes	were	processed	as	described	above	in	Western	Blotting.	
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Table	2-2:	CRISPR	and	TALEN	sequences.	
CRISPR Sequences 
Gene Species gRNA Targeted Sequence (PAM) 
Hspb5b Zebrafish 5'- ACGTGATCTCCTCATTGTAC(TCC)-3' 
HSPB7 Human 5'-(CCC)ACTCGGAGCCCCTGGCCTTC-3' 
Gata5 Zebrafish 5'- GGGCGCGAGTGTGTGAACTG(CGG)-3' 
        
TALEN sequences 
Gene Species Targeted Sequence RVD sequences 
Hspb7 Zebrafish 5'-CCTCCTCATCTTCATCCTCT-3' 
HD HD NG HD HD NG HD NI NG HD 
NG NG HD NI NG HD HD NG HD NG  
    5'-TACATGGAGAAGAGCCGAGG-3' 
HD HD NG HD NN NN HD NG HD NG 
NG HD NG HD HD NI NG NN NG NI  
Gata4 Zebrafish 5'-GCGTCCAGGCGGGTGG-3' 
NH HD NH NG HD HD NI NH NH HD 
NH NH NH NG NH NH 
    5'-GTCAGACTACCACAAC-3' 
NH NG NG NH NG NH NH NG NI NH 
NG HD NG NH NI HD 
Gata6 Zebrafish 5'-CTTCCTCCCGGCGGATCGGA-3' 
HD NG NG HD HD NG HD HD HD NH 
NH HD NH NH NI NG HD NH NH 
    5'-TGTCAGACGAGCACCACAAC-3' 
NH NG NG NH NG NH NH NG NH HD 
NG HD NH NG HD NG NH NI HD 	
	 	69	
Table	2-3:	Genotyping	primers	
Genotyping 
TE # Species Gene Sequence Use Details 
5669 Human HSPB7 AAGATTTCCAGCCCCCTCT 
HSPB7 
CRISPR 1-3 
5670 Human HSPB7 ACCTGTTTTCATGGCCACAT 
HSPB7 
CRISPR 1-3 
5671 Human HSPB7 GTGGGCTGTAGGAATGAGGA 
HSPB7 
CRISPR 4 
5672 Human HSPB7 CCCTGGAAGAAAGGATCTGG 
HSPB7 
CRISPR 4 
5675 Human HSPB7 CAGGGACAGTCGGCCTTAT 
HSPB7 
CRISPR 1-3 
5676 Human HSPB7 ACCTGTTTTCATGGCCACAT 
HSPB7 
CRISPR 1-3 
5785 Human HSPB7 CTCACAGCAGCCCATCCC 
HSPB7 
CRISPR 4 
5786 Human HSPB7 CTTCTCAGCCCGCACCTC 
HSPB7 
CRISPR 4 
5789 Human HSPB7 GTGGCCACATCTGTCTTGGT 
HSPB7 
CRISPR 1-3 
5012 Zebrafish hspb7 GCCTCATGCAGCTGACATATT Hspb7 TALEN 
5013 Zebrafish hspb7 CTAATGAGCGCGAGCAATTC Hspb7 TALEN 
5168 Zebrafish hspb7 TGAGAAAGCTGCTGAGTGGA Hspb7 TALEN 
5169 Zebrafish hspb7 ATCCAAAGTCGTCAGCGAAG Hspb7 TALEN 
5673 Zebrafish gata4 TTTTGCATGCCTATTCCTTTG Gata4 TALEN 
5674 Zebrafish gata4 GGGTTTGGTTTTGCTGATGT Gata4 TALEN 
5734 Zebrafish gata6 CCGCCAGTAATTGATCACAA Gata6 TALEN 
5735 Zebrafish gata6 GATTGTCCTTCGGCTTGGTA Gata6 TALEN 
5885 Zebrafish hspb5b TGCAGTGAAAGAGGCAAATG 
Hspb5b 
CRISPR 12 
5886 Zebrafish hspb5b ACGCGTGACTCCTCAACTTT 
Hspb5b 
CRISPR 12 
5887 Zebrafish hspb5b TGAAAACCATGCTGCCTGTA 
Hspb5b 
CRISPR 12 
5888 Zebrafish hspb5b CGTCCTGTGTGTAAAAAGAAACA 
Hspb5b 
CRISPR 12 
5990 Zebrafish gata4 TCACTGCTCTCTCCCCCTTT Gata4 TALEN 
5991 Zebrafish gata4 GTTGCAGACTGGCTCTCCTT Gata4 TALEN 
5992 Zebrafish gata6 TGCATGCCTGGACACTTTTT Gata6 TALEN 
5993 Zebrafish gata6 CTCTCCCTCCGCGTTTCTG Gata6 TALEN 
5994 Zebrafish gata6 GGACTGTCATGCGCAAACT 
WC7, 
negative 
5995 Zebrafish gata4 GGTGGGTTTATCCTGCACA 
WC5, WC6, 
F, negative 
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Table	2-3:	Genotyping	primers	continued.	
 
5996 Zebrafish gata4 GTCTGACAGTTTGTAAACCCAGT 
WC6 R, 
positive 
5997 Zebrafish gata4 GGACCCCAGATTAATATGTGG 
indel, F, 
positive 
6074 Zebrafish gata5 CAAGTCGCACCTTGAAAACA 
Gata5 
CRISPR 
6075 Zebrafish gata5 TGGCTAGGTTTAAACAGGACAA 
Gata5 
CRISPR 
6076 Zebrafish gata5 TGCTTCATTGACTTTGTTGTCA 
Gata5 
CRISPR 
6077 Zebrafish gata5 ACCATGCAGCCTCTCAAAAT 
Gata5 
CRISPR 
6311 Zebrafish gata4 TTGCAGTGATTATTTATGCACATT Gata4 TALEN 
6312 Zebrafish gata4 CAGCAGACAGGACACTCACC Gata4 TALEN 
6313 Zebrafish gata6 AAATATTTGTGGAATTGATGATCC Gata6 TALEN 
6314 Zebrafish gata6 TGTTCAAAGCAAAGGGAGAG Gata6 TALEN 
6346 Zebrafish gata5 CGCGAGTGTGTGAACTGC 
WC8, 10, 
11, F, 
negative 
6347 Zebrafish gata5 GAAGGGCGCGAGTGTGT 
WC9, F, 
negative 	 	
	 	71	
Table	2-4:	qPCR	Primers	
     
qPCR  
TE # Species Gene Sequence Use Details 
4522 General eGFP GCAGAAGAACGGCATCAAGGT Forward 
4523 General eGFP ACGAACTCCAGCAGGACCATG Reverse 
5642 Human HSPB7 CAGGCAACATCAAGACCCTA Forward 
5643 Human HSPB7 CTTGTGAGCGAAGGTGTTCA Reverse 
5644 Human FLNC GTGTCCTATCTGCCGACTGC Forward 
5645 Human FLNC CGGTGATCTTCAGTGACACG Reverse 
5646 Human FLNC CACATCAAGCTCGTGTCCAT Forward 
5647 Human FLNC CTGCTTGGGCGTCTGTTT Reverse 
6121 Human HSPB5 CTTTGACCAGTTCTTCGGAG Forward 
6122 Human HSPB5 CCTCAATCACATCTCCCAAC Reverse 
6123 Human HSPB8 CAGAGGAGTTGATGGTGAAGAC Forward 
6124 Human HSPB8 GTTGAGTAAGGAGGGACCTG Reverse 
6125 Human FLNC ACAACCATGACTACTCCTACAC Forward 
6126 Human FLNC GTTCACAGAGAATGCTTGTTCC Reverse 
6127 Human BAG3 GCCTGTGTACCACAAGATCC Forward 
6128 Human BAG3 AGTTTCTCGATGGGTCATGG Reverse 
6129 Human CTGF TTGGCCCAGACCCAACTA Forward 
6130 Human CTGF GCAGGAGGCGTTGTCATT Reverse 
6131 Human XBP1t CGCTGAGGAGGAAACTGAA Forward 
6132 Human XBP1t TGTTCCAGCTCACTCATTCG Reverse 
6133 Human XBP1s CTGAGTCCGCAGCAGGTG Forward 
6134 Human XBP1s ACTGGGTCCAAGTTGTCCAG Reverse 
6135 Human CHOP GCACCTCCCAGAGCCCTCACTCTCC3 Forward 
6136 Human CHOP GTCTACTCCAAGCCTTCCCCCTGCG3 Reverse 
6137 Human GRP78 ATCATCAACGAGCCTACGG Forward 
6138 Human GRP78 CGCTGGTCAAAGTCTTCTCC Reverse 
6139 Human LC3A TCCCGGACCATGTCAACAT Forward 
6140 Human LC3A ACCATGCTGTGCTGGTTCAC Reverse 
6141 Human LC3B ACCATGCCGTCGGAGAAG Forward 
6142 Human LC3B ATCGTTCTATTATCACCGGGATTTT Reverse 
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Table	2-4:	qPCR	Primers	continued 
6143 Human HSF1 CCGGCGGGAGCATAGACGAGAGG Forward 
6144 Human HSF1 GACGGAGGCGGGGGCAGGTTCACT Reverse 
6304 Human HSPB5 ATTGGGTGTGGACAGAAAGC Forward 
6305 Human HSPB5 AGGCAGGGTAGGAAAGGAAA Reverse 
6306 Human HSPB5 CTGACCCCTCACACTCACCT Forward 
6307 Human HSPB5 AGAAGTTAGGGGACGGAGGA Reverse 
4664 Mouse HSPB7 GCCAAGGAAACATCAAGACC Forward 
4665 Mouse HSPB7 TTCATGACTGTGCCATCAGC Reverse 
5529 Mouse FLNC GGAGTCCTTTCCCTGTCCAT Forward 
5530 Mouse FLNC GACCTTTGACGGTGACCTTG Reverse 
5531 Mouse FLNC CCCATGGCTCCTGGTAACTA Forward 
5532 Mouse FLNC GGATGTTTCGTGAAGGCTGT Reverse 
5533 Mouse YAP TTCAATGCCGTCATGAACC Forward 
5534 Mouse YAP GAGTGAGCTCGAACATGCTG Reverse 
5535 Mouse TAZ GCAGACATCTGCTTCACCAA Forward 
5536 Mouse TAZ TTCCCTTCTGGGAAGATGTG Reverse 
5537 Mouse FLNA GAAAGCCAGTGAAGCACACA Forward 
5538 Mouse FLNA GGCCAGCTTCAGTACAATCC Reverse 
5539 Mouse BAG3 GCTGGGAGATCAAAATCGAC Forward 
5540 Mouse BAG3 TTGGCTGAAGATGCAGTGTC Reverse 
1586 Zebrafish gata5 TCAACAGTGTCTGGCGCTAC Forward 
1587 Zebrafish gata5 GCCTGCATATGGAGAAGCTG Reverse 
1588 Zebrafish gata6 ATGGACTCAGCCGACCATTA Forward 
1589 Zebrafish gata6 ACAGTGTTGTGGTGCTCGTC  Reverse 
1849 Zebrafish b-actin GACAACGGCTCCGGTATG Forward 
1850 Zebrafish b-actin CATGCCAACCATCACTCC Reverse 
2357 Zebrafish 18S TCGCTAGTTGGCATCGTTTATG Forward 
2358 Zebrafish 18S CGGAGGTTCGAAGACGATCA Reverse 
2361 Zebrafish gata4 AACCACCTCCTATAACTCAAGCA Forward 
2362 Zebrafish gata4 GTTAACGGAGGACTGGTGGA Reverse 
2666 Zebrafish eomesa CATCGCTGTAACGGCTTACC Forward 
2667 Zebrafish eomesa TCGCTCTCTGGAGCTGTGTA Reverse 
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Table	2-4:	qPCR	Primers	continued. 
2668 Zebrafish eomesb CGCAGGTGTATCTCTGCAAC Forward 
2669 Zebrafish eomesb CGTCATGTTGAAGCTGAGGA Reverse 
4453 Zebrafish hspb7 GATCTTTCATGTGTCCGAAGG Forward 
4454 Zebrafish hspb7 GATTGTTTGAGGTGGTGACG Reverse 
4526 Zebrafish hspb12 TAACCTGGAGACGGACATCAG Forward 
4527 Zebrafish hspb12 TCCGGGGATGTAGTACTTCTGG Reverse 
4754 Zebrafish bax GAGCTGCACTTCTCAACAACTTT Forward 
4755 Zebrafish bax CTGGTTGAAATAGCCTTGATGAC Reverse 
4756 Zebrafish hsp70 CATCGACGCCAACGGG Forward 
4757 Zebrafish hsp70 CCAGGGAGTTTTTAGCAGAAATCTT Reverse 
5541 Zebrafish flnca CCAGCTCTATGCCAACATCA Forward 
5542 Zebrafish flnca CTAGGACCGTGGACACCAAC Reverse 
5543 Zebrafish flncb GGCCCTACAAAGTGGACATC Forward 
5544 Zebrafish flncb CTTCAAACCAGGCCCATAAG Reverse 
5545 Zebrafish titin AATTTCGGAGGATGATGTGC Forward 
5546 Zebrafish titin GGAATCGTTTTGTTCCCTCA Reverse 
5547 Zebrafish titin CCAACAGTCTCCCTCTCCTG Forward 
5548 Zebrafish titin TCATCACAGGGGACTTGACA Reverse 
5549 Zebrafish yap GGTTGAGAAAGCTGCCAGAC Forward 
5550 Zebrafish yap AGTGCACCAGGAGAAACTGC Reverse 
5551 Zebrafish taz TTTCACTCCAGTTTCTTCAGCA Forward 
5552 Zebrafish taz CCTTGATTCAGCCTTTCCAA Reverse 
5626 Zebrafish map1lc3a CGAGTCGACCGACAATTTAGC Forward 
5627 Zebrafish map1lc3a TCCTTGCAACGATCAGCGAA Reverse 
5628 Zebrafish map1lc3b AATGTGACGATTGGACACGAGT Forward 
5629 Zebrafish map1lc3b AGTACAACAGCTCACGGTTATGC Reverse 
5691 Zebrafish hspb1 ATGAACACGGCTTCATTTCC Forward 
5692 Zebrafish hspb1 GCGGAGCTTCAACAGTCAGG Reverse 
5693 Zebrafish hspb8 ACCGACCAAAGTGAGAGGTG Forward 
5694 Zebrafish hspb8 GCATTTACGGAGCTCTGAGG Reverse 
5695 Zebrafish hspb11 AGAGCTCGCCGTTAAACAAG Forward 
5696 Zebrafish hspb11 AATAGGATCCCTTCCCATCG Reverse 
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Table	2-4:	qPCR	Primers	continued 
5697 Zebrafish hspb5a CCCAGGCTTCTTCCCTTATC Forward 
5698 Zebrafish hspb5a GTGCTTCACATCCAGGTTGA Reverse 
5699 Zebrafish hspb5b CCTACTGACGGCCAAATGTT Forward 
5700 Zebrafish hspb5b GGCATCAGCAGCAGACAATA Reverse 
5710 Zebrafish ctgfa GTGTGATTGCTCTGCTGTTCC Forward 
5711 Zebrafish ctgfa GGTGAACACTGGGGCGGC Reverse 
5712 Zebrafish ctgfb CTGGAACAGCATTCACCAGAG Forward 
5713 Zebrafish ctgfb CTCGTCTGGGCAATCACAGG Reverse 
5854 Zebrafish bip AAGAGGCCGAAGAGAAGGAC Forward 
5855 Zebrafish bip AGCAGCAGAGCCTCGAAATA Reverse 
5856 Zebrafish ddit3 AAGGAAAGTGCAGGAGCTGA Forward 
5857 Zebrafish ddit3 TCACGCTCTCCACAAGAAGA Reverse 
5858 Zebrafish dnajc3 TCCCATGGATCCTGAGAGTC Forward 
5859 Zebrafish dnajc3 CTCCTGTGTGTGAGGGGTCT Reverse 
5860 Zebrafish edem1 ATCCAAAGAAGATCGCATGG Forward 
5861 Zebrafish edem1 TCTCTCCCTGAAACGCTGAT Reverse 
5862 Zebrafish xbp1t GGGTTGGATACCTTGGAAA Forward 
5863 Zebrafish xbp1t AGGGCCAGGGCTGTGAGTA Reverse 
5864 Zebrafish xbp1s TGTTGCGAGACAAGACGA Forward 
5865 Zebrafish xbp1s CCTGCACCTGCTGCGGACT Reverse 
5866 Zebrafish xbp1t GAGGAGCCCACAAAGTCCTC Forward 
5867 Zebrafish xbp1t CGAAGTGCTTTTTCCTCTGG Reverse 
5868 Zebrafish rpp0 CTGAACATCTCGCCCTTCTC Forward 
5869 Zebrafish rpp0 TAGCCGATCTGCAGACACAC Reverse 
6287 Zebrafish hur TGGTTGTTGCAGTTTTATCAGG Forward 
6288 Zebrafish hur CCTATTCACCTGAATCTCTGGG Reverse 
6289 Zebrafish hur ATTTGTGTAGATTGGGAATGGC Forward 
6290 Zebrafish hur TCCACATTGACTTCCACAAAAG Reverse 
6291 Zebrafish hur CTTTTGTGGAAGTCAATGTGGA Forward 
6292 Zebrafish hur TCATTTACAAACCTGATGCCTG Reverse 	
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Table	2-5:	Sequencing	Primers	
Sequencing  
TE # Species Gene Sequence Use Details 
5668 General TracR AAAAGCACCGACTCGGTGCC iCas CRISPR 
px330 General px330 GACTATCATATGCTTACCGT 
px330 
plasmid 
px330new General px330 TTTCTTGGGTAGTTTGCAGTTTT 
px330 
plasmid 
T7 General T7 TAATACGACTCACTATAGGG   
5027 Mouse hspb7 CCTACGAGAGGATGGTAGCC 
mORF 
plasmid 
6478663 
5028 Mouse hspb7 GGGAAGCCAGAGAGATAGCC 
mORF 
plasmid 
6478663 			
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CHAPTER	3: KNOCKDOWN	OF	HSPB7	IN	
ZEBRAFISH	EMBRYOS	LEADS	TO	DEFECTS	IN	
CARDIOGENESIS	AND	ASYMMETRY	
Introduction	The	zinc	finger	protein	Gata4	is	known	to	have	roles	in	cardiac	morphogenesis	in	human,	 mouse	 and	 zebrafish.	 Previous	 work	 by	 the	 Evans	 laboratory	 has	demonstrated	 that	 in	 both	 gata4	 morphants156,	 and	 in	 embryos	 expressing	 a	dominant	 negative	 Gata487,	 heart	 tube	 looping	 is	 disturbed.	 This	 indicates	 that	following	specification	of	cardiomyocytes,	Gata4	is	required	for	cardiomyocytes	to	correctly	 interpret	morphogenetic	 cues.	As	discussed	 in	Chapter	1,	depletion	of	Gata4	leads	to	defective	heart	development	and	subsequent	progressive	cardiac	pathologies.	It	follows	that	the	genes	regulated	by	Gata4	in	the	developing	embryo	contribute	to	both	cardiomorphogenesis	and	continued	cardiac	function.	However,	as	 a	 master	 transcription	 factor,	 Gata4	 regulates	 a	 large	 number	 of	 genes,	 the	identity	and	functions	of	many	of	which	remain	to	be	uncovered.		
A	 previous	 graduate	 student	 in	 our	 laboratory,	 Gabriel	 Rosenfeld,	 performed	 a	screen	 for	genes	 that	are	regulated	by	gata4	 in	developing	zebrafish	heart,	 and	identified	a	list	of	candidates.	The	small	heat	shock	protein	hspb7	was	a	member	of	this	list	and	proved	interesting	for	further	study	for	a	number	of	reasons.	First,	
hspb7	 is	 expressed	 exclusively	 within	 striated	 muscle,	 most	 abundantly	 in	 the	heart,	suggesting	that	it	fulfils	a	muscle-specific	function123,128,132.	Second,	the	role	of	hspb7	in	muscle	was	not	at	all	well	delineated,	but	in	vitro	studies	had	suggested	that	 it	 was	 able	 to	 prevent	 buildup	 of	 protein	 aggregates126,127.	 Third,	 and	excitingly,	 a	 number	 of	 genome-wide	 association	 studies	 had	 linked	
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polymorphisms	in	human	HSPB7	with	alteration	in	the	risk	of	cardiac	pathologies	in	 various	 human	 populations157–161.	 We	 hypothesized	 that	 hspb7	 played	 an	important	role	in	heart	development	and/or	function,	and	set	out	to	investigate	the	phenotype	of	hspb7	depletion	in	the	zebrafish.		
The	studies	described	in	this	chapter	were	performed	in	collaboration	with	Gabriel	Rosenfeld,	 PhD	 and	 are	 published120.	 All	 of	 the	 work	 presented	 herein	 was	performed	by	myself	except	where	noted	in	the	figure	legends.	
Hspb7	is	expressed	in	the	developing	zebrafish	heart	As	hspb7	has	not	previously	been	comprehensively	studied	in	zebrafish,	we	wished	to	better	understand	the	temporal	and	spatial	expression	pattern	of	hspb7	during	zebrafish	development.		Gabriel	 performed	 whole	 mount	 in	 situ	 hybridization	 (WISH)	 for	 hspb7	 and	observed	that	hspb7	 is	ubiquitously	expressed	during	somitogenesis	and	is	then	specifically	upregulated	in	the	developing	cardiac	mesoderm	at	25	somites	(Figure	3-1B).	Hspb7	is	specifically	expressed	in	the	heart	tube	during	jogging	and	looping	(Figure	 3-1C,D).	 By	 qPCR,	 I	 confirmed	 initial	 upregulation	 of	 hspb7	 during	segmentation	stages	(Figure	3-1E).		
We	did	not	detect	hspb7	expression	during	gastrulation,	however	another	group	was	able	to	demonstrate	the	presence	of	hspb7	transcripts	at	shield	stage,	and	in	the	Kupffer’s	Vesicle,	by	ISH	with	a	different	probe162.	This	suggests	that	our	WISH	probe	was	not	sensitive	enough	to	pick	up	the	earliest	expression.		
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Figure	3-1:	Expression	of	hspb7	during	zebrafish	development.	
In	situ	hybridization	at	14som	(A),	22hpf	(B),	24hpf	(C)	and	48hpf	(D)	shows	hspb7	
expression	 in	 the	 developing	 cardiomyocytes	 (arrow),	 cardiac	 cone	 (white	
arrowhead)	and	developing	heart	(black	arrowhead).	(E)	qPCR	expression	for	hspb7	
identified	 upregulation	 of	 transcript	 commencing	 at	 the	 10som	 stage.	 In	 situ	
hybridization	studies	were	performed	in	collaboration	with	Gabriel	Rosenfeld,	PhD.		
Defects	in	cardiomorphogenesis	in	hspb7	morphants	Since	hspb7	is	specifically	expressed	in	the	developing	heart,	we	hypothesized	that	depletion	 of	 hspb7	would	 lead	 to	 defects	 in	 cardiomorphogenesis.	 In	 order	 to	
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answer	 this	 question,	 Gabriel	 designed	 morpholinos	 targeting	 the	 start	 codon	(7MO)	 or	 a	 splice	 site	 (7MOs)	 of	 hspb7	 (Figure	 3-2A).	 I	 injected	 increasing	concentrations	 of	 7MO	 and	 7MOs	 into	 wildtype	 zebrafish	 fertilized	 eggs	 and	observed	the	effect	of	hspb7	knockdown	on	embryonic	phenotype.	We	identified	a	cardiac	 phenotype	 which	 presented	 as	 abnormal	 heart	 morphology.	 By	 3dpf,	morphant	 embryos	 had	 a	 variety	 of	 phenotypes	 including	 malformations,	 in	particular	atrial	ballooning,	as	well	as	failure	to	loop	resulting	in	a	linear	heart	tube	(Figure	3-2B,C).		
Figure	 3-2:	 Knockdown	 of	 hspb7	 with	 morpholinos	 leads	 to	 defects	 in	
cardiomorphogenesis.		(A)Structure	 of	hspb7	 gene	 showing	 targeting	 location	 of	morpholinos	 7MO	 and	
7MOs.	 (B)	 Representative	 cardiac	 phenotypes	 at	 72hpf	 in	 tg(myl7::gfp)	 embryos	
injected	with	0.5mM	7MO.	(C)	Quantification	of	cardiac	phenotypes	at	72hpf.		
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Closer	 analysis	 by	 Gabriel	 Rosenfeld	 identified	 decreases	 in	 ventricular	cardiomyocyte	size,	but	not	number,	in	hspb7	morphants†††.	
Alteration	in	jogging	in	hspb7	morphants	When	monitoring	the	development	of	the	heart	in	embryos	injected	with	7MO,	I	observed	 that	 in	 a	 significant	 percentage	 of	morphant	 embryos,	 the	 heart	 tube	either	failed	to	jog	left	and	remained	central,	or	jogged	to	the	right	(Figure	3-3).	In	order	to	facilitate	easy	visualization	of	the	heart,	this	experiment	was	performed	in	 the	 tg(myl7:gfp)	 transgenic	 line,	 which	 expresses	 green	 fluorescent	 protein	(GFP)	under	the	control	of	the	cardiac	myosin	promoter.		
Figure	3-3:	Hspb7	depletion	leads	to	randomization	in	cardiac	jogging.		
(A)	Representative	images	of	32hpf	tg(myl7:gfp)	embryos	injected	with	0.5mM	7MO.	
Dotted	line	marks	the	midline.	(B)	Quantification	of	jogging	phenotypes.		
																																																								
†††	Ventricular	cardiomyocyte	size	was	decreased	at	48hpf	when	analyzed	in	tg(myl7:mKate-caax)	embryos.	Myocyte	 shape	was	 also	 altered.	 It	 is	 important	 to	 note	 that	 decrease	 in	 size	may	 be	secondary	to	other	defects	in	cardiomorphogenesis	or	to	defects	in	cytoskeletal	function.		
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Interestingly	 this	 phenotype	 was	 exaggerated	 with	 concomitant	 depletion	 of	Gata4120,	indicating	the	two	genes	may	genetically	interact.		
Randomization	 of	 jogging	 in	hspb7	morphants	 is	 suggestive	 of	 a	 role	 for	hpsb7	either	in	establishment	of	asymmetry,	or	the	ability	of	cardiomyocytes	to	follow	patterning	cues.	Early	patterning	in	the	zebrafish	is	directed	by	a	transitory	organ	called	 the	 Kupffer’s	 vesicle	 (KV),	 which	 is	 analogous	 to	 the	 murine	 node.	 I	performed	in	situ	for	an	early	marker	of	the	establishment	of	asymmetry,	southpaw	
(spaw)	which	is	predominantly	expressed	on	the	left-hand	side	of	normal	embryos	at	the	18	somite	stage.		In	embryos	injected	with	7MO,	spaw	expression	was	altered	with	 most	 embryos	 exhibiting	 bilateral	 expression	 (Figure	 3-4).	 This	 indicates	early	disturbance	to	the	establishment	of	asymmetry	in	the	hspb7	morphants.		
Figure	3-4:	Expression	of	the	early	marker	of	asymmetry,	spaw,	is	altered	in	
embryos	depleted	of	hspb7.	
(A)	Representative	dorsal	images	of	in	situ	hybridization	for	spaw	performed	in	18	
somite	 stage	 embryos	 injected	 with	 0.5mM	 7MO.	 (B)	 Quantification	 of	 spaw	
expression	patterns	in	hspb7	morphants	shows	that	the	majority	no	longer	exhibit	
asymmetric	expression.				
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Closer	analysis	by	Gabriel	Rosenfeld	revealed	defects	in	the	function	of	the	KV	of	
hspb7	morphants.	As	discussed	earlier,	 the	Marvin	 laboratory	published	data	 to	visualize	hspb7	expression	in	the	KV162,	strengthening	the	evidence	for	this	role.		
Discussion	In	this	chapter,	we	used	a	morpholino-based	knockdown	approach	to	investigate,	for	 the	 first	 time,	 the	 role	 of	 the	 small	 heat	 shock	 protein	 hspb7	 during	development.	Our	inquiries	generated	some	interesting	insights.		
First,	we	found	that	knockdown	of	hspb7	in	the	developing	zebrafish	precipitated	defects	 in	 cardiogenesis.	 This	 is	 indicative	 of	 a	 role	 for	 hspb7	 in	 myocyte	differentiation,	ability	to	follow	morphogenetic	cues	or	in	myocyte	function.	Both	the	expression	pattern	and	morphant	phenotype	we	observed	allow	us	to	conclude	that	 hspb7	 is	 not	 required	 for	 cardiomyocyte	 specification.	 Initial	 heart	 tube	formation	(Figure	3-3),	chamber	specification	and	cardiomyocyte	proliferation	are	grossly	successful,	allowing	us	to	presume	that	hspb7	depletion	does	not	interfere	with	 a	 number	 of	 pathways	 that	 have	 been	 implicated	 in	 these	 early	 steps	 of	cardiomorphogenesis163.	 	We	observed	that	ventricular	myocyte	size	and	shape,	and	 overall	 cardiac	 morphology	 (Figure	 3-2),	 are	 compromised.	 Studies	 into	similar	phenotypes	have	ascertained	that	these	defects	can	arise	as	a	consequence	of	 alterations	 in	 either	 blood	 flow	 or	 cardiac	 contractility18.	 Based	 on	 the	expression	pattern	of	hspb7,	it	is	a	strong	hypothesis	that	alteration	in	contractility	may	be	responsible	for	the	defects	in	cardiomorphogenesis	we	observed.	It	is	also	interesting	that	the	phenomenon	of	altered	contractility	is	also	associated	with	the	types	 of	 the	 human	 heart	 disease	 linked	 with	 HSPB7	 polymorphisms	 through	GWAS	studies158–160.	
	 	83	
In	addition	to	the	defects	in	cardiomorphogenesis,	we	identified	that	knockdown	of	hspb7	leads	to	defects	in	the	establishment	of	left-right	asymmetry.	Alterations	in	heart	tube	jogging	were	visualized	and	quantified	(Figure	3-3),	and	disturbance	of	 the	 underlying	 signaling	 pathways	 were	 confirmed	 with	 ISH	 for	 markers	including	spaw	(Figure	3-4),	lefty1	and	lefty2120.	In	an	observation	that	may	at	first	seem	surprising,	mis-expression	of	asymmetry	markers	was	found	in	over	80%	of	morphants	whereas	alteration	of	jogging	was	only	seen	in	around	50%.		However,	in	human	and	mouse	disease	with	failure	to	correctly	establish	left-right	signaling	cues,	situs	inversus	is	seen	in	around	50%	of	affected	individuals164.	This	suggests	that	 additional	 signaling	 cues	 control	 downstream	 patterning,	 allowing	asymmetrical	organ	development	on	either	the	right	or	left	in	a	stochastic	manner.	Thus,	from	our	data,	20%	of	morphants	retain	normal	left-hand	signaling,	and	of	the	 80%	with	 aberrant	 establishment	 of	 asymmetry	 we	 expect	 half	 to	 jog	 left	anyway.		
We	 ascertained	 that	 the	 asymmetry	 and	 defective	 cardiomorphogenesis	phenotypes	are	independent	of	each	other120,	however,	there	are	some	interesting	overlaps	between	the	mechanics	of	the	KV	and	of	the	cardiomyocyte	that	allow	us	to	speculate	regarding	the	molecular	role	of	hspb7.		
Previous	 work	 has	 demonstrated	 that	 overexpression	 of	 Hspb7	 prevents	 the	formation	 of	 F-actin	 stress	 fibers	 in	 cultured	 cardiomyocytes126.	 In	 both	 the	cardiomyocyte	and	the	beating	cilia	of	the	KV,	the	actin	cytoskeleton	retains	cell	shape	 and	 function	 in	 a	 high-motion	 environment.	 If	 hspb7	 has	 a	 role	 in	 the	maintenance	of	the	actin	cytoskeleton,	or	in	the	regulation	of	signaling	pathways	or	 structures	 that	 interact	 with	 the	 actin	 cytoskeleton,	 loss	 of	 hspb7	 might	 be	expected	 to	 cause	 problems	 for	 both	 of	 these	 contracting	 cell	 types.	 A	 role	
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regulating	cytoskeletal	dynamics	would	be	in	keeping	with	published	roles	for	a	number	of	other	members	of	the	HSPB	family165.	Although	all	cell	types	have	an	actin	cytoskeleton,	given	the	expression	pattern	of	hspb7,	we	would	expect	 that	this	 role	 is	 either	 specifically	 required	 in	 continuously	 contracting	 cells,	 or	 is	fulfilled	by	a	different	protein	in	alternate	organs.		
The	findings	discussed	in	Chapter	4	were	replicated	shortly	after	their	publication	by	a	separate	published	study	from	the	Marvin	laboratory162.			 	
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CHAPTER	4: HSPB7	 MUTANT	 ZEBRAFISH	 EXHIBIT	
CARDIAC	 PATHOLOGIES	 THAT	 SENSITIZE	 THEM	 TO	
EXERCISE	STRESS	
Introduction	As	discussed	in	Chapter	3,	the	initial	work	that	I	completed	with	Gabriel	Rosenfeld	appeared	 to	 confirm	 our	 hypothesis	 that	 hspb7	 has	 an	 important	 role	 in	 the	developing	 zebrafish	 cardiomyocyte.	 However,	 we	 had	 not	 established	 the	molecular	role	of	hspb7.	In	addition,	there	are	several	important	caveats	that	must	be	noted	of	morpholino	studies.	The	first	is	that	the	morpholino	has	a	limited	time	frame	in	which	it	is	able	to	effectively	deplete	the	expression	of	its	target	protein.	Eventually,	the	morpholino	is	depleted	through	dilution	by	cellular	proliferation	or	 degradation.	 Secondly,	 some	 morpholinos	 are	 associated	 with	 a	 number	 of	common	 side	 effects,	 including	 cardiac	 malformation.	 Of	 key	 importance,	comparisons	of	morphant	and	mutant	phenotypes	have	exposed	discrepancies166.	Therefore,	 it	 was	 important	 to	 validate	 the	 observations	 we	 had	 made	 in	 the	morphant	model.	Recent	advances	in	genome	editing	technologies	such	as	TALEN	and	 CRISPR	 have	 made	 it	 feasible	 to	 generate	 targeted	 mutations	 in	 the	zebrafish60,62,167.	 With	 these	 tools	 in	 hand,	 I	 next	 sought	 to	 generate	 and	characterize	hspb7	mutant	zebrafish.		
Generation	of	mutant	hspb7	lines	We	 generated	mutant	 hspb7	 alleles	 using	 Transcription	 Activator-Like	 Effector	Nuclease	 (TALEN)	 technology.	 In	 the	 absence	 of	 information	 regarding	 critical	functional	domains	of	Hspb7,	Gabriel	designed	TALENs	to	target	mutations	near	the	5’	end	of	the	gene,	reasoning	that	an	indel	leading	to	an	early	frameshift	was	
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likely	to	cause	a	deleterious	mutation	(Figure	4-1).	By	exploiting	the	presence	of	a	HpyCH4V	 restriction	 site	 in	 the	 wildtype	 allele,	 I	 was	 able	 to	 monitor	 the	generation	and	transmission	of	mutant	alleles	by	RFLP	analysis	of	PCR	products	that	included	the	predicted	TALEN	cut	site.		
Figure	4-1:	Generation	of	mutant	hspb7	alleles.		
Structure	 and	 partial	 sequence	 of	 the	 hspb7	 gene,	 showing	 TALEN	 targeting	
proximal	to	the	start	codon	and	resultant	mutant	alleles	WC3	and	WC4.	
I	recovered	two	mutant	alleles	from	separate	founder	fish	that	were	predicted	to	encode	proteins	missing	a	large	proportion	of	the	normal	Hspb7	protein	(Figure	4-1).	Both	alleles	generate	a	frameshift	immediately	after	a	polyserine	stretch	near	the	 N-terminus	 of	 hspb7.	 The	 first	 allele,	 hspb7WC3,	 is	 expected	 to	 result	 in	 the	synthesis	 of	 an	 almost	 entirely	 novel	 predicted	 protein	 approximately	 half	 the	mass	of	wildtype	Hspb7.	The	second	frameshift	allele	causes	an	early	stop	codon,	truncating	the	predicted	protein	to	only	27	amino	acids,	and	was	named	hspb7WC4.	Both	mutations	lie	in	the	middle	of	exon	1	and	are	not	predicted	to	interfere	with	splicing	of	hspb7	mRNA.	I	tested	if	the	premature	stop	codons	predispose	mutant	
hspb7	 mRNAs	 to	 nonsense-mediated	 decay,	 but	 qPCR	 analysis	 indicated	 that	
hspb7WC3	and	hspb7WC4	transcripts	are	expressed	at	levels	similar	to	wildtype	hspb7	
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(Figure	 4-2B).	 Since	 both	 transcripts	 still	 encode	 the	 N-terminal	 of	 the	 Hspb7	protein,	this	is	not	unexpected.	
Figure	4-2:	Loss	of	Hspb7	expression	in	mutant	embryos..		
	(A)	Western	blot	of	protein	lysates	from	adult	zebrafish	hearts	shows	loss	of	Hspb7	
protein	 in	animals	homozygous	 for	 either	of	 the	hspb7	mutations.	 (B)	qPCR	data	
showing	that	hspb7WC3	and	hspb7WC4	are	expressed	at	levels	comparable	to	wildtype	
hspb7	in	5dpf	zebrafish	embryos.	
I	also	performed	western	blotting	experiments	and	confirmed	that	Hspb7	protein	was	absent	 in	 the	hearts	of	 adult	 zebrafish	homozygous	 for	 either	of	 the	hspb7	mutant	 alleles	 (Figure	 4-2A).	 Thus,	 I	 demonstrated	 that	 both	 hspb7WC3	 and	
hspb7WC4	represent	null	alleles	of	hspb7	and	that	these	lines	will	be	deficient	for	any	normal	role	of	Hspb7	in	the	zebrafish.		
Zebrafish	tolerate	hspb7	mutant	alleles	Embryos	homozygous	for	the	mutant	hspb7	alleles	were	recovered	from	crosses	of	heterozygous	fish	in	the	expected	Mendelian	ratios	(Figure	4-3).		
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Figure	4-3:	Genotyping	of	embryos	from	a	hspb7	heterozygous	incross.		
Left:	 Example	 PCR	 demonstrating	 genotyping	 strategy	 for	 hspb7	 alleles.	 The	
restriction	 site	 for	 HpyCH4V	 is	 lost	 in	 the	 hspb7	mutant	 allele.	 Quantification	 of	
embryonic	 genotypes	 demonstrates	 that	 hspb7WC3/WC3	 alleles	 are	 transmitted	 at	
expected	Mendelian	ratios	(21.9%	Wildtype,	50.3%	Heterozygous,	27.8%	Mutant).	
Homozygous	 hspb7WC3	 or	 hspb7WC4	 mutants	 showed	 no	 gross	 morphological	defects	(Figure	4-4A).	In	order	to	better	visualize	the	hearts	of	hspb7	mutant	fish,	I	 crossed	 the	 hspb7WC3	 allele	 onto	 the	 Tg(myl7::gfp)	 background	 and	 observed	cardiac	development	across	the	first	week	of	life.	In	the	absence	of	Hspb7,	the	vast	majority	of	hearts	were	seen	to	undergo	timely	jogging	and	looping	and	to	have	normal	size	and	morphology	(Figure	4-4A,B),	although	there	is	a	variable	increase	of	0-20%	in	cardiac	abnormalities	in	hspb7	maternal	zygotic	(MZ)	mutants.	Fish	homozygous	for	either	of	the	two	mutant	hspb7	alleles	were	viable	to	adulthood	and	 fertile.	 These	 findings	 were	 surprising	 given	 our	 previous	morphant	 data.	However,	 as	 our	 lab,	 and	 others,	 have	 repeatedly	 observed	 compensatory	mechanisms	in	play	in	zebrafish	mutants,	I	hypothesized	that	something	similar	may	be	offsetting	the	loss	of	hspb7.	This	is	further	explored	in	Chapter	6.		
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Figure	4-4:	Phenotyping	of	hspb7	mutant	embryos.		
(A)	 Representative	 brightfield	 images	 of	 wildtype	 or	 homozygous	 hspb7	 mutant	
24hpf	embryos.	Also	shown	are	representative	72hpf	hearts	from	wildtype	or	hspb7	
mutant	lines	crossed	onto	a	tg(myl7:gfp)	background.	(B)	Quantification	of	normal	
hearts	at	72hpf	in	wildtype	or	homozygous	hspb7	mutant	animals	(n=200)	
Normal	response	to	heat	stress	in	hspb7	mutants	Although	expression	of	hspb7	is	not	upregulated	during	heat	shock123,	I	reasoned	that,	as	a	heat	shock	protein,	its	role	is	likely	to	be	more	important	during	periods	of	cardiac	or	general	stress.		I	asked	whether	hspb7	mutant	animals	were	less	able	to	 deal	 with	 a	 generalized	 heat	 challenge.	 I	 incubated	 embryos	 at	 the	 raised	temperature	of	32°C	following	gastrulation.	There	was	not	an	increase	in	cardiac	abnormalities	 in	 hspb7	 mutants	 that	 was	 greater	 than	 that	 seen	 in	 wildtype	controls,	 nor	was	 there	 a	 greater	 increase	 in	 randomization	 of	 cardiac	 jogging	(Figure	4-5).	However,	I	did	notice	that	an	increase	in	temperature	led	to	a	notable	increase	 in	 right-jogging	 heart	 tubes	 in	 embryos	 of	 all	 genotypes.	 To	 my	
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knowledge,	this	finding	has	not	been	previously	reported	and	may	be	of	interest	to	those	 studying	 the	 pathways	 that	 control	 the	 establishment	 of	 left-right	asymmetry.		
Figure	 4-5:	 Phenotyping	 of	 wildtype	 and	 hspb7	mutant	 embryos	 incubated	
under	normal	(28C)	or	heat	shock	(32C)	conditions.		
(A)	Heat	shock	leads	to	partial	randomization	of	heart	tube	jogging	in	both	wildtype	
and	hspb7	mutant	 embryos.	 (B)	Heat	 shock	 does	 not	 lead	 to	 increases	 in	 cardiac	
malformations.		
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Adult	hspb7WC3/WC3	fish	have	increased	susceptibility	to	
exercise-induced	stress	When	I	bred	homozygous	null	animals,	I	noticed	a	statistically	significant	increase	in	mortality	 rate	 in	male	 fish	 (Figure	 4-6).	 I	 reasoned	 that	 the	mating	 process,	particularly	 for	 the	 vigorously	 swimming	 male,	 represents	 a	 strenuous	cardiovascular	activity.		
Figure	4-6:	Tracking	mortality	of	hspb7	mutants.		
Kaplan-Meier	 curve	 showing	 survival	 of	 hspb7	mutant	 male	 and	 female	 animals	
following	commencement	of	breeding	at	105	days	post	fertilization.	
I	hypothesized	that	death	indicated	initial	decreased	capacity	to	cope	with	cardiac	stress	 in	 hspb7WC3/WC3	 animals.	 To	 investigate	 the	 phenomenon	 in	 a	 controlled	manner,	batches	of	male	and	female	adult	zebrafish	were	subjected	to	an	enforced	swimming	 exercise	 paradigm.	 Genotyped	 groups	 of	 either	 hspb7WC3/WC3	 fish	 or	wildtype	controls	were	paced	at	50	cms-1	for	30	minutes,	every	day	for	5	days	(Fig	Figure	4-7A).	This	represents	a	high	intensity	anaerobic	exercise	regime,	with	a	water	 flow	 approaching	 the	 critical	 swimming	 speed	 (Ucrit)	 of	 zebrafish168.	We	observed	that	hspb7	mutant	animals	spent	a	greater	amount	of	time	than	wildtype	
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controls	‘resting’	at	the	back	of	the	tank	(23.37%	of	swim	time	for	HSPB7WC3/WC3	versus	2.78%	of	swim	time	for	wildtype	animals,	Figure	4-7B,C).		
Figure	4-7:	Hspb7	mutant	adults	are	unable	to	maintain	tank	position	during	
high-intensity	exercise.		
(A)	High-intensity	exercise	paradigm	 for	zebrafish.	 (B)	Representative	 tracking	of	
fish	location	in	the	tank	during	the	final	minute	of	exercise	shows	that	hspb7WC3/WC3	
fish	 are	more	 likely	 to	 remain	 at	 the	 back	 of	 the	 tank.	 (C)	 Quantification	 of	 fish	
location.	
Strikingly,	around	30%	of	hspb7WC3/WC3	animals	died	during	the	first	few	days	of	enforced	exercise	(Figure	4-8).	
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Figure	4-8:	Increased	mortality	in	hspb7	mutant	animals	subjected	to	a	high	
intensity	exercise	regime.		
Kaplan-Meier	 curve	 showing	 increase	 in	 mortality	 in	 hspb7WC3/WC3	 fish	 following	
commencement	of	exercise	regime.	Dotted	lines	indicate	timing	of	exercise	sessions	
(n=20)	
However,	66%	of	animals	that	died	were	female,	indicating	that	the	gender	bias	we	observed	in	post-mating	mortality	is	more	likely	due	to	differences	in	behavior	during	mating	rather	than	a	gender-specific	compromise	of	cardiac	health.		
Interestingly,	I	observed	that	hspb7WC3/WC3	animals	consumed	around	1.5	fold	the	amount	 of	 oxygen	 as	wildtype	 controls	 when	 first	 exposed	 to	 exercise	 (Figure	4-9A).	However,	 following	repeated	exposure	 to	 the	exercise	 regime,	 the	use	of	oxygen	 by	hspb7	mutant	 animals	 decreased	 to	 below	 that	 of	wildtype	 controls	(Figure	4-9B).	 It	 is	 important	 to	note	 that	 the	decrease	 in	oxygen	 consumption	coincides	with	the	loss	of	~30%	of	animals	in	whom	the	exercise	machine	induced	mortality	(after	day	3	of	exercise).			
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Figure	4-9:	Oxygen	 consumption	 is	altered	 in	hspb7	mutants	 subjected	 to	a	
high	intensity	exercise	paradigm.		
(A)	 Initially	hspb7	mutants	use	around	1.4	 fold	 the	amount	of	oxygen	as	wildtype	
controls	under	the	same	swimming	conditions.	(B)	Over	time,	the	amount	of	oxygen	
used	by	hspb7	mutants	decreases	to	levels	equal	to,	or	lower	than,	that	of	wildtypes.	
Solid	lines	represent	line	of	best	fit.	Dotted	lines	represent	95%	confidence	intervals	
for	the	lines	of	best	fit.		
I	hypothesize	that	inter-animal	variation	contributes	to	this	phenomenon	in	one	of	two	ways.	Either	the	animals	that	die	are	those	that	are	initially	using	much	higher	levels	 of	 oxygen	 than	 their	 siblings;	 or	 the	 animals	 that	 die	 are	 those	 that	 are	unable	to	upregulate	some	compensatory	pathway	that	allows	them	to	tolerate	the	exercise	 stress	 –	 and	 in	 doing	 so	 decreases	 oxygen	 consumption.	 Since	 the	relationship	 between	 oxygen	 consumption	 and	 cardiac	 function	 is	 exceedingly	complicated,	I	opted	not	to	further	pursue	this	phenotype,	but	note	it	herein	for	the	sake	of	completeness.	
	Hspb7WC3/WC3	mutant	adults	exhibit	heart	pathology	I	hypothesized	that	exercise	stress	may	exacerbate	a	cardiac	dysfunction	that	 is	not	obvious	in	unstressed	mutants.	I	dissected	the	hearts	from	adult	zebrafish	and	quantified	their	size.	I	observed	a	striking	and	significant	increase	in	ventricular	
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size	 in	 hspb7WC3/WC3	 and	 hspb7WC4/WC4	 adults	 when	 compared	 with	 wildtype	animals	 or	 heterozygotes	 (Figure	 4-10).	 Strikingly,	 the	 increase	 in	 mean	ventricular	 area	 to	 body	 weight	 index	 (wildtype	 3.01,	 hspb7WC3	 4.70,	 hspb7WC4	5.16)	exceeded	the	increase	reported	to	be	induced	by	cardiotoxin	doxorubicin56,	suggesting	that	the	hspb7	mutants	have	a	marked	cardiomyopathy.	Notably,	 the	ventricles	 of	hspb7	mutants	 also	 appeared	 abnormally	 shaped,	with	 a	 rounded	appearance	(Figure	4-10B)	compared	to	wildtype	controls	(Figure	4-10A).		
Figure	4-10:	The	hearts	of	hspb7	mutant	adults	are	enlarged	and	abnormally	
shaped.	
Representative	images	of	dissected	ventricles	and	outflow	tracts	from	(A)	wildtype	
and	(B)	hspb7WC3/WC3	adults.	Shown	are	hearts	from	10mo	animals	with	the	atria	
removed	 for	 clear	 viewing.	 (C)	 Quantification	 of	 ventricular	 area	 to	 body	weight	
index	(VA/BW)	showed	heart	enlargement	in	animals	homozygous	for	either	of	the	hspb7	mutations.	Each	point	represents	one	animal.	Data	combined	for	10mo	and	
18mo	zebrafish.		
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In	order	to	further	explore	the	abnormalities	in	hspb7	WC3/WC3	hearts,	I	processed	adult	 hspb7WC3/WC3	 mutant	 zebrafish	 for	 general	 histopathological	 analysis.	Inspection	of	the	gross	anatomy	by	a	pathologist	revealed	that	60%	of	mutant	fish	exhibited	hearts	that	appeared	rounded	when	compared	with	wildtype	controls.	Notably,	80%	of	mutant	fish	were	found	to	exhibit	diffuse,	marked	hepatocellular	vacuolation	(Figure	4-11A,B).	This	phenotype	might	be	indicative	of	hepatic	injury	downstream	from	cardiac	dysfunction169,170169,170.		
Figure	4-11:	Abnormal	liver	histology	in	hspb7	adults.	
Trichrome-stained	images	of	adult	(A,C)	wildtype	and	(B,D)	hspb7WC3/WC3	zebrafish	
liver	(A,B)	and	skeletal	muscle	(C,D).	Representative	images.	
The	skeletal	muscle	of	hspb7WC3/WC3	animals	did	not	exhibit	fibrotic	lesions	(Figure	4-11C,D),	 allowing	me	 to	 conclude	 that	 differences	 in	 ability	 to	maintain	 swim	speed	are	not	secondary	to	skeletal	muscle	dysfunction.		
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Heart	pathology	was	evaluated	comparing	trichrome	stained	cardiac	sections	from	mutant	or	wildtype	animals.	This	revealed	mild	multifocal	cardiac	fibrosis	in	100%	of	 hspb7WC3/WC3	 hearts,	 which	 was	 not	 seen	 in	 control	 wildtype	 hearts	 (Figure	4-12A,B).		
Figure	4-12:	hspb7WC3/WC3	adult	hearts	exhibit	fibrosis.		
Trichrome	staining	of	3	month	old	wildtype	(A,B)	and	hspb7	mutant	(C,D)	hearts.	
Focal	fibrotic	lesions	(arrowheads)	are	seen	in	all	(5/5)	hspb7	mutant	but	never	in	
wildtype	samples.	Representative	images.	
For	 closer	 observation	 of	 abnormalities	 in	 the	 myocardium	 of	 hspb7	mutants,	hearts	were	dissected	from	adult	mutant	or	wildtype	zebrafish	and	analyzed	by	transmission	electron	microscopy	(TEM),	which	revealed	sarcomeric	disarray	in	homozygous	mutant	 hearts	 (Figure	 4-13).	 This	 suggests	 that	 in	 the	 absence	 of	Hspb7,	there	is	an	underlying	cardiopathology,	which	likely	predisposes	mutant	animals	to	exercise-induced	stress	that	can	lead	to	cardiac	failure.		
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Figure	4-13:	hspb7	mutant	hearts	exhibit	abnormalities	visible	by	TEM.		
TEM	 images	 of	 3-month-old	 wildtype	 and	 hspb7WC3/WC3	 hearts.	 Wildtype	 hearts	
exhibit	repeated,	regular	sarcomeric	striations	with	organized	mitochondria.	Hspb7	
mutant	hearts	show	defects	including	breakdown	of	sarcomeric	organization	(white	
arrows)	 and	 electron-dense	 dark-staining	 areas	 (arrowheads)	 indicative	 of	 the	
presence	of	aggregates.	(H)	Quantification	of	abnormalities	from	blinded	analysis	of	
TEM	images.	Each	dot	represents	a	unique	25000X	image.	
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Discussion	and	Future	Directions	
Hspb7	mutant	zebrafish	develop	normally.	I	used	TALEN	technology	to	generate	hspb7	mutant	zebrafish	lines,	which	I	initially	hypothesized	would	 corroborate	 the	data	myself,	 and	others,	 had	generated	by	morpholino	depletion	of	hspb7	(see	Chapter	3).	Surprisingly,	global	loss	of	hspb7	is	 tolerated	 during	 zebrafish	 embryogenesis	 and	hspb7	mutants	 are	 viable	 and	fertile.	This	is	particularly	unexpected	in	light	of	data	that	hspb7	is	very	abundantly	expressed	in	adult	zebrafish	heart,	in	particular	in	the	ventricle	(Table	4-1,24).		
Table	4-1:	Differential	expression	of	hspb7	in	adult	zebrafish	heart	chambers.	
Analysis	of	data	from	chamber-specific	RNAseq	in	the	adult	zebrafish	heart	(Singh	et	al.	201624)	showing	high	expression	of	hspb7	in	the	ventricle.	Myl7	and	other	small	
heat	shock	proteins	included	for	comparison	of	FKPM	values.		
Despite	the	lack	of	strong	phenotype	in	the	hspb7	mutant	embryo,	I	am	confident		that	 the	 hspb7WC3	 and	 hspb7WC4	mutant	 alleles	 lead	 to	 complete	 loss	 of	 Hspb7	protein.	 There	 is	 a	 small	 amount	 of	 residual	 signal	 when	Western	 blotting	 for	Hspb7	in	mutant	heart	(Figure	4-2),	however,	the	antibody	used	to	perform	this	assay	is	a	polyclonal	mix	that	likely	recognizes	the	N-terminal	of	the	protein,	which	would	still	be	translated	from	either	of	the	mutant	alleles.	The	WC3	allele	goes	out	of	frame	but	continues	to	encode	an	amino	acid	sequence.	The	resultant	protein	is	predicted	 to	have	 a	mass	only	7kDa	 less	 than	 the	wildtype	Hspb7.	Thus,	 it	 is	 a	reasonable	 hypothesis	 that	 the	 residual	 signal	 might	 be	 from	 the	 polyclonal	
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antibody	recognizing	the	N-terminal	of	this	‘junk’	peptide.	The	low	level	of	signal	compared	with	wildtype	 (around	 10%)	 suggests	 that	 this	 peptide	 is	much	 less	stable	than	Hspb7.		
As	mentioned	briefly	above,	one	possible	explanation	for	the	lack	of	developmental	defects	is	that	the	zebrafish	compensate	for	loss	of	hspb7	through	upregulation	of	compensatory	pathways	and/or	genes	that	attenuate	any	cardiac	pathologies.	This	idea	is	explored	in	Chapter	5	and	in	Appendix	A.			
Discovery	of	exercise-induced	mortality	in	hspb7	mutant	adults.	Despite	 normal	 development,	 I	 discovered	 that	 high-intensity	 exercise,	 which	would	 cause	 an	 acute	 increase	 in	 cardiac	 workload,	 leads	 to	 exercise-induced	mortality	in	around	40%	of	adults.	I	uncovered	a	mild	cardiac	pathology	in	hpsb7	mutants,	which	is	grossly	asymptomatic	until	the	animal	is	subjected	to	stress.	The	requirement	 for	 an	 additional	 stressor	 to	 precipitate	 a	 phenotype	 in	 the	hspb7	mutant	 zebrafish	 is	 particularly	 exciting	 as	 it	 better	 models	 the	 complex	pathogenesis	 seen	 in	 much	 of	 human	 heart	 disease,	 in	 which	 environmental	stresses	and	individual	genetic	variation	impact	disease	severity	and	outcome.		
It	is	interesting	that	the	majority	(~60%)	of	hspb7	mutants	tolerate	the	exercise	insult	despite	the	fact	that	all	mutant	hearts	examined	exhibited	around	the	same	mild	level	of	fibrosis,	and	most	had	increased	in	ventricular	size.	One	possibility	is	that	additional	 inter-animal	variation	accounts	for	this	variability.	This	could	be	due	 to	 differential	 inheritance	 of	 alleles	 of	 modulator	 genes.	 Our	 wildtype	zebrafish	lines	are	generated	from	crossing	two	unique	strains	(AB	and	Tubingen),	allowing	for	substantial	genetic	variability.		
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Potential	 causes	of	 cardiomegaly	and	 sarcomeric	 abnormalities	 in	hspb7	
mutants.	The	generation	of	hspb7	mutant	 lines	was	not	as	 informative	as	I	had	originally	hoped	 regarding	 the	 molecular	 role	 of	 Hspb7	 within	 the	 cardiomyocyte.	 The	mechanism	behind	the	cardiomegaly,	mild	fibrosis	and	increased	mortality	that	I	observed	 is	 less	 easy	 to	 predict	 than	 would	 be	 the	 pathway	 behind	 a	 specific	malfunction	in	cardiogenesis.	However,	the	literature	does	provide	some	possible	hints.		Cardiac	enlargement	in	humans	is	most	commonly	caused	by	growth	of	existing	individual	myocytes	rather	than	their	proliferation4.	However,	the	zebrafish	heart	has	an	increased	regenerative	capacity.	The	ventricles	of	adult	zebrafish	subjected	to	high	intensity	exercise	regimes	exhibit	increase	in	both	heart	size	and	number	of	 cardiomyocyte	 nuclei,	 indicating	 that	 the	 zebrafish	 compensates	 for	 cardiac	overload	 through	hyperplasia	 rather	 than	hypertrophy171.	 The	 zebrafish	 is	 also	able	to	retain	normal	physiological	function	following	exercise	overload-induced	cardiomegaly,	 whereas	 human	 hearts	 typically	 have	 decreases	 in	 measures	 of	cardiac	function,	such	as	fractional	shortening4.	 In	contrast,	cardiomegaly	of	the	zebrafish	 heart	 following	 treatment	 with	 the	 cardiotoxin	 doxorubicin	 leads	 to	pathological	 alterations	 in	 these	 functional	 measurements56.	 These	 divergent	findings	make	it	difficult	to	immediately	interpret	the	observation	of	cardiomegaly	in	hspb7	mutant	animals.	However,	 the	>50%	increase	 in	mean	VA/BW	that	we	
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observed	is	larger	than	that	recorded	in	either	of	these	two	prior	studies‡‡‡.	Since	the	 increases	 caused	by	 cardiotoxins	 are	higher	 and	 closer	 to	 the	 increases	we	observed,	 and	 given	 the	 concomitant	 cardiac	 fibrosis,	 we	 hypothesize	 that	cardiomegaly	in	the	hpsb7	mutants	is	pathological	and	is	having	an	adverse	effect	on	 cardiac	 function.	 Recordings	 of	 functional	 parameters	 such	 as	 fractional	shortening,	or	re-expression	of	atrial	natriuretic	 factor	 in	 the	adult	heart	would	help	to	confirm	this.		
Through	high	magnification	imaging	of	hspb7	depleted	cardiomyocytes	by	electron	microscopy	we	were	 able	 to	 observe	 some	 abnormalities,	 including	 sarcomeric	disarray.	 This	 phenomenon	 is	 most	 often	 observed	 in	 hypertrophic	cardiomyopathy	 caused	 by	mutation	 of	 genes	 that	 encode	 sarcomeric	 proteins,	predominantly	MYH7	and	MYBPC35.	This	observation	leads	us	to	suggest	a	model	whereby	hspb7	depletion	leads	to	loss	of	sarcomeric	integrity	resulting	in	myofiber	dysfunction	and	subsequent	hypertrophic	cardiomyopathy.	Closer	assessment	of	ventricular	wall	thickness	in	our	mutants	should	allow	us	to	observe	whether	the	observed	increase	in	ventricular	area	resembles	hypertrophic	cardiomyopathy.	
Potential	causes	of	cardiac	fibrosis	in	hspb7	mutants.	We	also	observed	increases	in	cardiac	fibrosis	in	hspb7	mutant	animals.	Cardiac	fibrosis	 is	 a	 hallmark	 of	 heart	 disease	 and	 is	 found	 in	 heart	 failure	 driven	 by	
																																																								
‡‡‡	Increase	of	around	20%	(VA/BL	increase	from	5	to	6)	for	exercise	and	30%	(VA/BW	increase	from	 4.0	 to	 5.1)	 for	 doxorubicin	 treatment.	 Raw	 data	was	 not	 provided	 so	 these	 numbers	 are	estimated	from	graphed	data.	
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mutations	in	cytoskeletal	components,	calcium	modulators,	epigenetic	regulators	and	transcriptional	factors	as	well	as	following	cardiac	infarction4.	The	deposition	of	 extracellular	 matrix	 within	 the	 muscle	 leads	 to	 impairment	 of	 muscle	contractility	and	ultimately	decreases	 in	 the	ability	of	 the	heart	 to	pump	blood.	Thus,	the	phenomenon	is	both	a	symptom	of	and	a	contributor	to	pathology.	The	mechanisms	 involved	 in	 the	 stimulation	 of	 cardiac	 fibrosis	 are	 not	 fully	understood.	 The	 TGFb	 signaling	 pathway	 is	 known	 to	 be	 a	 driver	 of	 fibrotic	deposition	 in	 many	 tissue	 types,	 including	 collagen-producing	 cardiac	fibroblasts172.	 TGFb	 signaling	 leading	 to	 fibrosis	 in	 the	 heart	 is	 believed	 to	 be	predominantly	activated	by	TGF-b1,	secreted	by	cardiac	fibroblasts.		Expression	of	TGF-b1	 is	 known	 to	 be	 increased	 in	 response	 to	 Angiotensin	 II	 signaling,	downstream	of	renin	release	by	the	kidneys.	Decrease	in	renal	perfusion	leads	to	renin	production,	leading	to	a	potential	systemic	pathology	whereby	loss	of	hspb7	leads	to	a	decrease	in	cardiac	output,	resulting	in	decreased	kidney	perfusion	and	increased	renin	production,	driving	TGF-b	signaling	and	causing	cardiac	fibrosis.	Cardiac	fibrosis	further	compromises	cardiac	output,	worsening	the	situation.	
An	 interesting	 additional	 hypothesis	 is	 that	 loss	 of	 hspb7	 affects	 the	 cardiac	fibroblasts	in	a	cell	autonomous	manner.	Hspb7	 is	expressed	in	cardiomyocytes,	but	 unvalidated	 RNAseq	 data	 found	 in	 the	 literature	 indicates	 that	 it	 is	 also	expressed	 in	adult	 cardiac	 fibroblasts173§§§.	Cell-type	specific	depletion	of	hspb7	would	best	answer	this	question.		
																																																								
§§§	HSPB7	counted	at	17.4FKPM	in	adult	human	cardiac	fibroblasts	and	1.99FKPM	in	fetal	human	cardiac	fibroblasts,	indicating	that	it	is	upregulated	with	age.	These	counts	are	considerably	lower	than	those	found	in	whole	zebrafish	ventricle,	which	is	composed	of	both	myocytes	and	fibroblasts.		
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Conclusions	In	 conclusion,	 these	 studies	 are	 the	 first	 to	 generate	 and	 characterize	 an	hspb7	mutant	 model	 system.	 	 I	 identified	 a	 cardiac	 pathology	 in	 adult	 hspb7	 mutant	zebrafish	that	was	lethal	in	a	subset	of	mutant	animals	exposed	to	exercise	stress.	Careful	 phenotyping	 of	 the	 hearts	 of	 adult	 hspb7	 mutant	 zebrafish	 revealed	cardiomegaly,	sarcomeric	abnormalities	and	cardiac	fibrosis.		
These	 observations	 demonstrate	 that	 the	 hspb7	 mutant	 zebrafish	 has	 a	cardiomyopathy	 in	 which	 genetic	 and	 environmental	 interaction	 determines	disease	 outcome.	 The	 contributions	 of	 multiple	 small	 influences	 on	 overall	pathology	 is	 a	 phenomenon	 that	 is	 also	 observed	 in	 human	 complex	 cardiac	disease,	suggesting	that	the	hspb7	mutant	zebrafish	will	be	a	useful	tool	for	future	identification	of	modifier	genes	and	pathways	that	can	influence	the	development	and	progression	of	cardiomyopathy.		
Finally,	 by	 considering	 the	 observed	 phenotypes	 in	 the	 context	 of	 the	 larger	literature	 surrounding	 cardiac	 pathologies,	 I	 was	 able	 to	 generate	 testable	hypotheses	regarding	the	molecular	role	of	Hspb7	in	the	cardiomyocyte,	which	are	explored	in	the	following	Chapter.	
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CHAPTER	5: HSPB7	BINDS	TO	THE	SARCOMERIC	
PROTEIN	FLNC	AND	PREVENTS	ITS	AGGREGATION	
Introduction	In	order	to	make	testable	hypotheses	regarding	the	role	of	HSPB7	in	the	heart	as	a	whole,	and	to	understand	the	pathology	in	hspb7	mutant	zebrafish,	it	is	important	to	better	understand	its	function	at	a	cellular	and	molecular	level.	For	this	purpose,	a	model	system	was	required	in	which	HSPB7	is	expressed,	and	in	which	it	would	be	possible	to	successfully	perform	biochemical	experiments.	The	zebrafish	is	not	ideally	suited	to	this	purpose,	due	to	the	small	size	of	the	heart	and	the	general	lack	of	zebrafish	protein-specific	antibodies.		
HSPB7	is	expressed	in	the	murine	HL-1	cell	line	I	 initially	 turned	 to	 the	 murine	 atrial	 cardiac	 cell	 line	 HL-1,	 which	 is	 the	 only	available	 cardiac	 cell	 line	 that	 can	 be	 maintained	 and	 beats	 spontaneously	 in	culture68.	I	confirmed	by	Western	blotting	experiments	and	by	immunofluorescent	staining	(IF)	that	HSPB7	is	indeed	expressed	in	HL-1	cells	(Figure	5-1).	Using	IF	I	observed	that	HSPB7	is	expressed	throughout	the	cytoplasm	of	the	HL-1	cell,	but	does	not	 appear	 to	be	 completely	 excluded	 from	 the	nucleus.	This	 finding	 is	 in	keeping	with	previously	published	staining	for	a	tagged	HSPB7	isoform	expressed	ectopically	in	293T	cells174.	The	appropriate	expression	and	localization	of	HSPB7	in	 HL-1	 cells,	 in	 combination	 with	 the	 fact	 that	 these	 cells	 also	 express	 other	cardiac	proteins	and	form	functional	sarcomeres175,	recommended	this	cell	line	to	me	as	an	appropriate	choice	for	further	biochemical	studies.		
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Figure	5-1:	HSPB7	is	expressed	in	HL-1	cells.		
(A)Immunofluorescent	staining	for	HSPB7	(red)	shows	a	predominantly	cytoplasmic	
localization.	(B)	Western	blot	for	HSPB7	in	HL-1	cell	lysate.	The	protein	is	relatively	
stable	at	4°C	for	16	hours	post-lysis.		
HSPB7	binds	to	large	cytoskeletal	proteins	FLNC	and	
TITIN	Although	the	cellular	function	of	HSPB7	is	unclear,	it	has	been	shown	capable	of	preventing	aggregation	of	certain	proteins	by	in	vitro	assays126,127,	contingent	on	the	 presence	 of	 intact	 cellular	 autophagic	 machinery127.	 Seeking	 clues	 to	 its	function,	 I	sought	 to	 identify	proteins	 that	HSPB7	can	bind	 in	cardiomyocytes.	 I	first	 ascertained	 that	 HL-1	 lysates	 could	 be	 incubated	 overnight	 at	 4°C	 with	minimal	degradation	of	HSPB7	(Figure	5-1B).	I	immunoprecipitated	HSPB7	from	HL-1	 lysates	 and	 confirmed	 capture	 of	 the	majority	 of	 the	 protein	 by	Western	blotting	experiments	(Figure	5-2A).	In	order	to	confirm	that	I	could	detect	proteins	pulled	 down	 specifically	 with	 anti-HSPB7,	 and	 not	 with	 a	 control	 IgG,	 I	
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electrophoresed	 the	 lysates	 following	 precipitation	 and	 assessed	 pull-down	results	with	a	silver	stain	of	the	gel	(Figure	5-2B).		
Figure	 5-2:	 Successful	 immunoprecipitation	 of	 HSPB7	 and	 associated	
complexes	from	HL-1	cells.		
(A)	Western	blot	showing	specific	and	near-complete	capture	of	HSPB7	protein	from	
HL-1	 lysates	 following	 overnight	 immunoprecipitation	 at	 4°C.	 (B)	 Silver	 stain	 of	
immunoprecipitated	 proteins	 visualizes	 a	 number	 of	 protein	 bands	 that	 are	
specifically	pulled	down	with	anti-HSPB7	and	not	with	an	isotype	matched	control.		
Protein	bands	that	precipitated	specifically	with	anti-HSPB7	and	not	with	an	IgG	control	were	subjected	to	in-gel	trypsinolysis	and	identified	by	unbiased	tandem	mass-spectrometry	 (Figure	 5-3).	 Bands	 were	 identified	 using	 the	 less	 specific	Coomassie	stain,	due	to	the	unsuitability	of	silver-stained	gels	for	processing	for	mass	spectrometry.	I	identified	the	large	cytoskeletal	proteins	Filamin	and	TITIN	as	potential	HSPB7	binding	partners.	Although	Titin	is	an	interesting	target	which	
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has	 been	 shown	 to	 be	 indispensable	 for	myofibrillogenesis	 and	 cardiomyocyte	function176,177,	it	is	also	the	largest	protein	encoded	by	the	genome.	The	enormous	technical	challenge	of	conducting	biochemical	experiments	with	a	protein	of	this	magnitude	biased	my	decision	to	investigate	the	relationship	between	the	Filamins	and	HSPB7	more	closely.		
Figure	5-3:	Identification	of	binding	partners	of	HSPB7.		
Coomassie-stained	 gel	 with	 bands	 specific	 to	 immunoprecipitation	 of	 HSPB7	
identified	 and	 labelled.	 Unbiased	 mass	 spectrometer-based	 peptide	 identification	
identifies	Filamin-C	and	Titin	as	HSPB7	interaction	partners.	
HSPB7	 was	 reported	 previously	 to	 bind	 the	 ubiquitous	 isoform	 Filamin	 A132.	However,	note	that	coverage	for	peptides	from	FLNC	was	extensive	(Figure	5-3),	while	the	few	peptides	mapped	by	mass	spectrometry	as	coming	from	Filamin	A	or	Filamin	B	are	completely	conserved	in	FLNC.	Furthermore,	I	was	able	to	confirm	through	western	blotting	 experiments	 that	HSPB7	 co-immunoprecipitated	with	FLNC,	but	strikingly	not	the	A	isoform	(Figure	5-4).		
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Figure	5-4:	HSPB7	binds	specifically	to	FLNC.	
	(A)	Immunoprecipitation	of	HSPB7	or	Filamin-A	from	HL-1	cells	demonstrates	that	
they	do	not	interact.	(B)	Filamin-C	is	co-immunoprecipitated	with	HSPB7	from	HL-1	
cells.		
FLNC	 is	 the	muscle-specific	 isoform	of	 filamin,	with	 roles	 in	myogenesis178	 and	sarcomeric	 maintenance8,35,179.	 Given	 that	 HSPB7	 is	 expressed	 exclusively	 in	striated	muscle	and	at	a	higher	level	in	the	heart,	FLNC	is	an	excellent	candidate	for	a	functional	chaperone	target,	and	HSPB7	may	aid	in	either	protecting	FLNC	and	other	large	sarcomeric	proteins	from	damage,	or	facilitating	the	processing	of	these	proteins	after	damage	has	occurred.	I	reasoned	that	the	cardiac	phenotype	I	had	observed	in	hspb7	mutant	zebrafish	might	potentially	be	caused	by	alterations	in	 FLNC	 activity	 or	 regulation.	 Mutations	 in	 FLNC	 that	 affect	 its	 function	 or	predispose	it	to	aggregation	are	associated	with	a	range	of	myopathies	in	human	patients8,	including	some	cases	that	are	restricted	to	the	heart7,180.	Interestingly,	recent	modelling	of	one	of	these	mutations	in	mice	revealed	that	the	myopathy	is	exaggerated	by	acute	exercise181.		
HSPB7	is	not	required	for	HL-1	cell	survival	but	
appears	to	sensitize	the	cells	to	stress.	In	 the	 human	 and	mouse	 diseases	 discussed	 above,	 the	 filaminopathy	 leads	 to	cellular	 phenotypes	 including	 the	 formation	 of	 aggregates	 within	 the	cardiomyocyte	 and	 progressive	 degenerative	 myofibrillar	 changes.	 In	 order	 to	
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assess	whether	these	alterations	are	found	in	HSPB7	null	cardiomyocytes,	I	first	asked	whether	HSPB7	is	a	required	protein	in	the	HL-1	cell.	The	data	generated	in	the	zebrafish	suggested	that	HSPB7	is	not	required	for	cardiomyocyte	survival	or	proliferation.	 I	 utilized	 siRNA	 to	 knock	 down	 HSPB7	 (Figure	 5-5)	 and	 did	 not	observe	 alterations	 in	 cell	 survival	 (as	 assessed	 by	 trypan	 blue	 staining)	when	compared	with	a	control	siRNA.		
Given	both	the	role	of	HSPB7	as	a	chaperone	protein,	protecting	cells	from	protein	damage;	and	the	requirement	for	external	stress	to	precipitate	a	phenotype	in	the	
hspb7	mutant	 zebrafish,	 I	 hypothesized	 that	 the	phenotype	of	HSPB7	would	be	most	apparent	under	conditions	of	stress.	HL-1	cells	were	treated	with	increasing	concentrations	 of	 the	 cardiotoxic	 drug	 doxorubicin,	 and	 their	 survival	 was	assessed	 by	 trypan	 blue	 staining.	 Cells	 that	 had	 been	 transfected	 with	 siRNA	targeted	against	HSPB7	appeared	to	be	more	sensitive	to	doxorubicin	than	those	that	had	not	(Figure	5-5B).	However,	the	percentage	of	surviving	cells	seemed	to	vary	from	treatment	to	treatment.	
When	considering	the	potential	reasons	for	this	heterogeneity,	I	considered	more	carefully	 the	model	 system	 in	which	 I	was	working.	Whilst	 the	HL-1	cell	 line	 is	routinely	used	in	the	field,	it	has	a	number	of	caveats.	First,	the	cardiomyocytes	are	not	fully	differentiated	(which	allows	them	to	proliferate	and	be	passaged),	which	means	 that	 sarcomeric	 structures	 are	 incompletely	 formed.	 Second,	 within	 a	culture	 of	 HL-1	 cells	 there	 is	 heterogeneity	 in	 cell	 shape,	 size	 and	 beating	frequency.	
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Figure	5-5:	HL-1	cells	survive	in	the	absence	of	HSPB7	but	are	more	sensitive	to	
toxic	insult.		
(A)	Western	blot	for	HSPB7	shows	loss	of	protein	at	72	hours	post	transfection	with	
specific	 siRNA.	 (B)	 Quantification	 of	 living	 cells	 using	 trypan	 blue,	 3	 days	 post-
transfection	 with	 siRNA	 and	 following	 12	 hours	 treatment	 with	 doxorubicin	
hydrochloride	or	vehicle	control.		
This	heterogeneity	 is	also	reflected	 in	 the	 transcriptome	and	proteome	of	 these	cells;	 most	 importantly	 for	 my	 purposes,	 only	 a	 subset	 of	 HL-1	 cells	 were	expressing	HSPB7,	confounding	attempts	to	examine	the	effect	of	loss	of	HSPB7.		A	final	 consideration	 is	 that	 there	 are	 inherent	 differences	 between	 murine	 and	human	cardiomyocytes.	For	these	reasons,	I	decided	to	generate	a	stable	HSPB7	loss-of-function	model	in	a	system	that	better	modeled	cell	biology	of	the	human	heart.		
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Generation	of	HSPB7-/-	human	ESC-derived	CMs.	In	order	to	test	if	HSPB7	function	is	conserved	across	vertebrate	species,	and	to	facilitate	biochemical	investigation	into	the	molecular	role	of	HSPB7	in	a	human	cardiomyocyte,	I	used	the	inducible	CRISPR/Cas9	system145	to	target	mutations	to	the	HSPB7	locus	in	human	embryonic	stem	cells	(hESCs).	I	recovered	clonal	lines	in	 which	 HSPB7	 was	 predicted	 to	 be	 homozygous	 null	 (Figure	 5-6A).	 I	 also	identified	 lines	 that	 had	 proceeded	 ‘unsuccessfully’	 through	 CRISPR	 targeting,	retaining	wildtype	HSPB7,	and	used	these	as	control	“wildtype”	lines.		
HSPB7	is	not	expressed	in	ESCs,	and	both	wildtype	and	HSPB7-/-	clones	maintained	normal	 ESC	 morphology,	 expressing	 comparable	 levels	 of	 pluripotency	 genes,	including	SOX2,	NANOG	and	KLF4	(Figure	5-6B).		
I	used	a	directed	differentiation	protocol	(modified	from	Lian	et	al	(2012)149)	to	generate	 beating	 cardiomyocytes	 from	 the	 hESC	 lines	 and	was	 able	 to	 confirm	through	flow	cytometry	(Figure	5-6C,D)	and	IF	(Figure	5-6E)	successful	generation	of	 cardiomyocytes	 in	numbers	 comparable	 in	both	wildtype	and	mutant	HSPB7	lines.	IF	in	hESC-CMs	also	confirmed	that	HSPB7	protein	is	absent	from	the	mutant	cells	(Figure	5-6E).	HSPB7	mutant	cardiomyocytes	were	competent	to	differentiate	to	cardiac	fate	and	observed	to	form	beating	sheets.		
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Figure	 5-6:	 Generation	 of	 HSPB7	 mutant	 hESC	 and	 hESC-derived	
cardiomyocytes.		
(A)	 Structure	 and	 partial	 sequence	 of	 the	 human	 HSPB7	 gene,	 showing	 CRISPR	
targeting	 immediately	 downstream	 of	 the	 start	 codon	 and	 resultant	 HSPB7	
homozygous	and	compound	heterozygous	mutant	clones	 that	were	recovered.	 (B)	
qPCR	 quantification	 of	 expression	 levels	 of	 pluripotency	 markers	 are	 normal	 in	
HSPB7	 mutant	 hESC	 clones.	 HSPB7	 mutant	 lines	 are	 competent	 to	 generate	
cardiomyocytes,	and	do	not	have	HSPB7	protein	as	shown	by	flow	cytometry	(C,D)	
and	immunofluorescence	(E),	both	performed	on	day	10	of	differentiation.	(F)	qPCR	
qunatification	of	cardiac	HSPB	family	members	in	hESC-CMs.			 	
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This	was	not	unexpected	given	that	hspb7	mutant	zebrafish	have	functional	hearts,	and	 that	 knockdown	 of	 HSPB7	 in	 HL-1	 cells	 did	 not	 lead	 to	 cardiomyocyte	deterioration.	Taken	together,	these	findings	lead	to	the	conclusion	that	HSPB7	is	not	 required	 for	 successful	 cardiomyocyte	 specification	 or	 basic	 cardiomyocyte	function.	 However,	 if	 HSPB7	 functions	 as	 a	 sarcomeric	 cytoskeletal	 chaperone	protein,	we	considered	that	the	differentiated	mutant	cells	might	display	protein	aggregation	phenotypes.	
FLNC	aggregates	in	HSPB7	mutant	cardiomyocytes	To	compare	levels	of	aggregate	formation,	the	filter	trap	assay	was	employed	(Vos	et	al.,	2010).	Cardiomyocytes	derived	from	HSPB7	mutant	hESC	lines	showed	an	increase	in	FLNC	aggregates	when	compared	with	cardiomyocytes	derived	from	wildtype	control	lines	(Figure	5-7A,B).	I	also	observed	an	increase	in	puncta	when	staining	for	FLNC	by	immunofluorescence.		
These	 findings	 demonstrate	 abnormalities	 in	 human	 cardiomyocytes	 lacking	HSPB7.	 However,	 the	 lack	 of	 overt	 pathology	 suggests	 that	 in	 human	cardiomyocytes,	as	in	zebrafish,	the	cell	is	able	to	tolerate	the	detrimental	effect	that	absence	of	HSPB7	has	on	cardiomyocyte	 function,	perhaps	by	upregulating	pathways	that	remove	aggregated	proteins.			
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Figure	5-7:	Increase	in	FLNC	aggregation	in	HSPB7mutant	hESC-CMs.		
(A)	Filter	trap	assay	probing	for	Filamin	C	in	lysates	from	day	10	hESC-CMs	shows	
increase	in	FLNC-containing	aggregates	in	HPSB7-/-	cardiomyocytes	when	compared	
to	 wildtype.	 Representative	 image.	 (B)	 Quantification	 of	 filter	 trap	 assays.	 n=5.	
Immunofluorescence	 for	 cardiac	 troponin	 (red)	 and	 FLNC	 (green)	 in	 hESC-CMs	
derived	from	HSPB7	wildtype	(C)	or	HSPB7	(D)	mutant	lines.	White	arrowheads	mark	
puncta.		 	
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Autophagy	is	enhanced	in	HSPB7	mutant	
cardiomyocytes	Some	members	of	the	sHSP	family	are	known	to	be	involved	in	protein	degradation	pathways,	including	specific	types	of	chaperone-assisted	autophagy46.	HSPB7	has	been	 linked	 to	 the	autophagic	process,	because	 the	ability	of	HSPB7	 to	prevent	aggregation	of	poly-glutamate	proteins	was	attenuated	in	the	absence	of	the	key	autophagic	 protein	 Atg5127.	 Damaged	 FLNC	 has	 been	 recently	 shown	 to	 be	degraded	 in	 a	 rat	 aortic	 cell	 line	 through	 the	 process	 of	 Chaperone	 Assisted	Selective	Autophagy	(CASA),	in	which	a	CASA	protein	complex	facilitates	transport	of	 the	 damaged	 protein	 to	 the	 autophagosome46.	 Given	 these	 links,	 we	hypothesized	that	to	compensate	for	loss	of	HSPB7,	mutant	cardiomyocytes	might	enhance	autophagic	processes	to	facilitate	removal	of	damaged	proteins.	This	was	tested	 by	 measuring	 autophagy	 levels	 through	 visualization	 of	 the	 autophagy	marker	 LC3.	 I	 stained	 differentiated	wildtype	 and	HSPB7	mutant	 hESC-derived	cardiomyocytes	for	LC3	(Figure	5-8A,B)	and	quantified	the	number	and	size	of	LC3	positive	puncta	as	described153.	I	observed	an	increase	in	the	number	and	size	of	puncta	 in	 HSPB7	 mutant	 cardiomyocytes	 when	 compared	 with	 control	 lines	(Figure	 5-8C),	 demonstrating	 an	 upregulation	 of	 autophagy	 in	 the	 absence	 of	
HSPB7.	
	 	117	
Figure	 5-8:	 Upregulation	 of	 autophagic	 processes	 in	 HSPB7	 null	
cardiomyocytes.		
Representative	images	of	 immunofluorescence	for	LC3B	(green)	in	wildtype	(A)	or	
HSPB7	mutant	 (B)	 hESC-CMs.	 Co-stained	 with	 anti-cardiac	 troponin	 T	 (red)	 and	
counterstained	with	 DAPI	 (blue).	 (C)	 Quantification	 of	 LC3B	 puncta	 in	 hESC-CMs	
shows	an	increase	in	average	puncta	number	in	HSPB7	mutant	cardiomyocytes.		
Overall	LC3B	levels	were	seen	to	be	slightly	increased	over	wildtype	by	western	blot	 in	 both	 HSPB7	mutant	 hESC-CM	 and	 adult	 hspb7WC3/WC3	 zebrafish	 hearts	(Figure	5-9).	Increased	LC3B	protein	level	is	not	directly	correlated	with	increased	autophagy.	 However,	 in	 conjunction	 with	 the	 observation	 of	 increased	 LC3B	puncta,	this	is	strong	evidence	that	the	autophagic	program	is	activated	in	HSPB7	null	cardiomyocytes.	
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Figure	 5-9:	 Autophagy	 marker	 LC3B	 is	 increased	 in	 HSPB7	 mutant	
cardiomyocytes.		
Western	 blot	 for	 LC3B	 in	 lysates	 from	 hESC-CM	 (A)	 or	 adult	 zebrafish	 heart	 (B).	
Quantification	by	densitometry	(right)	indicates	a	slight	increase	in	LC3B	in	cells	or	
hearts	that	are	lacking	HSPB7.	
Upregulation	of	FLNC	expression	in	HSPB7	mutant	
cardiomyocytes.		A	separate	arm	of	 the	CASA	process	also	 leads	 to	upregulation	of	expression	of	degraded	proteins46.	This	is	especially	important	in	muscles	for	maintaining	the	stoichiometry	of	the	sarcomere.	Following	on	from	our	discoveries	that	FLNC	is	prone	 to	 aggregation	 in	 HSPB7	 null	 cardiomyocytes	 (Figure	 5-7),	 and	 a	concomitant	upregulation	in	autophagy	(Figure	5-8,	Figure	5-9),	we	hypothesized	that	the	CASA	process	is	activated	in	these	cells.	 I	performed	qPCR	analysis	and	
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discovered	that	expression	of	FLNC	is	upregulated	in	HSBP7	null	hESC-CMs	(Figure	5-10).	
Figure	5-10:	FLNC	expression	is	upregulated	in	HSPB7	mutant	hESC-CMs.	
qPCR	analysis	 of	 gene	 expression	 in	hESC-CMs	on	day	15	of	 differentiation	 shows	
upregulation	of	FLNC	expression	in	HSBP7	mutant	cardiomyocytes.	Data	is	pooled	
for	Wildtype	and	Clone	12	(HSPB7+/+)	and	Clone	26	and	30	(HSPB7-/-).	
Homozygous	hspb7	mutant	zebrafish	embryos	exhibit	
increased	sensitivity	to	autophagy	inhibition	The	 increase	 in	 autophagy	measured	 in	HSPB7	 mutant	 human	 cardiomyocytes	indicates	a	requirement	for	activation	of	this	pathway	in	order	to	maintain	normal	cardiac	function.	This	could	be	one	of	the	mechanisms	by	which	zebrafish	embryos	compensate	for	the	loss	of	Hspb7	during	cardiogenesis.	In	this	case,	hspb7	mutants	are	predicted	to	be	hyper-sensitive	to	the	loss	of	autophagy.	To	test	this	prediction,	we	 exposed	wildtype	 or	hspb7	mutant	 zebrafish	 embryos	 to	 a	 small	molecular	inhibitor	 of	 the	 pathway,	 Bafilomycin	 A1	 (BafA).	 BafA	 prevents	 the	 fusion	 of	autophagosomes	 with	 lysosomes,	 inhibiting	 the	 last	 step	 of	 autophagy.	 BafA	treatment	led	to	a	dose-dependent	increase	in	the	incidence	of	cardiomyopathy	in	
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both	hspb7WC3	and	hspb7WC4	homozygous	mutants,	 but	 not	 in	wildtype	 controls	(Figure	5-11).		
Figure	5-11:	Inhibition	of	autophagy	leads	to	cardiac	malformation	in	hspb7	
mutant	zebrafish	embryos.		
Representative	images	of	72hpf,	Bafilomycin	A-treated	wildtype	(A)	or	hspb7WC3.WC3	
(B)	 embryos	which	have	been	crossed	onto	a	 tg(myl7:gfp)	background	 showing	a	
cardiac	malformation	with	expansion	of	the	atrium	and	an	undersized	ventricle	in	
the	hspb7WC3/WC3	fish.	(C)	Quantification	of	the	percentage	of	embryos	with	cardiac	
abnormalities	 at	 48hpf	 following	 24	 hours	 of	 treatment	 with	 increasing	
concentrations	of	Bafilomycin	A.	n=40	for	each	treatment	group.	(D)	hspb7	mutant	
embryos	consistently	exhibit	significant	increases	in	cardiac	abnormalities	following	
treatment	iwth	Bafilomycin.	
We	also	exposed	control	or	hspb7	mutant	 embryos	 to	 chloroquine	diphosphate	(CQ)	or	3-methyladenine	(3-MA),	autophagy	inhibitors	with	different	mechanisms	of	action.	Similar	to	BafA,	both	CQ	and	3-MA	led	to	increases	in	cardiac	defects	in	
hspb7	mutant	 embryos	but	not	 in	wildtype	 controls.	This	 confirms	 that	normal	cardiogenesis	in	hspb7	mutant	embryos	is	reliant	on	autophagy.		
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Discussion	To	understand	the	role	of	HSPB7	in	the	cardiomyocyte,	 I	used	a	range	of	model	systems	to	best	answer	a	number	of	specific	questions.		
I	 discovered	 that	 in	 cardiomyocytes	 FLNC	 is	 an	 endogenous	binding	partner	 of	HSPB7	and	that	FLNC	aggregates	form	in	the	absence	of	HSPB7.	FLNC	is	a	large	sarcomeric	protein	that	interacts	with	both	Z-disc	components	and	sarcolemma-associated	proteins,	 leading	 to	 speculation	 that	 it	may	 act	 as	 both	 an	 assembly	point	 for	 myofibrils	 in	 early	 myogenesis178,182	 and	 as	 a	 mediator	 of	 signal	transduction	 from	 the	 sarcolemma	 to	 the	 sarcomere8,35,	 facilitating	 myofibril	maintenance.	Loss	of	FLNC	is	associated	with	defects	in	myogenesis178,	and	human	mutations	are	associated	with	a		range	of	skeletal	and	cardiac	myopathies7,8,180,183,	many	 of	 which	 are	 associated	 with	 the	 formation	 of	 pathological	 aggregates	containing	 FLNC.	 I	 observed	 aggregates	 in	 cardiomyocytes	 lacking	 HSPB7,	indicating	that	 loss	of	HSPB7	may	affect	 the	stability	or	processing	of	FLNC.	My	data	indicate	that	HSPB7	also	binds	to	at	least	one	other	large	sarcomeric	protein,	TITIN.	Further	studies	are	needed	to	determine	if	HSPB7	is	a	dedicated	chaperone	for	these	two,	or	if	this	role	is	generalized	to	many	large	sarcomeric	proteins.	My	results	are	consistent	with	a	recent	report	that	HSPB7	can	bind	FLNC	in	skeletal	muscle136.	 Knockout	 of	 HSPB7	 in	 skeletal	 muscle	 caused	 lethal	 progressive	myopathy,	found	to	be	most	severe	in	the	diaphragm136.	Contrary	to	this	report,	I	did	not	observe	hallmarks	of	progressive	myopathy	in	the	skeletal	muscle	of	hspb7	mutant	zebrafish,	but	it	is	interesting	to	note	that	the	diaphragm	is	the	one	muscle	that,	like	the	heart,	must	move	continuously	in	order	to	maintain	life.	Either	this	function	is	not	conserved	in	zebrafish	(which	of	course	lack	a	diaphragm),	or	loss	
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of	Hspb7	is	better	compensated	in	the	skeletal	muscle	of	zebrafish	compared	with	mouse.	
I	 hypothesized	 that	HSPB7	may	 bind	 to	 proteins	 that	 need	 to	 be	 processed	 by	autophagy,	since	this	function	has	been	demonstrated	for	family	member	HSPB846,	expressed	more	generally	in	all	striated	muscle.	I	found	that	autophagic	processes	are	enhanced	 in	HSPB7-depleted	cardiomyocytes	and	 that	 impairing	autophagy	during	embryogenesis	causes	lethal	cardiomyopathy	in	developing	hspb7	mutant	embryos.	Recent	studies	have	suggested	that	damaged	FLNC	is	among	the	proteins	degraded	 by	 autophagy,	 a	 catabolic	 cellular	 process	 for	 the	 breakdown	 and	recycling	 of	 extraneous	 or	 defective	 proteins	 and	 complexes46.	 The	 role	 of	autophagy	in	the	heart	is	known	to	be	relatively	complex.	Key	autophagic	proteins	are	 required	 for	 normal	 cardiac	 development184,	 and	 autophagic	 turnover	 is	known	 to	 occur	 in	 the	 healthy	 heart185.	 Increases	 in	 autophagy	 are	 seen	 in	situations	of	cardiac	stress,	presumably	in	response	to	an	increase	in	damaged	and	dysfunctional	 proteins	 downstream	 of	 mechanical	 or	 oxidative	 stressors.	However,	either	too	little	or	too	much	autophagy	is	pathological	under	conditions	of	cardiac	stress54,58,186,	indicating	that	the	process	must	be	carefully	balanced.	A	model	consistent	with	my	data	is	that	the	absence	of	HSPB7	leads	to	an	increase	in	damage	or	unfolding	of	FLNC,	resulting	in	compensatory	activation	of	autophagic	pathways	to	prevent	aggregate	formation.		
A	 recent	 study	 also	 described	 a	 potential	 role	 for	 FLNC	 in	 the	 fast	 repair	 of	myofibrillar	microdamage35,	indicating	a	potential	role	as	a	signaling	hub	for	the	efficient	reassembly	of	sarcomeric	structures.	Given	this	finding,	a	decrease	in	the	availability	of	functional	FLNC	caused	by	mutation	of	hspb7	could	have	effects	on	the	ability	of	the	myocyte	to	repair	damage	at	multiple	steps.	The	importance	of	
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FLNC	for	both	muscle	function	and	repair	could	explain	the	increase	in	fibrosis	and	mortality	 observed	 in	 hspb7	 mutant	 zebrafish.	 I	 expect	 that	 FLNC	 depletion	amplifies	 the	 effects	 of	 high	 intensity	 exercise	 to	 a	 pathological	 level,	 leaving	cardiomyocytes	with	a	burden	of	unstable	sarcomeric	lesions	that	results	in	death	in	a	subset	of	mutant	animals.		
Conclusions	My	 study	 provides	 novel	 insight	 into	 how	 HSPB7	 regulates	 proteostatic	mechanisms	that	function	in	a	cardiomyocyte,	and	a	new	model	for	human	stress-dependent	 cardiomyopathy.	 Future	 studies	 need	 to	 investigate	 the	 relationship	between	 HSPB7	 and	 the	 delivery	 of	 FLNC	 to	 autophagic	 organelles.	 Given	 the	complex	role	of	autophagy	 in	 the	sarcomere,	direct	 therapeutic	manipulation	 is	likely	to	be	inherently	risky.	However,	by	manipulating	specific	components	like	HSPB7	 that	 have	 a	 regulatory	 role,	 redirection	 or	 optimization	 of	 autophagic	processes	might	 be	 achieved	 that	 will	 be	 clinically	 beneficial	 for	 patients	 with	disorders	of	aggregation.		
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CHAPTER	6: GENERATION	AND	
CHARACTERIZATION	OF	ZEBRAFISH	WITH	MUTATIONS	
IN	GATA4	AND	GATA6	
Introduction	The	GATA	transcription	factors	are	a	family	of	zinc	finger	transcription	factors	that	regulate	 transcriptional	 programs	 in	 a	 number	 of	 developing	 organs.	 Our	laboratory	was	 interested	 in	 further	 investigating	the	roles	of	Gata4,	Gata5,	and	Gata6	in	the	developing	zebrafish.	Previous	work	by	both	our	own	laboratory82,154,	and	 others187,	 has	 utilized	 the	 morpholino	 system	 to	 knockdown	 gata	 family	members	 in	 the	 developing	 zebrafish.	 Briefly,	 these	 studies	 identified	 roles	 for	
gata4,	 -5	and	 -6	 in	 the	mesendoderm	and	mesendoderm-derived	organs,	which	aligns	with	the	roles	of	the	murine	and	human	homologues.	Interestingly,	studies	in	 multiple	 systems	 have	 indicated	 redundancy	 between	 the	 GATA	factors92,108,109,116.			I	set	out	to	make	use	of	novel	genome	editing	technologies	to	generate	zebrafish	lines	 in	which	different	combinations	of	gata4,	 -5	and	-6	had	been	mutated,	allowing	us	to	further	investigate	these	redundancies.	In	addition,	these	 lines	will	give	us	more	 information	about	 the	specific	 roles	of	each	GATA	protein	 at	 various	 points	 in	 development,	 and	 could	 reveal	 any	 previously-recorded	phenotypes	 that	were	due	 to	 off-target	 effects	 of	morpholinos,	 or	 are	caused	by	acute	knockdown	but	not	genetic	lesion.		
Generation	of	gata4	mutant	fish	The	DNA	 binding	 domain	 of	 the	 GATA	 factor	 proteins	 is	 composed	 of	 a	 highly	conserved	 motif	 in	 which	 a	 series	 of	 cysteine	 residues	 coordinate	 a	 zinc	 ion,	stabilizing	 the	 protein	 structure.	 Previous	 work	 from	 our	 laboratory	 has	
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demonstrated	that	mutation	of	a	single	C-X-X-C	motif	in	the	zinc	finger	closest	to	the	C-terminal	of	a	GATA	protein	leads	to	a	complete	loss	of	DNA	binding	activity71,	a	phenomenon	also	seen	in	other	zinc	fingers188.	Thus,	I	injected	mRNA	encoding	TALENs	 targeted	 to	 the	DNA	encoding	 this	same	amino	acid	 in	zebrafish	gata4,	reasoning	 that	 even	 a	 small	 mutation	 would	 lead	 to	 complete	 loss	 of	 protein	function	 (Figure	 6-1A).	 Following	 breeding	 of	 founder	 zebrafish,	 I	 recovered	 a	range	of	mutant	gata4	alleles	predicted	to	interfere	with	protein	function	(Figure	6-1B).	Moving	forward,	I	chose	to	focus	on	an	allele	that	encoded	a	premature	stop	codon,	 truncating	 gata4	before	 the	 second	 zinc	 finger;	 and	 on	 a	mutation	 that	specifically	deletes	the	C-X-X-C	motif	and	two	adjacent	amino	acids.	These	alleles	will	be	referred	to	as	gata4WC6	and	gata4WC5.	
Figure	6-1:	TALEN-mediated	generation	of	mutations	in	gata4.	
(A)	 Structure	 and	 partial	 sequence	 of	 zebrafish	 gata4.	 (B)	 Predicted	 protein	
sequences	 of	 recovered	 Gata4	 mutants.	 Alleles	 WC5	 and	 WC6	 are	 of	 particular	
interest	for	further	studies	and	are	highlighted	in	bold.	
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In	the	absence	of	the	creation	or	loss	of	a	unique	restriction	enzyme	recognition	sequence,	 I	 designed	 a	 PCR	 genotyping	 strategy	 for	 the	 gata	 alleles,	 which	 is	detailed	in	Chapter	2	of	this	thesis.	
Gata4	homozygous	mutants	develop	normally	but	are	
recovered	in	lower	than	expected	numbers.		To	my	surprise,	unlike	the	gata4	morphants,	or	previously	detailed	mutations	in	murine	or	human	GATA4,	zebrafish	were	able	to	tolerate	homozygous	mutation	in	
gata4.	Homozygous	mutant	animals	were	identified	in	clutches	of	embryos	from	heterozygous	crosses	and	were	viable	to	adulthood	and	fertile.	Maternal-zygotic	homozygous	 (MZ)	 mutant	 animals	 carrying	 either	 of	 the	 two	 gata4	 alleles	developed	normally	and	resembled	wildtype	embryos	(Figure	6-2).			
Figure	 6-2:	 Gata4	 mutant	 zebrafish	 have	 normal	 phenotypes	 during	
embryogenesis.	
Brightfield	images	of	wildtype	and	gata4	mutant	embryos	at	3dpf.	
	 	127	
Despite	a	normal	body	plan	and	no	gross	developmental	defects,	I	observed	that	24hpf	 gata4	 mutants	 consistently	 appeared	 several	 hours	 less	 developed	 than	wildtype	embryos	of	the	same	age.	I	closely	tracked	the	development	of	clutches	of	gata4	mutant	embryos	and	identified	a	very	specific	delay	in	their	development	which	commenced	at	sphere	stage	(4hpf)****	(Figure	6-3A).		
The	 time	 taken	 for	 gata4	 mutants	 to	 achieve	 dome	 stage	 (4.33hpf)	 was	significantly	longer	than	that	taken	for	wildtype	embryos	(Figure	6-3B).	The	delay	increased	 from	around	1	hour	at	dome	stage	 to	around	2	hours	at	 shield	 stage	(6hpf).	 Following	 shield	 stage,	 gata4	 mutants	 resumed	 normal	 rates	 of	development,	 so	 that	 the	 2-hour	 delay	 was	 retained	 at	 Prim	 5	 (24hpf).	 This	suggests	 that	 specific	processes	occurring	between	 sphere	 and	 shield	 stage	 are	compromised	by	the	lack	of	Gata4.		
	
																																																								
****	 Stages	 of	 zebrafish	 embryo	 development	 were	 named	 and	 given	 ‘normal’	 timepoints	 as	previously	described10.			
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Figure	6-3:	Gata4	mutant	embryos	are	developmentally	delayed	during	early	
gastrulation.	
(A)	Visualization	of	the	time	taken	for	batches	of	wildtype	and	gata4	mutant	embryos	
to	 achieve	 each	 developmental	 stage.	 Points	 are	mean	 time	±	 S.D.	 Yellow	 arrows	
demarcate	boundaries	of	delayed	period.	Sketch	illustrations	adapted	from	Kimmel	et	 al.	 (1995)10.	 (B)	 Quantification	 of	 time	 taken	 to	 reach	 specific	 stages	 of	
development	highlights	significant	delay	in	gata4	mutant	embryos.	(n=3	batches).	
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Gata4	mutants	are	specifically	delayed	in	early	
embryogenesis	The	delay	observed	during	gastrulation	of	the	gata4	mutants	suggests	that	gata4	is	required	during	early	embryogenesis	in	zebrafish.	I	wanted	to	discover	whether	loss	of	gata4	may	also	lead	to	other	earlier	or	later	defects	in	some	percentage	of	homozygous	mutants.	To	identify	broad	periods	of	development	in	which	gata4	homozygous	mutants	might	be	lost,	I	genotyped	the	offspring	from	heterozygous	crosses	at	3dpf,	and	in	adulthood.	No	abnormal	embryo	death	was	observed	before	3dpf.	 I	 discovered	 that	 gata4	 homozygotes	 are	 not	 recovered	 at	 expected	frequencies	(Figure	6-4).		
Figure	6-4:	Homozygous	gata4	mutants	are	not	recovered	in	expected	ratios.	
(A)	Quantification	of	genotypes	of	embryos	from	crosses	of	adults	heterozygous	for	
any	gata4	mutation.	Lower	than	expected	recovery	of	homozygous	gata4	mutants	is	
observed	regardless	of	where	the	gata4WC6	(B)	or	gata4WC5	(C)	allele	is	considered.		
At	3dpf,	we	recovered	17.93%	homozygous	mutants,	significantly	different	from	the	expected	25%	(n=500,	p<0.0001).	Recovery	of	homozygous	mutant	genotypes	fell	further	to	11.5%	in	adult	animals	(n=52,	p<0.05),	demonstrating	an	additional	loss	of	gata4	mutant	animals	after	3dpf.		
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These	results	suggest	both	an	earlier	and	a	later	effect	of	gata4	mutation	than	the	developmental	delay	detailed	above.		
Overexpression	of	gata6	in	gata4	mutant	embryos	The	overall	normal	development	of	gata4	mutant	embryos	was	unexpected,	and	I	hypothesized	that	other	gata	factors	may	be	compensating	for	the	loss	of	gata4.	As	discussed	above,	this	phenomenon	has	been	previously	observed,	although	never	before	to	the	extent	of	complete	rescue.	I	extracted	RNA	from	zebrafish	embryos	at	 timepoints	 during	 the	 first	 3	 days	 of	 development	 and	 quantified	 gene	expression	by	qPCR.	I	observed	upregulation	of	gata6	in	gata4	null	animals.	
Figure	 6-5:	 gata6	 expression	 is	 upregulated	 in	 gata4	 homozygous	 mutant	
embryos	at	50%	epiboly.	
Quantification	of	expression	of	a	subset	of	gata	factors	in	wildtype	and	gata4	mutant	
embryos	at	50%	epiboly	by	qPCR.		
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Generation	of	gata6	mutants	In	order	to	study	the	role	of	gata6	in	the	developing	zebrafish	embryo,	we	utilized	the	same	strategy	that	we	had	applied	for	gata4.	TALENs	were	designed	to	target	the	second	zinc	finger	(Figure	6-6A)	and	I	recovered	animals	harboring	a	gata6	allele	with	a	14	base	pair	deletion	leading	to	a	frame	shift	(gata6WC7),	leading	to	loss	of	the	second	zinc	finger	and	the	C-terminal	of	the	protein	(Figure	6-6B).	The	same	 allele	 was	 recovered	 from	multiple	 F0	 injected	 animals	 and	 is	 likely	 the	product	of	microhomology-mediated	repair	around	the	TALEN	site.		
Figure	6-6:	TALEN-mediated	generation	of	a	gata6	mutant	allele.	
(A)	Structure	and	partial	sequence	of	the	zebrafish	gata6	gene.	(B)	Predicted	protein	
sequence	of	a	recovered	gata6	allele.	
Abnormal	development	in	gata6	mutant	zebrafish	Unlike	gata4	mutants,	gata6	mutants	were	recovered	at	much	closer	to	expected	ratios	 at	 3dpf	 (Figure	 6-7C),	 however	 they	 also	 presented	with	 severe	 defects.	Phenotyping	 of	 clutches	 of	 embryos	 from	gata6	 heterozygous	 crosses	 revealed	~20%	 of	 embryos	with	 abnormal	 phenotypes	 at	 3dpf.	 By	 light	microscopy	we	observed	severe	defects	in	cardiomorphogenesis	with	concomitant	cardiac	edema,	yolk	sac	edema	and	an	abnormally	thin	tail	(Figure	6-7B,C).		
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Figure	6-7:	Gata6	mutation	leads	to	lethal	abnormalities.	Gata6WC7/WC7	 embryos	 display	 developmental	 abnormalities	 by	 (A)	 48hpf,	 which	
become	more	 severe	by	 (B)	72hpf.	Representative	 images.	Quantification	of	gata6	
genotype	in	embryos	from	adults	carrying	heterozygous	gata6WC7	alleles	at	(C)	3dpf	
and	(D)	3	months.	
Genotyping	of	embryos	revealed	that	100%	of	embryos	(8/8)	presenting	with	this	phenotype	were	 homozygous	 for	 the	 gata6WC7	 allele.	 However,	 around	 25%	 of	
gata6	homozygous	mutants	(3/11)	appeared	grossly	normal.	When	adult	animals	from	 a	 heterozygous	 cross	were	 genotyped,	 I	 did	 not	 recover	 any	 homozygous	
gata6	mutants	(Figure	6-7D),	indicating	that	even	those	that	appear	normal	at	3dpf	subsequently	perish.	In	addition,	I	recovered	significantly	less	heterozygotes	in	the	surviving	animals	than	predicted	by	Mendelian	genetics	(44.4%	instead	of	66.7%,	p<0.01).	This	suggests	that	haploinsufficiency	for	gata6	 is	sufficient	to	 lead	to	a	failure	to	thrive	phenotype.		
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Generation	and	phenotyping	of	gata4/gata6	
compound	mutants	Given	the	normal	phenotypes	seen	in	around	a	quarter	of	gata6	mutants	and	in	almost	 all	 gata4	 homozygous	 mutants,	 and	 following	 leads	 from	 published	literature,	 I	hypothesized	that	 these	two	transcription	 factors	are	compensating	for	each	other.	In	order	to	investigate	further	their	interactions,	I	bred	gata4	and	
gata6	heterozygous	animals	and	recovered	compound	heterozygous	 fish,	which	were	 predominantly	 phenotypically	 normal	 (Figure	 6-8A),	 viable	 to	 adulthood,	and	fertile.		
I	phenotyped	clutches	of	embryos	from	crosses	of	adult	compound	heterozygotes	and	 observed	 striking	 phenotypes	 by	 3dpf.	 Some	 embryos	 presented	 with	exclusively	 cardiac	 malformation	 and	 edema,	 similar	 to	 the	 gata6WC7/WC7	phenotype	 (Figure	6-7A,B),	whereas	others	had	a	combination	of	abnormalities	including	cardiac	malformation,	edema,	thin	tails	with	somite	abnormalities	and	craniofacial	abnormalities	(Figure	6-8A).	I	also	observed	compromised	blood	flow	in	some	embryos,	but	this	appears	to	be	due	to	cardiac	dysfunction	rather	than	defects	in	blood	or	vascular	development	(data	not	shown).	Finally,	I	noted	that	there	appear	to	be	abnormalities	in	the	shape	and	positioning	of	melanocytes	in	many	of	these	embryos,	but	this	phenotype	was	not	explored	further	at	this	time.		
Genotyping	of	phenotyped	embryos	revealed	that	the	abnormalities	we	observed	were	 predominantly	 present	 in	 embryos	 with	 homozygous	 mutation	 of	 gata6	(Figure	 6-8B).	 However,	 as	 I	 observed	 previously,	 some	 animals	 carrying	mutations	only	on	both	gata6	alleles	appeared	normal.	The	percentage	of	‘normal’-looking	gata6	mutants	decreased	with	concomitant	loss	of	gata4	alleles	and	0%	(7/7)	of	embryos	carrying	mutations	on	all	4	gata	alleles	presented	with	a	normal	
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phenotype	 at	 3dpf.	 This	 strengthens	 our	 hypothesis	 that	 gata4	 is	 able	 to	compensate	for	gata6	during	early	development	in	a	relatively	small	percentage	of	zebrafish.			
Figure	 6-8:	 Progressive	 loss	 of	 gata	 factors	 leads	 to	 increasingly	 severe	
developmental	abnormalities.		
Brightfield	phenotypes	of	embryos	from	a	cross	of	gata4WC5/+;gata6WC7/+	adults	show	
(A)	normal	development	of	compound	heterozygous	embryos	but	(B’)	craniofacial	
and	cardiac	abnormalities	and	(B’’)	tail	defects	in	embryos	lacking	both	gata4	and	gata6.	 Representative	 images.	 (C)	 Genotyping	 of	 embryos	 after	 phenotyping	with	
light	 microscopy	 reveals	 that	 major	 defects	 are	 predominantly	 associated	 with	
homozygous	gata6	mutation.	Overall	n=105.			
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Defects	in	cardiac	chamber	specification	and	cardiac	
morphogenesis	in	gata6	mutant	embryos.		In	order	 to	better	characterize	 the	abnormal	 cardiac	morphology	seen	 in	gata6	mutant	 embryos,	 I	 performed	 wholemount	 in	 situ	 hybridization	 (WISH)	 to	document	the	expression	patters	of	chamber-specific	cardiac	markers.	As	seen	by	brightfield	 microscopy,	 I	 observed	 linear	 heart	 tubes	 in	 the	 majority	 of	 gata6	mutant	embryos	with	ISH	for	atrial	marker	amhc	(Figure	6-9).		
Figure	 6-9:	 Gata6	 mutant	 embryos	 have	 abnormally	 shaped	 hearts	 with	
ectopic	amhc	expression.	Amhc	 staining	 patterns	 observed	 in	 3dpf	 embryos	 from	 cross	 of	gata4WC5/+;gata6WC7/+	 adults	 show	 a	 range	 from	 (A)	 normal	 amhc	 expression	
through	(B)	D-looped	hearts	and		(C)	unlooped	chambers	to	(D)	linear	heart	tubes.	
Representative	 images.	 (E)	 Quantification	 of	 genotypes	 after	 assessment	 of	 amhc	
expression	pattern	indicates	that	abnormalities	are	predominantly	associated	with	
homozygous	gata6	mutation.	
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Interestingly,	in	most	gata4;gata6	homozygous	mutants,	amhc	is	highly	expressed	throughout	 the	 bulk	 of	 the	 length	 of	 the	 linearized	 tube.	 In	 contrast,	 when	 I	performed	 WISH	 for	 vmhc,	 I	 observed	 a	 major	 reduction	 in	 staining	 in	 gata6	mutant	embryos	(Figure	6-10).	
Figure	6-10:	Decrease	in	vmhc	expression	in	gata6	mutant	embryos.	
Vmhc	 staining	 patterns	 observed	 in	 3dpf	 embryos	 from	 cross	 of	
gata4WC6/+;gata6WC7/+	 adults	 show	 a	 range.	 Representative	 images	 of	 (A)	 normal	
staining,	 (B)	central	ventricle,	 (C)	reduced	staining,	and	(D)	minimal	staining.	 (E)		
Quantification	of	genotypes	after	assessment	of	vmhc	expression	pattern	indicates	
that	decreases	in	vmhc	expression	are	predominantly	associated	with	homozygous	gata6	mutation.	n=40	
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In	combination,	 these	observations	suggest	that	that	the	ventricle	either	 fails	 to	properly	 specify	 or	 that	 ventricular	 progenitors	 fail	 to	 expand	 in	gata6	mutant	embryos.	
Loss	of	liver	and	pancreas	in	gata6	mutants	In	 addition	 to	 the	 easily	 observable	 defects	 in	 development	 in	 our	 compound	mutants,	we	hypothesized	that	other	organ	systems	may	be	compromised,	and	that	these	 defects	 may	 explain	 the	 delayed	 demise	 of	 those	 mutant	 embryos	 that	presented	with	a	normal	phenotype	at	the	3dpf	time	point.	
GATA4	and	GATA6	are	known	to	play	roles	in	the	development	of	the	murine	and	human	liver	and	pancreas83,107,111,189.	In	mice,	the	two	transcription	factors	appear	to	be	redundant	for	early	specification	of	hepatic	and	pancreatic	progenitors,	and	for	 pancreatic	 development189,	 but	 have	 unique	 later	 roles	 in	 hepatic	outgrowth104,112.	We	wanted	to	discover	whether	these	organs	develop	normally	in	gata	mutant	 zebrafish.	 Clutches	 of	 embryos	 from	 a	 compound	 heterozygous	incross	were	fixed	at	3dpf	and	we	performed	a	triple	WISH	stain	for	markers	of	the	liver	 (lfabp),	 pancreas	 (insulin)	 and	 thyroid	 (tg)	 and	 observed	 a	 range	 of	abnormalities	 in	 triple	WISH	 staining	 pattern	 (Figure	 6-11).	 In	 some	 embryos,	staining	 for	 the	 liver	 and	 pancreas	 was	 either	 completely	 misplaced	 into	 a	‘speckled’	pattern,	or	entirely	absent	(Figure	6-11D,E).		
	
	
	
	
	 	138	
Figure	 6-11:	 Hepatic	 and	 pancreatic	 agenesis	 in	 gata4;gata6	 double	
homozygous	mutants.	
(A-E)	Range	of	staining	patterns	observed	with	probes	for	tg	(yellow	dashes),	lfabp	
(green	 dashes)	 and	 ins	 (blue	 dashes)	 in	 3dpf	 embryos	 from	 cross	 of	gata4WC5/+;gata6WC7/+	adults.	Representative	images.	(F)	Quantification	of	genotypes	
after	 assessment	 of	 WISH	 phenotype	 reveals	 that	 loss	 of	 hepatic	 and	 pancreatic	
markers	is	associated	with	homozygous	mutation	of	gata6..	
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Randomization	of	asymmetry	with	decrease	in	
wildtype	gata	alleles.	In	addition	to	the	abnormalities	discussed	above,	I	observed	a	consistent	inversion	of	organ	placement	in	a	subset	of	embryos	from	the	gata4+/-;gata6+/-	cross.	This	phenotype	was	consistent	across	all	markers	studied	(A-D).		
Figure	6-12:	Inversion	of	organ	location	with	loss	of	wildtype	gata	alleles.	
Inverted	 staining	patterns	observed	 in	 (A)	amhc,	 (B,C)	 vmhc	and	 (D)	 triple	WISH	
performed	 in	 3dpf	 embryos	 from	 cross	 of	 gata4WC5/+;gata6WC7/+	 adults.	
Representative	 images.	 (E)	 Quantification	 of	 inversion	 phenotypes	 according	 to	
genotype.	 Genotyping	was	 performed	 after	 phenotyping.	 ‘Normal’	 refers	 to	 organ	
layout	 irrespective	 of	 intensity	 or	 shape	 of	 staining.	 ‘Other’	 phenotypes	 include	
staining	patterns	for	which	the	organ	location	was	entirely	abnormal	or	absent.	For	
control	WISH	images	see	Figures	6-9,	6-10	and	6-11.		
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For	amhc	(A)	or	vmhc	(B,C)	staining,	the	heart	was	normally	shaped	but	a	mirror	image	of	the	normal	conformation.	In	some	embryos,	vmhc	staining	revealed	both	inversion	 and	 reduced	 signal	 (C).	 Inverted	 organs	 appeared	 predominantly	 in	
gata6+/-	 embryos,	 but	 with	 increasing	 numbers	 with	 progressive	 decrease	 in	wildtype	gata4,	suggesting	that	overall	gata	load	plays	a	role	in	randomization	of	left-right	asymmetry.	The	more	severe	phenotypes	in	gata6	homozygous	mutants	preclude	 observation	 of	 inversion	 with	 organ-specific	 markers	 and	 were	designated	‘other’.		
Discussion	and	Future	Directions	
The	zebrafish	is	able	to	tolerate	mutation	of	gata4.		The	relatively	normal	development	of	zebrafish	homozygous	for	mutation	in	gata4	(Figure	6-2)	was	an	unexpected	finding	of	this	work,	given	the	lethality	of	GATA4	mutation	 in	 other	 species83,86,112,	 and	 the	 severe	 defects	 identified	 in	 previous	knockdown	studies	in	zebrafish82.	There	are	a	number	of	possible	explanations	for	this	 discrepancy.	 The	 first,	 and	 we	 believe	 most	 likely,	 hypothesis,	 is	 that	 the	zebrafish	is	particularly	well	able	to	compensate	for	loss	of	gata4	by	upregulation	of	the	alternative	transcription	factor	gata6.	Our	initial	analysis	does	indicate	that	
gata6	is	upregulated	in	gata4	mutants	(Figure	6-5),	and	an	observation	of	partial	functional	 redundancy	 of	 the	 two	 proteins	 in	 the	mouse	 has	 been	 observed	 in	previous	studies108,111,112.		
Complete	 rescue	 of	 gata4	 mutation	 by	 upregulation	 of	 gata6	 in	 most	 animals	seems	 to	be	unique	 to	 the	 zebrafish	 system,	despite	 comparable	 identity	 levels	between	 the	 two	 proteins	 in	 different	 species††††.	 Reports	 of	 compensatory	
																																																								
††††	Zebrafish	Gata4	and	Gata6	have	33.7%	identity	compared	with	33.6%	identity	for	mouse.	
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pathways	 allowing	 zebrafish	 to	 tolerate	 mutant	 alleles	 are	 growing	 in	 the	literature190,	making	 it	 tempting	 to	 hypothesize	 that	 the	 zebrafish	 is	 especially	robust	 amongst	 the	 model	 systems	 used	 in	 the	 laboratory	 at	 recognizing	 and	ameliorating	the	effects	of	genetic	lesions.	
Decreased	 recovery	 of	 gata4	 homozygous	 mutants	 may	 stem	 from	
alterations	in	germ	cells.		The	 finding	 of	 normal	 development	 in	 gata4	 mutants	 is	 tempered	 by	 the	observation	that	at	3dpf	they	are	recovered	at	quantities	around	25%	lower	than	Mendelian	genetics	would	predict	(Figure	6-4).	We	did	not	observe	lethal	defects	in	embryogenesis	between	the	4-cell	stage‡‡‡‡	and	the	3dpf	time	point	at	genotypes	were	determined.	Therefore,	loss	of	gata4	mutant	alleles	must	occur	either	at	the	level	of	gamete	generation	or	during	initial	cleavage.	The	former	explanation	is	a	tempting	 hypothesis,	 given	 reports	 of	 a	 role	 for	 GATA4	 in	 the	 testis191,192.	 We	observe	a	slight	decrease	in	recovery	of	heterozygous	gata4	mutants	at	3dpf§§§§,	strengthening	this	conjecture.	Further	careful	genetic	studies	of	pools	of	genotypes	recovered	 from	male	 and	 female	 heterozygote	 animals	may	 be	 able	 to	 confirm	which,	if	either,	pool	of	gametes	is	affected.		
Evidence	for	a	larval	or	juvenile	lethality	in	some	gata4	mutants.				There	was	also	a	40%	loss	of	homozygous	mutants	between	3dpf	and	3	months	post	 fertilization.	We	did	not	 observe	death	 of	gata4	mutants	 before	day	10	of	development,	 and	 hypothesize	 that	 loss	 of	 gata4	 may	 lead	 to	minor	 defects	 in																																																									
‡‡‡‡	 Clutches	 were	 sorted	 at	 the	 4-cell	 stage	 to	 remove	 any	 unfertilized	 eggs	 from	 further	observation.		§§§§	Given	normal	gameto-	and	embryogenesis,	one	would	anticipate	a	2:1	recovery	of	het:wildtype	genotypes	 regardless	 of	 ratios	 of	 mutant	 genotypes.	 Applying	 this	 assumption,	 heterozygous	embryos	are	recovered	at	around	15%	lower	than	expected	rates	at	3dpf	(46.6%	instead	of	54.6%,	Figure	6-4).		
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overall	growth	or	feeding	behavior	that	disadvantage	homozygous	mutants	when	in	competition	with	wildtype	or	heterozygous	mutant	siblings.	This	hypothesis	is	supported	by	preliminary	observations	of	normal	growth	and	survival	of	MZ	gata4	mutants	raised	separately	from	wildtype	juveniles.	We	note	that	a	similar	failure-to-thrive	 phenotype	may	 explain	 the	 low	 recovery	 of	gata6WC7/+	 adults	 (Figure	6-7).				
Potential	 alternative	 explanations	 are	 that	mutant	 alleles,	 haploinsufficiency	 or	even	 a	 dominant-negative	 mutant	 protein	 lead	 to	 later	 defects	 that	 present	problems	 during	 larval	 or	 juvenile	 stages.	 Careful	 monitoring	 of	 growth	 and	mortality	rates	of	isolated	mutants	compared	with	wildtype	siblings	should	be	able	to	rule	out	these	possibilities.	As	a	final	consideration,	gata4	is	known	to	play	a	role	in	 gut	 epithelium76,156,	 which	 raises	 the	 possibility	 that	 any	 observed	 growth	defects	might	be	secondary	to	abnormalities	in	nutrient	absorption.		
Developmental	 delay	 in	 gata4	 mutants	 is	 suggestive	 of	 gata4	 target	
pathways.	Our	ability	 to	 identify	 a	 finite	period	of	delay	 in	gata4	mutant	 gastrulation	 is	 a	testament	to	the	particular	benefits	of	the	zebrafish	model	system,	in	which,	unlike	in	mice,	we	are	 able	 to	observe	 this	process.	 It	 also	gives	us	 some	clues	 to	key	processes	 that	 are	 particularly	 sensitive	 to	 loss	 of	 gata4.	 The	 affected	 period	between	sphere	and	shield	stage	(Figure	6-3)	is	a	time	associated	with	a	complex	rearrangement	of	the	developing	germ	layers,	requiring	coordination	of	signaling	cues	and	cytoskeletal	rearrangements	in	the	participating	cells.	The	phenotype	of	developmental	 delay	 with	 ultimate	 recovery	 has	 been	 observed	 in	 previous	studies,	specifically	in	claudine	morphants193	and	eomesodermina194	mutants.	The	claudins	are	a	family	of	junctional	proteins	that	Gata4	has	been	shown	to	regulate	
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in	 the	 gut,	 suggesting	 that	 cell:cell	 junctions	may	be	 compromised	during	 early	epiboly	in	gata4	mutant	embryos.	Eomesodermin	is	a	transcription	factor	that	is	known	 to	 coordinate	 with	 Gata4	 to	 regulate	 gene	 expression,	 leading	 us	 to	hypothesize	 that	 alteration	 in	 regulation	 or	 cooperation	 with	 Eomes*****	 in	developing	gata4	mutants	may	contribute	to	epiboly	delay.	These	connections	give	us	 some	 interesting	 and	 likely	 avenues	 for	 further	 research.	 Preliminary	experiments	suggest	that	the	expression	levels	of	ClaudinE	and	Eomesa	are	altered	in	 gata4	 mutants	 during	 early	 gastrulation	 (Figure	 6-13)	 indicating	 that	dysregulation	 of	 these	 pathways	 is	 likely	 responsibly	 for	 the	 observed	 epiboly	delay	(Figure	6-3).		
Follow	 up	 experiments	 will	 confirm	 the	 finding	 of	 alteration	 in	 claudine	 and	
eomesa	 expression.	 Since	 Claudine	 is	 a	 junctional	 protein,	 experiments	 would	ideally	 also	 determine	 whether	 its	 localization	 is	 altered.	 Elucidation	 of	 the	alterations	 to	 these	genes	and	 the	pathways	by	which	 they	control	 epiboly	will	outline	the	role	of	Gata4	in	gastrulation.	Given	a	conserved	requirement	for	Gata4	in	 early	 mammalian	 development74,84	 (a	 timepoint	 that	 this	 technically	 near-impossible	 to	 access),	 the	 zebrafish	gata4	 mutant	model	 provides	 an	 excellent	model	system	in	which	to	explore	this	role.		
																																																								
*****	The	zebrafish	has	two	eomes	genes	(a	and	b).	Eomesa	has	a	role	in	the	initiation	and	progression	of	epiboly,	and	is	expressed	from	sphere	stage	onwards200.	Eomesb	 is	less	well	studied,	although	qPCR	analysis	suggests	that	it	is	also	expressed	during	gastrulation.		
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Figure	 6-13:	 Dysregulation	 of	 eomesa	 and	 claudine	 expression	 in	 gata4	
mutants.	
qPCR	 analysis	 of	 wildtype	 or	 gata4	 homozygous	 mutant	 embryos	 at	 timepoints	
ranging	from	sphere	to	24hpf	(Prim	5).	During	gastrulation	there	is	upregulation	of	eomesodermin	genes	and	cluadine	in	gata4	mutant	embryos.	
Regulation	of	ventricular	identity	by	gata6.		An	 exciting,	 novel	 observation	 from	 my	 WISH	 studies	 is	 a	 decrease	 in	 vmhc	expression	in	gata6	mutant	embryos	(Figure	6-10).	This	suggests	that	loss	of	gata6	compromises	the	identity	of	the	ventricular	cardiomyocyte	and	reveals	Gata6	as	a	potential	regulator	of	ventricular	cardiomyocyte	development.	The	expression	of	genes	 specific	 for	 ventricular	 versus	 atrial	 cardiomyocytes	 is	 known	 to	 be	regulated	by	 other	 cardiac	 transcription	 factors,	 including	Tbx5195	 and	 the	Nkx	family22,	 however	 the	 roles	 of	 GATA	 factors	 in	 this	 specification	 process	 is	 not	known.	However,	 in	agreement	with	my	finding	in	the	zebrafish,	work	from	our	
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laboratory	suggests	that	GATA6	overexpression	may	drive	ventricular	identity	in	hESC-CMs	(Tang	and	Evans,	Unpublished).		
I	 did	 not	 note	 a	 concomitant	 decrease	 in	 amhc	 expression	 in	 normally-shaped	
gata6	homozygous	mutant	hearts	(Figure	6-9A).	There	are	a	couple	of	potential	explanations	for	this	discrepancy.	First,	there	is	a	low	level	of	amhc	expression	in	the	 ventricle	 even	 in	 wildtype	 animals,	 which	may	 obscure	 the	 observation	 of	minor	upregulation	by	WISH.	 Second,	 it	may	be	 that	 the	 cardiomyocytes	 in	 the	ventricular	 portion	 of	 gata6	homozygous	mutant	 hearts	 are	 expressing	 neither	
vmhc	nor	amhc.		
However,	 I	 did	 observe	 expansion	 of	amhc	 expression	 across	 the	whole	 of	 the	linear	 heart	 tubes	 found	 in	 gata4;gata6	 double	 homozygous	 mutant	 embryos	(Figure	6-9C).	This	mirrors	the	large	reduction	in	vmhc	staining	observed	in	linear	heart	 tubes	 in	embryos	of	 the	same	genotype,	suggesting	 that	 in	 the	absence	of	
gata4	 and	gata6,	 the	heart	 is	both	misshapen	and	has	expanded	atrial	 identity.	Moving	forward,	it	will	be	important	to	confirm	that	the	loss	of	vmhc	and	expansion	of	amhc	are	occurring	in	the	same	hearts	through	double	WISH.	Following	this,	the	identity	of	the	myocytes	in	both	chambers	needs	to	be	better	confirmed.	This	can	be	achieved	through	assessing	the	expression	of	alternate	chamber	markers	such	as	myosin	binding	protein	1	Hb	(atrium)	and	actin,	alpha	1a	(ventricle)24.	Atrial	and	ventricular	 cardiomyocytes	 also	have	unique	electrophysiology,	which	 could	be	assessed	by	patch	clamp.		
Randomization	of	asymmetry	in	embryos	with	loss	of	multiple	gata	alleles.	An	 additional	 novel	 observation	 from	 these	 studies	 is	 the	 inversion	 of	 organ	location	 that	 arises	 predominantly	 in	 gata6+/-	 embryos	 (Figure	 6-12).	 The	consistency	 of	 this	 phenotype	 across	 multiple	 organs	 (heart,	 liver,	 pancreas)	
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indicates	an	early	disturbance	in	normal	patterning.	Interestingly,	there	are	rare	case	studies	in	the	literature	in	which	mutation	of	GATA4	leads	to	dextrocardia196,	suggesting	 that	 this	 role	 is	 conserved.	 To	 confirm	 the	 hypothesis	 that	 early	patterning	is	disturbed,	WISH	for	early	markers	of	left-right	asymmetry	(lefty1/2,	
spaw)	 should	 be	 performed.	 In	 addition,	 the	 development	 and	 function	 of	 the	Kupffer’s	vesicle	(analogous	to	the	mammanlian	node),	which	establishes	left-right	patterning,	can	be	analyzed.		
The	phenotype	of	inversion	is	seen	increasingly	with	progressive	loss	of	gata4	in	a	
gata6	heterozygous	background,	suggesting	that	the	two	transcription	factors	may	be	 able	 to	 compensate	 for	 each	 other	 in	 this	 pathway.	 It	 is	 less	 clear	whether	homozygous	mutation	of	gata6	also	leads	to	alterations	in	early	patterning	due	to	the	 severe	 defects	 in	 organ	 development.	 However,	 the	 experiments	 suggested	above	are	likely	to	clarify	this	point.		
An	intriguing	hypothesis	here	is	that	the	more	severe	defects	in	gata6	mutants	may	also	be	due	to	 the	 loss	of	patterning	cues,	which	subsequently	 lead	to	 failure	 in	tissue-specific	progenitors	 to	migrate	or	differentiate	appropriately.	 In	 the	 long	term,	tissue-specific	and	temporally	controlled	depletion	of	gata6	and/or	gata4	in	the	 instructional	 layers	of	 the	developing	embryo,	or	within	defined	progenitor	populations,	might	answer	this	question.	
Incomplete	 penetration	 of	 gata6	 mutant	 phenotype	 indicates	 partial	
redundancy	with	gata4.	Despite	the	predominance	of	a	severely	abnormal	phenotype	in	most	gata6WC7/WC7	embryos,	around	30%	of	homozygous	mutants	appear	normal	at	3dpf.	When	we	consider	specific	organ	systems	by	WISH	(Figure	6-9,	Figure	6-10,	Figure	6-11)	we	also	observe	normal	expression	of	tissue	markers.	Interestingly,	the	percentage	of	
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‘normal’	gata6	mutants	 at	 3dpf	 decreases	 progressively	with	 additional	 loss	 of	wildtype	gata4	alleles.	This	suggests	that	gata4	is	able	to	compensate	for	gata6	in	some	 embryos,	 although	 the	 rescue	 is	 clearly	 unable	 to	 sustain	 gata6	 mutants	through	the	larval	and	juvenile	stages.	
A	question	that	arises	from	the	observations	and	hypotheses	discussed	above	is	why	there	might	be	an	asymmetric	relationship	between	gata4	and	gata6,	in	which	the	latter	is	able	to	compensate	for	the	former,	but	not	vice	versa.	One	possibility	is	that	 the	 third	 transcription	 factor,	 gata5,	 is	 also	 playing	 an	 important	compensatory	 role	 in	gata4	mutants,	 and	 that	gata4	and	gata6	 thus	 have	 only	partially	 overlapping	 roles.	 Although	 we	 do	 not	 see	 upregulation	 of	 gata5	transcript	at	the	timepoints	we	have	so	far	considered	(Figure	6-5),	there	may	be	transient	or	delayed	upregulation	of	gata5	 transcript,	or	 indeed	stabilization	or	relocalization	of	Gata5.		To	begin	to	address	this	question,	we	are	developing	gata5	mutant	and	combination	gata4,	-5	and	-6	mutant	lines	(see	Appendix	C).		
Conclusions	In	conclusion,	these	studies	are,	to	our	best	knowledge,	the	first	to	generate	and	characterize	zebrafish	that	harbor	homozygous	mutations	in	gata4	and/or	gata6.		
We	used	light	microscopy	and	WISH	to	detail	abnormalities	in	the	development	of	multiple	 organ	 systems	 in	 embryos	harboring	mutations	 in	 the	gata	 genes.	We	capitalized	on	 the	ability	 to	observe	gastrulation	 in	 the	developing	 zebrafish	 to	pinpoint	the	precise	period	of	delay	in	gata4	mutant	development,	allowing	us	to	make	strong	hypotheses	about	the	pathways	that	gata4	is	regulating	during	early	epiboly.		
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Finally,	our	findings	uphold	previously	described	roles	for	gata6	in	cardiac,	hepatic	and	pancreatic	development,	but	intriguingly	suggest	that	gata4	is	dispensable	in	the	zebrafish	model	system.	This	finding	hints	at	a	unique	ability	of	the	zebrafish	to	sense	genetic	 lesion	 in,	and	compensate	 for,	a	master	regulator	 transcription	factor.			 	
	 	149	
APPENDIX	A:	HSPB5	COMPENSATES	FOR	
LOSS	OF	HSPB7	IN	THE	HEART.	
Introduction	The	findings	of	mild	cardiac	dysfunction	in	hspb7	mutant	zebrafish,	discussed	in	Chapter	 4,	 are	 in	 contrast	with	 those	 from	 previous	 studies,	 in	which	we1	 and	others2	used	morpholinos	to	knock	down	Hspb7	during	zebrafish	embryogenesis	and	 observed	 embryonic	 lethality	 with	 randomization	 of	 left-right	 asymmetry,	cardiac	 malformation	 and	 a	 change	 in	 the	 size	 of	 ventricular	 cardiomyocytes.	Discrepancies	between	morphant	and	mutant	phenotypes	are	often	reported	 in	recent	 zebrafish	 literature3.	 As	 a	 result,	 debate	 has	 arisen	 over	 the	 accuracy	 of	morpholino	 data.	 However,	 several	 groups,	 including	 our	 own,	 have	 identified	compensatory	mechanisms	that	arise	following	genetic	mutation	but	not	following	acute	knockdown	of	the	same	gene4.	It	is	possible	that	the	morphant	phenotypes	were	 caused	 by	 off-targeting	 effects,	 given	 recent	 reports	 that	 morphant	 and	mutant	phenotypes	can	be	concernedly	discordant3.	Alternatively,	consistent	with	other	reports4,	it	is	possible	that	the	mutants	(but	not	morphants)	compensate	for	loss	 of	 Hspb7.	 and	 discrepancies	 have	 been	 uncovered	 between	morphant	 and	mutant	phenotypes	for	some	genes3.		
Hspb5b/HSPB5	 is	 upregulated	 in	 HSPB7	 mutant	
cardiomyocytes	In	order	to	investigate	whether	an	alternative	small	heat	shock	protein	could	be	compensating	for	loss	of	hspb7	in	the	zebrafish,	I	performed	qPCR	for	a	panel	of	small	 heat	 shock	 proteins	 that	 are	 known	 to	 be	 expressed	 in	 the	 heart5.	 I	discovered	that	hspb7	mutants	show	increased	expression	levels	of	hspb5b,	a	sister	
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sHSP	gene	that	could	conceivably	compensate	for	loss	of	Hspb7	(Appendix	Figure	A-1A).	
	
Appendix	Figure	A-1:	Upregulation	of	HSPB5	in	HSPB7	null	cardiomyocytes	
qPCR	analysis	of	 small	heat	shock	and	control	mRNA	expression	 in	(A)	embryonic	
zebrafish	hearts	 isolated	by	microdissection	and	(B)	hESC-derived	cardiomyocytes	
on	 day	 15	 of	 differentiation.	 hESC-CM	 data	 is	 pooled	 for	Wildtype	 and	 Clone	 12	
(HSPB7+/+)	and	Clone	26	and	30	(HSPB7-/-).	
Excitingly,	 when	 I	 performed	 a	 matching	 qPCR	 analysis	 for	 small	 heat	 shock	protein	 expression	 in	 wildtype	 or	 HSPB7	 null	 hESC-CMs,	 I	 observed	 a	 similar	upregulation	of	 the	human	HSPB5	(also	known	as	CRYAB)	 transcript	 (Appendix	Figure	A-1B).	This	suggests	that	HSPB5	upregulation	is	a	conserved	response	to	loss	of	HSPB7.	
HSPB5	is	a	more	ubiquitously	expressed	member	of	the	sHSP	family.	 Important	roles	for	HSPB5	have	been	demonstrated	in	the	eye,	where	HSPB5	aggregates	are	associated	with	cateractogenesis6,	and	in	the	nervous	system7,	where	it	transduces	signals	from	the	dopamine	receptor	to	modulate	responsivity	to	immune	stimuli8,	and	where	loss	of	HSPB5	leads	to	worsening	of	experimental	encephalomyelitis7.		
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Interestingly,	 despite	 the	 animal	 model	 links	 to	 the	 immune	 system	 and	neurological	 function,	 human	 mutations	 in	 HSPB5	 are	 associated	 with	 the	development	 of	 skeletal	 muscle	 and	 cardiac	 myopathies9,10,	 as	 well	 as	 with	congenital	 cataract	 formation.	 Expression	 of	 human	HSPB5	mutant	 proteins	 in	mice	leads	to	similar	myopathies	downstream	of	alterations	in	the	cellular	redox	balance11,	suggesting	that	these	are,	at	least	in	part,	gain-of-function	phenotypes.		
Generation	of	hspb5b	mutant	zebrafish	lines	In	order	to	investigate	the	extent	to	which	hspb5b	is	able	to	compensate	for	loss	of	
hspb7,	I	am	using	CRISPR	technology	to	generate	hspb5b	mutant	zebrafish	lines.	As	for	hspb7	TALENs,	 the	sgRNA	selected	 targets	 the	5’	end	of	 the	gene	(Appendix	Figure	 A-2A),	 in	 order	 to	 generate	 early	 mutations	 that	 render	 the	 resultant	protein	completely	inactive.	
Embryos	from	F0	adults	injected	with	the	CRISPR	targeting	hspb5b	were	screened	by	 T7E1	 assay	 for	 transmission	 of	 mutant	 alleles	 (Appendix	 Figure	 A-2B)	 and	clutches	of	embryos	carrying	mutations	are	being	raised.	Intriguingly,	injection	of	this	CRISPR	leads	to	enhanced	rates	of	embryonic	cardiomyopathy	 in	the	hspb7	mutant	background,	compared	to	injection	in	wildtype	embryos	(Appendix	Figure	A-2C).	This	strengthens	the	hypothesis	of	a	compensatory	role	for	Hspb5b,	which	allows	 the	 embryos	 to	 tolerate	 hspb7	 mutations,	 and	 facilitates	 our	 ability	 to	evaluate	Hspb7	function	in	adult	fish.	
I	 have	 recovered	 several	 mutant	 alleles	 of	 hspb5b,	 including	 a	 26	 base	 pair	mutation	 that	 leads	 to	 a	 frameshift	 and	 subsequent	 premature	 stop	 codon	(Appendix	 Figure	 A-2D).	 Mouse	 models	 of	 HSPB5	 loss-of-function	 survive	
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embryogenesis	 and	 heterozygotes	 are	 fertile7,	 leading	me	 to	 hypothesize	 that	 I	should	be	able	to	recover	zebrafish	homozygous	for	hspb5b	mutation.	
Appendix	Figure	A-2:	Generation	of	hspb5b	mutant	zebrafish	lines.	
(A)	 Schematic	 showing	 structure	 of	 zebrafish	 hspb5b	 gene	with	 arrow	 indicating	
locus	 targeted	 by	 the	 CRISPR.	 (B)	 T7E1	 assay	 showing	 successful	 generation	 of	
mutations	 in	pools	 of	 10	 embryos	 injected	with	CRISPR-Cas9	 complexes	 targeting	
hspb5b.	(C)	Quantification	of	phenotypes	observed	in	F0	injected	embryos	of	wildtype	
or	hspb7	mutant	genotype,	showing	an	increase	in	both	total	body	defects	and	heat	
defects	in	hspb7	null	embryos	when	compared	with	wildtype	controls.	(D)	Sequence	
of	wildtype	hspb5b	and	a	frameshift	mutation	that	leads	to	a	premature	stop	codon	
and	is	predicted	to	lead	to	a	loss	of	normal	protein	function.	
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Generation	 of	 cardiomyocyte-specific	 hspb5b	
mutations	in	zebrafish	Due	to	the	multi-system	roles	of	HSPB5,	I	also	wanted	to	make	a	cardiomyocyte-specific	 loss-of-function	 model.	 I	 adapted	 a	 tissue-specific	 zebrafish	 CRISPR	system	designed	by	 the	Zon	 labarotory12	 by	 cloning	 the	 cardiomyocyte	 specific	
myl7	promoter	into	a	Tol2	vector	to	drive	expression	of	Cas9	and	GFP	(Plasmid	EM02,	Appendix	Figure	A-3A).	Injection	of	this	construct	at	the	one	cell	stage,	in	combination	 with	 tol2	 mRNA	 led	 to	 mosaic	 expression	 of	 GFP	 in	 embryonic	zebrafish	hearts,	indicating	successful	integration	of	the	transgene.		
Appendix	 Figure	 A-3:	 Generation	 of	 zebrafish	 with	 cardiomyocyte-specific	
mutation	of	hspb5b.		
(A)	EM02	Vector	map	showing	myl7	promoter	driving	expression	of	Cas9	protein	and	
GFP.	 An	hspb5b	 specific	 guide	RNA	 is	 cloned	 under	 the	U6	 promoter.	 (B)	Mosaic	
expression	of	GFP	in	the	heart	of	72hpf	embryos	injected	with	EM02	vector	and	Tol2	
mRNA,	indicating	successful	DNA	integration	and	subsequent	protein	expression.	(C)	
T7	 assay	 of	 gDNA	 extracted	 from	 hearts	 of	 adult	wildtype	 or	 EM02	 F0	 zebrafish	
showing	 generation	 of	 mutations	 in	 EM02-injected	 animals.	 The	 star	 indicates	
successful	 generation.	 The	 first	 two	 EM02	 hearts	 are	 from	 animals	 that	 did	 not	
transmit	 the	 EM02	 vector	 to	 their	 progeny,	 suggesting	 low	mosaicism.	 Animal	 3	
(annotated	with	a	star)	transmitted	GFP	expression	to	around	10%	of	embryos.		
I	isolated	gDNA	from	the	hearts	of	adult	zebrafish	injected	with	EM02	construct.	Hearts	were	taken	from	animals	that	did,	and	did	not,	transmit	GFP	positive	hearts	to	their	progeny.	T7E1	assay	indicated	the	presence	of	mutations	in	hspb5b	only	in	the	 hearts	 of	 zebrafish	 that	 successfully	 transmitted	 the	 myl7::Cas9-T2A-GFP	
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transgene.	An	important	caveat	in	the	use	of	these	lines	for	future	studies	is	that	the	 nature	 of	 the	 mutations	 in	 the	 heart	 of	 a	 given	 animal	 will	 be	 technically	challenging	to	ascertain	given	the	high	likelihood	of	mosaicism.		
Generation	of	HSPB5	mutant	hESC	lines.		As	a	complimentary	model	system	in	which	to	study	the	role	of	HSPB5	in	HSPB7	mutant	cardiomyocytes,	I	generated	HSPB5	null	hESCs	using	the	iCRISPR	system13.	Given	 the	 propensity	 of	 HSPB5	 mutations	 to	 themselves	 cause	 protein	aggregation9,10,	I	targeted	the	gRNA	to	the	start	codon	of	HSPB5	(Appendix	Figure	A-4).		
Appendix	Figure	A-4:	Generation	of	HSPB5	mutant	cardiomyocytes	
Schematic	of	the	structure	and	partial	sequence	of	the	human	HSPB5	gene.	Straight	
arrow	 indicates	CRISPR	 targeted	 location.	 Clone	12	and	Clone	57	 sequences	have	
complete	 loss	 of	 start	 codon	 (underlined	 in	 wildtype).	 Sequences	 from	 resultant	HSPB5	mutant	 clones	 derived	 from	wildtype	 (WT)	 or	HSPB7	 mutant	 (Clone	 24)	
hESCs	are	detailed.		
I	 successfully	 recovered	 hESC	 clones	 in	 which	 the	 start	 codon	 of	 HSPB5	 was	deleted.	It	is	a	strong	hypothesis	that	cardiomyocytes	derived	from	hESCs	carrying	these	mutations	will	be	entirely	absent	of	HSPB5	protein.		
No	 large	 differences	 in	 hESC	 survival	 or	 proliferation	were	 observed	 following	mutation	 of	 HSPB5,	 although	 this	 has	 not	 been	 confirmed	 by	 direct	 assay.	 The	
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normal	 expression	 of	 pluripotency	markers	 in	 these	HSPB5	mutant	 clones	will	need	to	be	confirmed,	however	previous	work	performed	in	HSPB5	mutant	iPSC	lines	suggests	that	they	are	unlikely	to	be	altered14.	
Discussion	and	Future	Directions	Intriguingly,	I	documented	an	upregulation	in	hspb5b	in	the	hearts	of	hspb7WC3/WC	embryos,	and	observed	a	similar	upregulation	of	HSPB5	in	our	HSPB7-/-	hESC-CMs.	The	 drosophila	 homolog	 of	 HSPB5	 has	 been	 shown	 to	 act	 as	 a	 chaperone	 for	Cheerio,	the	drosophila	filamin	protein15.	I	hypothesize	that	upregulation	of	HSPB5	may	be	at	least	partially	compensating	for	loss	of	HSPB7	in	our	mutant	models.	In	order	 to	 address	 this	 hypothesis,	 I	 have	 generated	 zebrafish	 lines	 carrying	mutations	in	hspb5b	and	hESC	lines	with	complete	loss	of	HSPB5.	In	addition,	I	have	generated	a	cardiomyocyte-specific	CRISPR	system	to	drive	mutation	of	hspb5b	in	zebrafish	in	a	tissue-specific	manner.	
In	the	immediate	future,	I	intend	to	cross	specific	hspb5b	mutations	into	animals	homozygous	for	hspb7WC3	or	hspb7WC4.	I	hypothesize	that	compound	homozygotes	will	 exhibit	 an	 increase	 in	 cardiac	 abnormalities	 when	 compared	 to	 siblings.	Additionally,	I	hypothesize	that	hspb7WC3/WC3;hspb5bWC12/WC12	animals	will	be	less	able	 to	 tolerate	 exercise	 challenge	 and	 will	 exhibit	 a	 worsening	 of	 the	cardiomyopathies	 seen	 in	 hspb7	 mutant	 zebrafish,	 as	 described	 in	 Chapter	 4.	Additionally,	 I	 expect	 that	 exposure	 of	 compound	 homozygote	 embryos	 to	autophagy	 inhibitors	 will	 precipitate	 defects	 in	 cardiomorphogenesis	 in	compound	mutants	but	not	hspb5b	null	animals.		
I	am	also	working	to	generate	cardiomyocytes	from	hESCs	that	have	mutations	in	
HSPB5.	I	predict	that	loss	of	HSPB5	in	an	HSPB7	mutant	background	will	increase	
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the	 propensity	 of	 FLNC	 to	 aggregate,	 and	 will	 magnify	 the	 upregulation	 of	autophagy	that	I	have	observed	in	these	cells.		
These	data	will	confirm	that	HSPB5/hspb5b	is	compensating	for	loss	of	HSPB7	in	the	cardiomyocyte.		
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APPENDIX	B:	GENERATION	OF	GATA5	MUTANT	
ZEBRAFISH	
Introduction	As	discussed	extensively	 in	 this	 thesis,	 the	GATA	factor	proteins	play	 important	roles	 in	 the	 development	 and	 function	 of	 various	 organ	 systems.	 GATA5	 is	 a	member	of	the	subfamily	of	GATA	factors,	alongside	GATA4	and	GATA6,	that	are	important	 in	 the	 development	 of	 mesendoderm	 and	 mesendoderm-derived	organs.	Our	laboratory	has	previously	identified	redundancy	between	gata5	and	
gata6	 in	 zebrafish	 development109,	 and	 there	 is	 evidence	 for	 functional	redundancy	 between	murine	 GATA5	 and	 the	 other	 GATA	 factors	 in	 the	mouse	heart197,198.	To	complement	the	work	described	in	Chapter	7	of	this	thesis,	and	to	further	investigate	the	unique	and	redundant	roles	of	gata5	 in	zebrafish,	we	set	out	to	generate	gata5	null	zebrafish	lines.		
Generation	of	gata5	mutant	fish	Following	the	same	reasoning	as	discussed	in	Chapter	7,	we	designed	a	CRISPR	to	target	 the	 zinc	 finger	 domain	 of	 gata5	 (	 Appendix	 Figure	 B-1A,B).	 Successful	generation	of	mutant	alleles	was	confirmed	by	T7E1	assay	performed	on	pools	of	embryos	 injected	with	 CRISPR	 constructs	 at	 the	 single	 cell	 stage.	 F0	 fish	were	screened	for	transmission	of	mutant	alleles.	From	F1	fish	we	recovered	a	variety	of	gata5	mutant	alleles,	summarized	in		Appendix	Figure	B-1.	Of	particular	interest	to	 us	were	 a	 10	 base	 pair	 deletion	 that	 leads	 to	 a	 frame	 shift	 and	 a	 predicted	truncation	 of	 Gata5	 with	 complete	 loss	 of	 both	 zinc	 fingers	 and	 the	 entire	 C	terminal	of	the	protein	(gata5WC8),	and	an	18bp	deletion	that	lead	to	disturbance	exclusively	of	the	C-X-X-C	motif	(gata5WC9).	
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	Appendix	Figure	B-1:	Generation	and	identification	of	mutant	gata5	alleles.	
(A)	Structure	of	gata5	 gene	 showing	 the	 locations	of	 the	zinc	 finger	domains	and	
CRISPR	 target	 zone.	 (B)	Partial	 nucleotide	 sequence	detail	 of	 the	N-terminal	 zinc	
finger	of	gata5,	showing	targeting	region	of	CRISPR.	(C)	Partial	amino	acid	sequence	
of	Gata5	protein	detailing	alleles	recovered	from	F1	fish	following	CRISPR	targeting.	
Homozygous	mutation	of	gata5	recapitulates	the	Faust	
mutant	phenotype	We	crossed	 two	F1	animals	 that	were	heterozygous	 for	 the	gata5WC9	allele	 and	observed	 the	 phenotypes	 of	 the	 resultant	 pool	 of	 embryos.	 Around	 25%	 of	embryos	had	noticeable	defects	in	cardiac	development	by	24hpf,	at	which	time	they	 did	 not	 have	 visible	 heart	 tubes.	 By	 48hpf,	 this	 subset	 of	 embryos	 had	developed	 bilateral	 edema	 (Appendix	 Figure	 B-2B).	 In	 some	 embryos	 beating	patches	 of	 cardiomyocytes	 could	 be	 observed	 bilaterally,	whereas	 in	 others	 no	cardiac	 tissue	 could	 be	 determined	 by	 brightfield	 microscopy.	 Genotyping	 of	embryos	 following	 initial	 phenotyping	 revealed	 that	 all	 homozygous	 gata5	
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mutants	 displayed	 the	 characteristic	 bilateral	 edematous	 patches	 with	concomitant	lack	of	fully	formed	heart	tube	(Appendix	Figure	B-2C).	
Appendix	 Figure	B-2:	Gata5	mutant	 embryos	have	 severe	defects	 in	 cardiac	
development.	
Brightfield	images	of	(A)	normal	embryos	and	(B)	embryos	with	defects	in	cardiac	
migration	 at	 48hpf.	 White	 arrowheads	 point	 to	 edematous	 swellings.	 (C)	
Quantification	of	genotypes	for	normal	or	migration	defect	embryos	determined	that	
the	phenotype	of	abnormal	cardiogenesis	was	found	in	embryos	null	for	gata5.		
The	previously	characterized	gata5	mutant	allele,	faust,	displays	a	range	of	defects	in	the	migration	of	cardiac	progenitors199.	We	hypothesize	that	the	same	migration	defects	lead	to	the	bilateral	edema	and	occasional	bifid	hearts	we	observe	in	gata5	mutant	embryos.		
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Future	Directions	In	 the	 immediate	 future,	we	are	working	 to	characterize	 the	gata5	homozygous	mutant	phenotype.	The	faust	allele	is	a	well	characterized	mutant	of	gata5	with		
defects	in	the	development	of	the	heart	and	in	endoderm-derived	organs,	including	the	gut.	We	will	initially	confirm	that	these	abnormalities	are	also	seen	in	our	novel	
gata5	mutant	zebrafish,	through	WISH	and	qPCR	analysis.		
In	 addition,	 we	 are	 interested	 in	 the	 phenotypes	 of	 embryos	 carrying	 various	combinations	 of	 gata4,	 gata5	 and	 gata6	 mutant	 alleles.	 Our	 preliminary	observations	indicate	that	triple	heterozygous	(gata4WC6/+;gata5WC8/+;gata6WC7/+)	animals	 are	 recovered	 in	 expected	 ratios	 and	 develop	 normally.	 Excitingly	 we	observe	that	triple	heterozygotes	are	viable	to	at	 least	 larval	day	28,	suggesting	that	we	may	be	able	to	recover	triple	heterozygous	adults	and	perform	crosses	that	will	provide	us	with	a	full	gamut	of	gata	genotypes.			 	
	 	161	
BIBLIOGRAPHY	1.		 Mozaffarian	D,	Benjamin	EJ,	Go	AS,	Arnett	DK,	Blaha	MJ,	Cushman	M,	et	al.	Heart	 Disease	 and	 Stroke	 Statistics	 -	 2016	 Update:	 A	 Report	 From	 the	American	Heart	Association.	Circulation.	2015.	1-324	p.		2.		 Townsend	 N,	 Bhatnagar	 P,	 Wilkins	 E,	 Wickramasinghe	 K,	 Rayner	 M.	Cardiovascular	Disease	Statistics	2015.	2015.	1-144	p.		3.		 Benjamin	EJ,	Blaha	MJ,	Chiuve	SE,	Cushman	M,	Das	SR,	Deo	R,	et	al.	Heart	Disease	and	Stroke	Statistics—2017	Update:	A	Report	From	the	American	Heart	Association.	Circulation.	2017	Jan	25;131(6):e29–39.		4.		 Barry	SP,	Townsend	P	a.	What	 causes	a	broken	heart--molecular	 insights	into	heart	failure.	Int	Rev	Cell	Mol	Biol.	2010	Jan;284(10):113–79.		5.		 Richard	 P,	 Charron	 P,	 Carrier	 L,	 Ledeuil	 C,	 Cheav	 T,	 Pichereau	 C,	 et	 al.	Hypertrophic	 cardiomyopathy:	Distribution	of	disease	genes,	 spectrum	of	mutations,	and	implications	for	a	molecular	diagnosis	strategy.	Circulation.	2003;107(17):2227–32.		6.		 Sun	N,	Yazawa	M,	Liu	 J,	Han	L,	 Sanchez-Freire	V,	Abilez	OJ,	 et	 al.	Patient-specific	 induced	 pluripotent	 stem	 cells	 as	 a	 model	 for	 familial	 dilated	cardiomyopathy.	Sci	Transl	Med.	2012	Apr	18;4(130):130ra47.		7.		 Valdés-Mas	R,	Gutiérrez-Fernández	A,	Gómez	J,	Coto	E,	Astudillo	A,	Puente	D	a,	 et	 al.	Mutations	 in	 filamin	C	 cause	a	new	 form	of	 familial	hypertrophic	cardiomyopathy.	Nat	Commun.	2014	Jan;5:5326.		8.		 Fürst	 DO,	 Goldfarb	 LG,	 Kley	 RA,	 Vorgerd	 M,	 Olivé	 M,	 Van	 Der	 Ven	 PFM.	Filamin	 C-related	 myopathies:	 Pathology	 and	 mechanisms.	 Acta	Neuropathol.	2013;125(1):33–46.		9.		 Epstein	FH.	Cardiovascular	Disease	Epidemiology	-	A	journey	from	the	past	into	the	future.	Circulation.	1996;93(1755–1764).		10.		 Kimmel	CBCB,	Ballard	WW,	Kimmel	SR,	Ullmann	B,	Schilling	TF.	Stages	of	embryonic	development	of	the	zebrafish.	Dev	….	1995	Jul;10(3):253–310.		11.		 Bakkers	 J.	Zebrafish	as	a	model	to	study	cardiac	development	and	human	cardiac	disease.	Cardiovasc	Res.	2011;		12.		 Alexander	J,	Rothenberg	M,	Henry	GL,	Stainier	DY.	Casanova	plays	an	early	and	 essential	 role	 in	 endoderm	 formation	 in	 zebrafish.	 Dev	 Biol.	1999;215:343–57.		13.		 Kikuchi	 Y,	 Trinh	 LA,	 Reiter	 JF,	 Alexander	 J,	 Yelon	 D,	 Stainier	 DYR.	 The	zebrafish	bonnie	and	clyde	gene	encodes	a	Mix	family	homeodomain	protein	that	 regulates	 the	 generation	 of	 endodermal	 precursors.	 Genes	 Dev.	2000;14(10):1279–89.		14.		 Kupperman	E,	An	S,	Osborne	N,	Waldron	S,	 Stainier	DY.	A	sphingosine-1-phosphate	 receptor	 regulates	 cell	 migration	 during	 vertebrate	 heart	
	 	162	
development.	Nature.	2000	Jul	13;406(6792):192–5.		15.		 Buckingham	M,	Meilhac	S,	Zaffran	S.	Building	the	mammalian	heart	from	two	sources	of	myocardial	cells.	Nat	Rev	Genet.	2005	Nov;6(11):826–35.		16.		 Reischauer	 S,	 Arnaout	 R,	 Ramadass	 R,	 Stainier	 DYR.	 Actin	 Binding	 GFP	Allows	4D	In	Vivo	Imaging	of	Myofilament	Dynamics	in	the	Zebrafish	Heart	and	the	Identification	of	Erbb2	Signaling	as	a	Remodeling	Factor	of	Myofibril	Architecture.	Circ	Res.	2014	Sep	16;115:845–56.		17.		 Berdougo	E,	Coleman	H,	Lee	DH,	Stainier	DYR,	Yelon	D.	Mutation	of	weak	atrium/atrial	 myosin	 heavy	 chain	 disrupts	 atrial	 function	 and	 influences	ventricular	 morphogenesis	 in	 zebrafish.	 Development.	 2003	Dec;130(24):6121–9.		18.		 Auman	 HJ,	 Coleman	 H,	 Riley	 HE,	 Olale	 F,	 Tsai	 HJ,	 Yelon	 D.	 Functional	modulation	of	cardiac	form	through	regionally	confined	cell	shape	changes.	PLoS	Biol.	2007;5(3):0604–15.		19.		 Staudt	D,	Stainier	D.	Uncovering	the	molecular	and	cellular	mechanisms	of	heart	development	using	the	zebrafish.	Annu	Rev	Genet.	2012;46:397–418.		20.		 Sylva	M,	Van	den	Hoff	MJB,	Moorman	AFM.	Development	of	the	human	heart.	Am	J	Med	Genet	Part	A.	2014;164(6):1347–71.		21.		 Beis	D,	Bartman	T,	Jin	S-W,	Scott	IC,	D’Amico	L	a,	Ober	E	a,	et	al.	Genetic	and	cellular	 analyses	 of	 zebrafish	 atrioventricular	 cushion	 and	 valve	development.	Development.	2005	Sep;132(18):4193–204.		22.		 George	V,	Colombo	S,	Targoff	KL.	An	early	requirement	for	nkx2.5	Ensures	first	 and	Second	heart	 field	 ventricular	 identity	 and	 cardiac	 function	 into	adulthood.	Dev	Biol.	2014	Dec	20;400(1):10–22.		23.		 Junker	JP,	No??l	ES,	Guryev	V,	Peterson	KA,	Shah	G,	Huisken	J,	et	al.	Genome-wide	RNA	Tomography	in	the	Zebrafish	Embryo.	Cell.	2014;159(3):662–75.		24.		 Singh	AR,	Sivadas	A,	Sabharwal	A,	Vellarikal	SK,	Jayarajan	R,	Verma	A,	et	al.	Chamber	 specific	 gene	 expression	 landscape	 of	 the	 zebrafish	 heart.	 PLoS	One.	2016;11(1).		25.		 Wu	CC,	Kruse	F,	Vasudevarao	MD,	Junker	JP,	Zebrowski	DC,	Fischer	K,	et	al.	Spatially	 Resolved	 Genome-wide	 Transcriptional	 Profiling	 Identifies	 BMP	Signaling	as	Essential	Regulator	of	Zebrafish	Cardiomyocyte	Regeneration.	Dev	Cell.	2016;36(1):36–49.		26.		 Choi	W-Y,	Gemberling	M,	Wang	J,	Holdway	JE,	Shen	M-C,	Karlstrom	RO,	et	al.	In	 vivo	 monitoring	 of	 cardiomyocyte	 proliferation	 to	 identify	 chemical	modifiers	of	heart	regeneration.	Development.	2013	Mar;140(3):660–6.		27.		 Cripps	 R,	 Olson	 E.	 Control	 of	 cardiac	 development	 by	 an	 evolutionarily	conserved	transcriptional	network.	Dev	Biol.	2002;246:14–28.		28.		 Schlesinger	J,	Schueler	M,	Grunert	M,	Fischer	JJ,	Zhang	Q,	Krueger	T,	et	al.	The	cardiac	 transcription	 network	 modulated	 by	 Gata4,	 Mef2a,	 Nkx2.5,	 Srf,	histone	 modifications,	 and	 microRNAs.	 PLoS	 Genet.	 2011	
	 	163	
Feb;7(2):e1001313.		29.		 Hami	 D,	 Grimes	 AC,	 Tsai	 H-J,	 Kirby	 ML.	 Zebrafish	 cardiac	 development	requires	 a	 conserved	 secondary	 heart	 field.	 Development.	 2011	Jun;138(11):2389–98.		30.		 McCulley	DJ,	Black	BL.	Transcription	factor	pathways	and	congenital	heart	disease.	 Vol.	 100,	 Current	 topics	 in	 developmental	 biology.	 Elsevier	 Inc.;	2012.	253-77	p.		31.		 Hwang	PM,	Sykes	BD.	Targeting	the	sarcomere	to	correct	muscle	function.	Nat	Rev	Drug	Discov.	2015	May;14(5):313–28.		32.		 Huang	W,	 Zhang	 R,	 Xu	 X.	 Myofibrillogenesis	 in	 the	 developing	 zebrafish	heart:	A	functional	study	of	tnnt2.	Dev	Biol.	2009	Jul	15;331(2):237–49.		33.		 Skwarek-Maruszewska	 A,	 Hotulainen	 P,	 Mattila	 PK,	 Lappalainen	 P.	Contractility-dependent	actin	dynamics	in	cardiomyocyte	sarcomeres.	J	Cell	Sci.	2009	Jun	15;122(Pt	12):2119–26.		34.		 da	Silva	Lopes	K,	Pietas	A,	Radke	MH,	Gotthardt	M.	Titin	visualization	in	real	time	 reveals	 an	 unexpected	 level	 of	 mobility	 within	 and	 between	sarcomeres.	J	Cell	Biol.	2011;193(4):785–98.		35.		 Leber	 Y,	 Ruparelia	 AA,	 Kirfel	 G,	 Ven	 PFM	 Van	 Der.	 Filamin	 C	 is	 a	 highly	dynamic	protein	associated	with	 fast	 repair	of	myofibrillar	microdamage.	Hum	Mol	Genet.	2016;		36.		 Bergmann	O,	Bhardwaj	RD,	Bernard	S,	Zdunek	S,	Walsh	S,	Zupicich	J,	et	al.	Evidence	 for	 Cardiomyocyte	 Renewal	 in	 Humans.	 Science	 (80-	 ).	2009;324(5923):98–102.		37.		 Porrello	ER,	Mahmoud	AI,	Simpson	E,	Hill	J	a,	Richardson	J	a,	Olson	EN,	et	al.	Transient	regenerative	potential	of	the	neonatal	mouse	heart.	Science.	2011	Feb	25;331(6020):1078–80.		38.		 Mollova	M,	Bersell	K,	Walsh	S,	Savla	J,	Das	LT,	Park	S-Y,	et	al.	Cardiomyocyte	proliferation	contributes	to	heart	growth	in	young	humans.	Proc	Natl	Acad	Sci	U	S	A.	2013;110(4):1446–51.		39.		 Poss	KD,	Wilson	LG,	Keating	MT.	Heart	regeneration	in	zebrafish.	Science.	2002	Dec	13;298(5601):2188–90.		40.		 Naqvi	N,	Li	M,	Calvert	JW,	Tejada	T,	Lambert	JP,	Wu	J,	et	al.	A	proliferative	burst	during	preadolescence	establishes	 the	 final	 cardiomyocyte	number.	Cell.	2014	May	8;157(4):795–807.		41.		 Gupta	 V,	 Poss	 K.	 Clonally	 dominant	 cardiomyocytes	 direct	 heart	morphogenesis.	Nature.	2012;484(7395):479–84.		42.		 Maiuri	 MC,	 Zalckvar	 E,	 Kimchi	 A,	 Kroemer	 G.	 Self-eating	 and	 self-killing:	crosstalk	 between	 autophagy	 and	 apoptosis.	 Nat	 Rev	Mol	 Cell	 Biol.	 2007	Sep;8(9):741–52.		43.		 Li	WW,	Li	J,	Bao	JK.	Microautophagy:	Lesser-known	self-eating.	Cell	Mol	Life	
	 	164	
Sci.	2012;69(7):1125–36.		44.		 Chiang	HL,	Terlecky	 SR,	 Plant	CP,	Dice	 JF.	A	 role	 for	 a	70-kilodalton	heat	shock	 protein	 in	 lysosomal	 degradation	 of	 intracellular	 proteins.	 Science	(80-	).	1989;246(August):382–5.		45.		 Thompson	LM,	Aiken	CT,	Kaltenbach	LS,	Agrawal	N,	Illes	K,	Khoshnan	A,	et	al.	 IKK	 phosphorylates	 Huntingtin	 and	 targets	 it	 for	 degradation	 by	 the	proteasome	and	lysosome.	J	Cell	Biol.	2009;187(7):1083–99.		46.		 Arndt	V,	Dick	N,	Tawo	R,	Dreiseidler	M,	Wenzel	D,	Hesse	M,	et	al.	Chaperone-assisted	selective	autophagy	is	essential	for	muscle	maintenance.	Curr	Biol.	2010	Jan	26;20(2):143–8.		47.		 Ulbricht	 A,	 Gehlert	 S,	 Leciejewski	 B,	 Schiffer	 T,	 Bloch	W,	 Höhfeld	 J,	 et	 al.	Induction	and	adaptation	of	chaperone-assisted	selective	autophagy	CASA	in	response	to	resistance	exercise	in	human	skeletal	muscle	Induction	and	adaptation	of	chaperone-assisted	selective	autophagy	CASA	in	response	to	resistance	exercise	in	human	skeleta.	2015;8627(September).		48.		 Ulbricht	A,	Eppler	FJ,	Tapia	VE,	van	der	Ven	PFM,	Hampe	N,	Hersch	N,	et	al.	Cellular	 mechanotransduction	 relies	 on	 tension-induced	 and	 chaperone-assisted	autophagy.	Curr	Biol.	2013	Mar	4;23(5):430–5.		49.		 Rubinsztein	DC,	Codogno	P,	Levine	B.	Autophagy	modulation	as	a	potential	therapeutic	 target	 for	 diverse	 diseases.	 Nat	 Rev	 Drug	 Discov.	 2012	Sep;11(9):709–30.		50.		 Mizushima	N,	Levine	B,	Cuervo	AM,	Klionsky	DJ.	Autophagy	fights	disease	through	cellular	self-digestion.	Nature.	2008	Feb	28;451(7182):1069–75.		51.		 Green	DR,	Levine	B.	To	be	or	not	to	be?	How	selective	autophagy	and	cell	death	govern	cell	fate.	Cell.	2014;157(1):65–75.		52.		 Nakai	A,	Yamaguchi	O,	Takeda	T.	The	role	of	autophagy	in	cardiomyocytes	in	 the	 basal	 state	 and	 in	 response	 to	 hemodynamic	 stress.	 Nat	 Med.	2007;13:619–24.		53.		 Sybers	H,	Ingwall	J,	DeLuca	M.	Autophagy	in	cardiac	myocytes.	Recent	Adv	Stud	Card	Struct	Metab.	1976;12:453–63.		54.		 Nishida	K,	Kyoi	S,	Yamaguchi	O,	Sadoshima	J,	Otsu	K.	The	role	of	autophagy	in	the	heart.	Cell	Death	Differ.	2009	Jan;16(1):31–8.		55.		 Tannous	P,	Zhu	H,	Johnstone	JL,	Shelton	JM,	Rajasekaran	NS,	Benjamin	IJ,	et	al.	Autophagy	 is	an	adaptive	response	 in	desmin-related	cardiomyopathy.	Proc	Natl	Acad	Sci.	2008	Jul	15;105(28):9745–50.		56.		 Ding	 Y,	 Sun	 X,	 Huang	 W,	 Hoage	 T,	 Redfield	 M,	 Kushwaha	 S,	 et	 al.	Haploinsufficiency	of	 target	of	 rapamycin	attenuates	 cardiomyopathies	 in	adult	zebrafish.	Circ	Res.	2011	Sep	2;109(6):658–69.		57.		 Kawaguchi	T,	Takemura	G,	Kanamori	H,	Takeyama	T,	Watanabe	T,	Morishita	K,	et	al.	Prior	starvation	mitigates	acute	doxorubicin	cardiotoxicity	through	restoration	of	autophagy	in	affected	cardiomyocytes.	Cardiovasc	Res.	2012	
	 	165	
Dec	1;96(3):456–65.		58.		 Portbury	AL,	Willis	MS,	Patterson	C.	Tearin’	up	my	heart:	proteolysis	in	the	cardiac	sarcomere.	J	Biol	Chem.	2011	Mar	25;286(12):9929–34.		59.		 White	RM,	Sessa	A,	Burke	C,	Bowman	T,	LeBlanc	J,	Ceol	C,	et	al.	Transparent	adult	zebrafish	as	a	tool	for	in	vivo	transplantation	analysis.	Cell	Stem	Cell.	2008	Feb	7;2(2):183–9.		60.		 Hwang	WY,	Fu	Y,	Reyon	D,	Maeder	ML,	Tsai	SQ,	Sander	 JD,	et	al.	Efficient	genome	 editing	 in	 zebrafish	 using	 a	 CRISPR-Cas	 system.	 Nat	 Biotechnol.	2013;31(3):227–9.		61.		 Dahlem	TJ,	Hoshijima	K,	Jurynec	MJ,	Gunther	D,	Starker	CG,	Locke	AS,	et	al.	Simple	 methods	 for	 generating	 and	 detecting	 locus-specific	 mutations	induced	 with	 TALENs	 in	 the	 zebrafish	 genome.	 PLoS	 Genet.	 2012	Jan;8(8):e1002861.		62.		 Bedell	VVM,	Wang	Y,	Campbell	JMJ,	Poshusta	TLT,	Starker	CCG,	Krug	RGR,	et	al.	 In	 vivo	 genome	 editing	 using	 a	 high-efficiency	TALEN	 system.	Nature.	2012	Nov	1;491(7422):114–8.		63.		 Bongso	A,	Fong	CY,	Ng	SC,	Ratnam	S.	Isolation	and	culture	of	inner	cell	mass	cells	from	human	blastocysts.	Hum	Reprod.	1994	Nov;9(11):2110–7.		64.		 Takahashi	K,	Yamanaka	S.	Induction	of	pluripotent	stem	cells	from	mouse	embryonic	 and	 adult	 fibroblast	 cultures	 by	 defined	 factors.	 Cell.	 2006	Aug;126(4):663–76.		65.		 Kehat	I,	Kenyagin-Karsenti	D.	Human	embryonic	stem	cells	can	differentiate	into	myocytes	with	structural	and	functional	properties	of	cardiomyocytes.	J	Clin	Invest.	2001;108(3):407–14.		66.		 Barbuti	 A,	 Benzoni	 P,	 Campostrini	 G,	 Dell’Era	 P.	 Human	 derived	cardiomyocytes:	 A	 decade	 of	 knowledge	 after	 the	 discovery	 of	 induced	pluripotent	stem	cells.	Dev	Dyn.	2016;245(12):1145–58.		67.		 Yang	X,	Pabon	L,	Murry	CE.	Engineering	adolescence:	Maturation	of	human	pluripotent	stem	cell-derived	cardiomyocytes.	Circ	Res.	2014;114(3):511–23.		68.		 Claycomb	WC,	Lanson	N	a,	Stallworth	BS,	Egeland	DB,	Delcarpio	JB,	Bahinski	A,	 et	 al.	 HL-1	 cells:	 a	 cardiac	 muscle	 cell	 line	 that	 contracts	 and	 retains	phenotypic	characteristics	of	the	adult	cardiomyocyte.	Proc	Natl	Acad	Sci	U	S	A.	1998	Mar	17;95(6):2979–84.		69.		 Gunther	 A,	 Baumann	 A,	 Guenther	 A,	 Baumann	 A.	 Distinct	 expression	patterns	 of	 HCN	 channels	 in	 HL-1	 cardiomyocytes.	 BMC	 Cell	 Biol.	2015;16:18.		70.		 Evans	 T,	 Reitman	 M,	 Felsenfeld	 G.	 An	 erythrocyte-specific	 DNA-binding	factor	recognizes	a	regulatory	sequence	common	to	all	chicken	globin	genes.	Proc	Natl	Acad	Sci.	1988;85(16):5976–80.		71.		 Yang	HY,	Evans	T.	Distinct	roles	for	the	two	cGATA-1	finger	domains.	Mol	
	 	166	
Cell	Biol.	1992;12(10):4562–70.		72.		 Lentjes	MH,	Niessen	HE,	Akiyama	Y,	de	Bruïne	AP,	Melotte	V,	van	Engeland	M.	 The	 emerging	 role	 of	 GATA	 transcription	 factors	 in	 development	 and	disease.	Expert	Rev	Mol	Med.	2016;18:e3.		73.		 Chlon	TM,	Crispino	 JD.	Combinatorial	 regulation	of	 tissue	specification	by	GATA	and	FOG	factors.	Development.	2012;139(21):3905–16.		74.		 Kuo	CT,	Morrisey	EE,	Anandappa	R,	Sigrist	K,	Lu	MM,	Parmacek	MS,	et	al.	GATA4	transcription	factor	is	required	for	ventral	morphogenesis	and	heart	tube	formation.	Genes	Dev.	1997;11(8):1048–60.		75.		 Molkentin	JD,	Lin	Q,	Duncan	SA,	Olson	EN.	Requirement	of	the	transcription	factor	GATA4	for	heart	 tube	formation	and	ventral	morphogenesis.	Genes	Dev.	1997;11(8):1061–72.		76.		 Lepage	D,	Bélanger	É,	Jones	C,	Tremblay	S,	Allaire	JM,	Bruneau	J,	et	al.	Gata4	is	critical	to	maintain	gut	barrier	function	and	mucosal	integrity	following	epithelial	injury.	Sci	Rep.	2016;6(October):36776.		77.		 Beuling	E,	Kerkhof	IM,	Nicksa	GA,	Giuffrida	MJ,	Haywood	J,	aan	de	Kerk	DJ,	et	al.	Conditional	Gata4	deletion	in	mice	induces	bile	acid	absorption	in	the	proximal	small	intestine.	Gut.	2010;59(7):888–95.		78.		 Güemes	M,	Garcia	AJ,	Rigueur	D,	Runke	S,	Wang	W,	Zhao	G,	et	al.	GATA4	is	essential	for	bone	mineralization	via	ER??	and	TGF??/BMP	pathways.	J	Bone	Miner	Res.	2014;29(12):2676–87.		79.		 Delgado	 I,	 Carrasco	 M,	 Cano	 E,	 Carmona	 R,	 García-Carbonero	 R,	 Marín-Gómez	 LM,	 et	 al.	 GATA4	 loss	 in	 the	 septum	 transversum	 mesenchyme	promotes	liver	fibrosis	in	mice.	Hepatology.	2014;59(6):2358–70.		80.		 Chen	S,	Tang	J,	Cheng	J,	Li	J,	Jin	C,	Li	X.	Loss	of	Gata4	in	Sertoli	cells	impairs	the	 spermatogonial	 stem	 cell	 niche	 and	 causes	 germ	 cell	 exhaustion	 by	attenuating	chemokine	signaling.	2015;6(35).		81.		 Hu	YC,	Okumura	LM,	Page	DC.	Gata4	Is	Required	for	Formation	of	the	Genital	Ridge	in	Mice.	PLoS	Genet.	2013;9(7).		82.		 Holtzinger	 A,	 Evans	 T.	 Gata4	 regulates	 the	 formation	 of	multiple	 organs.	Development.	2005;4005–14.		83.		 Online	Mendelian	 Inheritance	 in	Man,	OMIM®.	 Johns	Hopkins	University,	Baltimore,	 MD.	 MIM	 Number:	 600576	 [Internet].	 [cited	 2017	 Jan	 29].	Available	from:	https://omim.org/600576	84.		 Watt	AJ,	Battle	M	a,	Li	J,	Duncan	SA.	GATA4	is	essential	for	formation	of	the	proepicardium	and	regulates	cardiogenesis.	Proc	Natl	Acad	Sci	U	S	A.	2004	Aug	24;101(34):12573–8.		85.		 Zeisberg	 E,	 Ma	 Q,	 Juraszek	 A,	 Moses	 K,	 Schwartz	 R,	 Izumo	 S,	 et	 al.	Morphogenesis	 of	 the	 right	 ventricle	 requires	 myocardial	 expression	 of	Gata4.	J	Clin	Invest.	2005;115:1522–31.		
	 	167	
86.		 Rajagopal	SK,	Ma	Q,	Obler	D,	Shen	J,	Manichaikul	A,	Tomita-Mitchell	A,	et	al.	Spectrum	 of	 heart	 disease	 associated	 with	 murine	 and	 human	 GATA4	mutation.	J	Mol	Cell	Cardiol.	2007;43(6):677–85.		87.		 Gupta	 V,	 Gemberling	M,	 Karra	 R,	 Rosenfeld	 GEE,	 Evans	 T,	 Poss	 KDD.	 An	Injury-Responsive	Gata4	Program	Shapes	 the	Zebrafish	Cardiac	Ventricle.	Curr	Biol.	2013	Jun	8;23(13):1–7.		88.		 Oka	T,	Maillet	M,	Watt	AJ,	Schwartz	RJ,	Aronow	BJ,	Duncan	S	a,	et	al.	Cardiac-specific	 deletion	 of	 Gata4	 reveals	 its	 requirement	 for	 hypertrophy,	compensation,	and	myocyte	viability.	Circ	Res.	2006	Mar	31;98(6):837–45.		89.		 Olson	EN,	Molkentin	JD.	Prevention	of	Cardiac	Hypertrophy	by	Calcineurin	Inhibition :	Hope	or	Hype?	Circ	Res.	1999	Apr	2;84(6):623–32.		90.		 Lowes	BD,	Minobe	W,	Abraham	WT,	Rizeq	MN,	Bohlmeyer	TJ,	Quaife	RA,	et	al.	 Changes	 in	 Gene	 Expression	 in	 the	 Intact	 Human	 Heart.	 J	 Clin	 Invest.	1997;100:2315–24.		91.		 Perrino	 C,	 Rockman	 H	 a.	 GATA4	 and	 the	 two	 sides	 of	 gene	 expression	reprogramming.	Circ	Res.	2006	Mar	31;98(6):715–6.		92.		 Bisping	E,	 Ikeda	S,	Won	Kong	S,	Tarnavski	O,	Bodyak	N,	McMullen	J,	et	al.	Gata4	 is	 required	 for	 maintenance	 of	 postnatal	 cardiac	 function	 and	protection	from	pressure	overload-induced	heart	failure.	Proc	Natl	Acad	Sci.	2006;103(39):14471–6.		93.		 Kobayashi	 S,	 Mao	 K,	 Zheng	 H,	 Wang	 X,	 Patterson	 C,	 O’Connell	 TD,	 et	 al.	Diminished	 GATA4	 protein	 levels	 contribute	 to	 hyperglycemia-induced	cardiomyocyte	injury.	J	Biol	Chem.	2007	Jul	27;282(30):21945–52.		94.		 Aries	A,	Paradis	P,	Lefebvre	C,	Schwartz	RJ,	Nemer	M.	Essential	role	of	GATA-4	in	cell	survival	and	drug-induced	cardiotoxicity.	Proc	Natl	Acad	Sci.	2004	May	4;101(18):6975–80.		95.		 Kobayashi	S,	Volden	P,	Timm	D,	Mao	K.	Transcription	factor	GATA4	inhibits	doxorubicin-induced	autophagy	and	cardiomyocyte	death.	J	Biol	….	2010;		96.		 Suzuki	Y,	Nagase	H,	Day	R,	Das	D.	GATA-4	regulation	of	myocardial	survival	in	the	preconditioned	heart.	J	Mol	Cell	….	2004;37:1195–203.		97.		 Kobayashi	 S,	 Lackey	 T,	 Huang	 Y,	 Bisping	 E,	 Pu	 WT,	 Boxer	 LM,	 et	 al.	Transcription	factor	gata4	regulates	cardiac	BCL2	gene	expression	in	vitro	and	in	vivo.	FASEB	J.	2006	Apr;20(6):800–2.		98.		 Chen	 B,	 Zhong	 L,	 Roush	 SF,	 Pentassuglia	 L,	 Peng	 X,	 Samaras	 S,	 et	 al.	Disruption	 of	 a	 GATA4/Ankrd1	 signaling	 axis	 in	 cardiomyocytes	 leads	 to	sarcomere	disarray:	 implications	 for	 anthracycline	 cardiomyopathy.	PLoS	One.	2012	Jan;7(4):e35743.		99.		 Rajasekaran	NS,	Connell	P,	Christians	ES,	Yan	L-J,	Taylor	RP,	Orosz	A,	et	al.	Human	 alpha	 B-crystallin	 mutation	 causes	 oxido-reductive	 stress	 and	protein	aggregation	cardiomyopathy	in	mice.	Cell.	2007	Aug	10;130(3):427–39.		
	 	168	
100.		 Bienengraeber	M,	Olson	TM,	Selivanov	V	a,	Kathmann	EC,	O’Cochlain	F,	Gao	F,	 et	 al.	 ABCC9	 mutations	 identified	 in	 human	 dilated	 cardiomyopathy	disrupt	catalytic	KATP	channel	gating.	Nat	Genet.	2004	Apr;36(4):382–7.		101.		 Duboscq-Bidot	L,	Charron	P,	Ruppert	V,	Fauchier	L,	Richter	A,	Tavazzi	L,	et	al.	Mutations	in	the	ANKRD1	gene	encoding	CARP	are	responsible	for	human	dilated	cardiomyopathy.	Eur	Heart	J.	2009	Sep;30(17):2128–36.		102.		 He	A,	Kong	SW,	Ma	Q,	Pu	WT.	Co-occupancy	by	multiple	cardiac	transcription	factors	identifies	transcriptional	enhancers	active	in	heart.	Proc	Natl	Acad	Sci.	2011	Apr	5;108(14):5632–7.		103.		 Schrode	 N,	 Saiz	 N,	 Di	 Talia	 S,	 Hadjantonakis	 AK.	 GATA6	 levels	modulate	primitive	endoderm	cell	fate	choice	and	timing	in	the	mouse	blastocyst.	Dev	Cell.	2014;29(4):454–67.		104.		 Zhao	R,	Watt	AJ,	Li	J,	Luebke-wheeler	J,	Morrisey	EE,	Duncan	SA.	GATA6	Is	Essential	for	Embryonic	Development	of	the	Liver	but	Dispensable	for	Early	Heart	Formation.	2005;25(7):2622–31.		105.		 Lepore	JJ,	Mericko	PA,	Cheng	L,	Lu	MM,	Morrisey	EE,	Parmacek	MS.	GATA-6	regulates	 semaphorin	 3C	 and	 is	 required	 in	 cardiac	 neural	 crest	 for	cardiovascular	morphogenesis.	J	Clin	Invest.	2006;116(4):929–39.		106.		 Endothelial	GATA-6	Deficiency	Promotes	Pulmonary	Arterial	Hypertension.		107.		 Online	Mendelian	 Inheritance	 in	Man,	OMIM®.	 Johns	Hopkins	University,	Baltimore,	 MD.	 MIM	 Number:	 601656	 [Internet].	 [cited	 2017	 Jan	 1].	Available	from:	https://omim.org/601656	108.		 Xin	M,	Davis	CA,	Molkentin	JD,	Lien	C-L,	Duncan	SA,	Richardson	JA,	et	al.	A	threshold	of	GATA4	and	GATA6	expression	 is	required	 for	cardiovascular	development.	Proc	Natl	Acad	Sci.	2006;103(30):11189–94.		109.		 Holtzinger	 A,	 Evans	 T.	 Gata5	 and	 Gata6	 are	 functionally	 redundant	 in	zebrafish	 for	specification	of	cardiomyocytes.	Dev	Biol.	2007;312(2):613–22.		110.		 Singh	 MK,	 Li	 Y,	 Li	 S,	 Cobb	 RM,	 Zhou	 D,	 Lu	 MM,	 et	 al.	 Gata4	 and	 Gata5	cooperatively	regulate	cardiac	myocyte	proliferation	 in	mice.	 J	Biol	Chem.	2010;285(3):1765–72.		111.		 Carrasco	M,	Delgado	I,	Soria	B,	Martín	F,	Rojas	A.	GATA4	and	GATA6	control	mouse	pancreas	organogenesis.	2012;122(10).		112.		 Borok	MJ,	Papaioannou	VE,	 Sussel	L.	Unique	 functions	of	Gata4	 in	mouse	liver	induction	and	heart	development.	Dev	Biol.	2016;410(2):213–22.		113.		 Svensson	 EC,	 Huggins	 GS,	 Lin	 H,	 Clendenin	 C,	 Jiang	 F,	 Tufts	 R,	 et	 al.	 A	syndrome	of	tricuspid	atresia	in	mice	with	a	targeted	mutation	of	the	gene	encoding	Fog-2.	Nat	Genet.	2000;25(3):353–6.		114.		 Bagu	 ET,	 Layoun	 A,	 Calvé	 A,	 Santos	 MM.	 Friend	 of	 GATA	 and	 GATA-6	modulate	 the	 transcriptional	 up-regulation	 of	 hepcidin	 in	 hepatocytes	during	inflammation.	BioMetals.	2013;26(6):1051–65.		
	 	169	
115.		 Beuling	E,	Bosse	T,	aan	de	Kerk	DJ,	Piaseckyj	CM,	Fujiwara	Y,	Katz	SG,	et	al.	GATA4	 mediates	 gene	 repression	 in	 the	 mature	 mouse	 small	 intestine	through	 interactions	 with	 friend	 of	 GATA	 (FOG)	 cofactors.	 Dev	 Biol.	2008;322(1):179–89.		116.		 Ang	 Y,	 Rivas	 RN,	 Ribeiro	 AJS,	 Pruitt	 BL,	 Snyder	 MP,	 Srivastava	 D,	 et	 al.	Disease	 Model	 of	 GATA4	 Mutation	 Reveals	 Transcription	 Factor	Cooperativity	in	Human	Article	Disease	Model	of	GATA4	Mutation	Reveals	Transcription	 Factor	 Cooperativity	 in	 Human	 Cardiogenesis.	 Cell.	2016;167(7):1734–1737.e22.		117.		 Ma	Y,	Wang	J,	Yu	Y,	Schwartz	RJ.	PKG-1??	mediates	GATA4	transcriptional	activity.	Cell	Signal.	2016;28(6):585–94.		118.		 Suzuki	H,	Katanasaka	Y,	Sunagawa	Y,	Miyazaki	Y,	Funamoto	M,	Wada	H,	et	al.	Tyrosine	phosphorylation	of	RACK1	triggers	cardiomyocyte	hypertrophy	by	regulating	 the	 interaction	between	p300	and	GATA4.	Biochim	Biophys	Acta	-	Mol	Basis	Dis.	2016;1862(9):1544–57.		119.		 Charron	F,	Tsimiklis	G,	Arcand	M,	Robitaille	L,	Liang	Q,	Molkentin	JD,	et	al.	Tissue-specific	 GATA	 factors	 are	 transcriptional	 effectors	 of	 the	 small	GTPase	RhoA.	Genes	Dev.	2001	Oct	15;15(20):2702–19.		120.		 Rosenfeld	 GE,	 Mercer	 EJ,	 Mason	 CE,	 Evans	 T.	 Small	 heat	 shock	 proteins	Hspb7	and	Hspb12	regulate	early	steps	of	cardiac	morphogenesis.	Dev	Biol.	2013	Jul	11;15(2):1–12.		121.		 Wojtowicz	I,	Jabłońska	J,	Zmojdzian	M,	Taghli-lamallem	O,	Renaud	Y,	Junion	G,	 et	 al.	 Drosophila	 small	 heat	 shock	 protein	 CryAB	 ensures	 structural	integrity	of	developing	muscles,	and	proper	muscle	and	heart	performance.	Development.	2015;142(5):994–1005.		122.		 Garrido	C,	Paul	C,	Seigneuric	R,	Kampinga	HH.	The	small	heat	shock	proteins	family:	 the	 long	 forgotten	 chaperones.	 Int	 J	 Biochem	 Cell	 Biol.	 2012	Oct;44(10):1588–92.		123.		 Marvin	M,	O’Rourke	D.	Developmental	expression	patterns	of	the	zebrafish	small	heat	shock	proteins.	Dev	….	2008;(December	2007):454–63.		124.		 Elicker	KS,	Hutson	LD.	Genome-wide	analysis	and	expression	profiling	of	the	small	heat	shock	proteins	in	zebrafish.	Gene.	2007	Nov	15;403(1–2):60–9.		125.		 Kappé	G,	Franck	E,	Verschuure	P,	Boelens	WC,	Leunissen	J	a	M,	de	Jong	WW.	The	human	 genome	 encodes	 10	 alpha-crystallin-related	 small	 heat	 shock	proteins:	HspB1-10.	Cell	Stress	Chaperones.	2003	Jan;8(1):53–61.		126.		 Ke	 L,	 Meijering	 R	 a	M,	 Hoogstra-Berends	 F,	 Mackovicova	 K,	 Vos	MJ,	 Van	Gelder	 IC,	 et	 al.	 HSPB1,	 HSPB6,	 HSPB7	 and	 HSPB8	 protect	 against	 RhoA	GTPase-induced	remodeling	in	tachypaced	atrial	myocytes.	PLoS	One.	2011	Jan;6(6):e20395.		127.		 Vos	MJ,	 Zijlstra	MP,	Kanon	B,	 van	Waarde-Verhagen	M	a	WH,	Brunt	ERP,	Oosterveld-Hut	 HMJ,	 et	 al.	 HSPB7	 is	 the	 most	 potent	 polyQ	 aggregation	suppressor	 within	 the	 HSPB	 family	 of	 molecular	 chaperones.	 Hum	 Mol	
	 	170	
Genet.	2010	Dec	1;19(23):4677–93.		128.		 Morrow	G,	Tanguay	RM.	Small	heat	shock	protein	expression	and	functions	during	development.	Int	J	Biochem	Cell	Biol.	2012	Oct;44(10):1613–21.		129.		 Vicart	P,	Caron		a,	Guicheney	P,	Li	Z,	Prévost	MC,	Faure		a,	et	al.	A	missense	mutation	in	the	alphaB-crystallin	chaperone	gene	causes	a	desmin-related	myopathy.	Nat	Genet.	1998	Sep;20(1):92–5.		130.		 Huang	 L,	 Min	 JN,	 Masters	 S,	 Mivechi	 NF,	 Moskophidis	 D.	 Insights	 into	function	and	regulation	of	small	heat	shock	protein	25	(HSPB1)	in	a	mouse	model	with	targeted	gene	disruption.	Genesis.	2007;45(8):487–501.		131.		 Christians	ES,	 Ishiwata	T,	Benjamin	IJ.	Small	heat	shock	proteins	 in	redox	metabolism:	 implications	 for	 cardiovascular	 diseases.	 Int	 J	 Biochem	 Cell	Biol.	2012	Oct;44(10):1632–45.		132.		 Krief	S,	Faivre	JJ-F,	Robert	P,	Le	Douarin	B,	Brument-larignon	N,	Lefrere	I,	et	al.	 Identification	 and	 Characterization	 of	 cvHsp.	 J	 Biol	 Chem.	1999;274(51):36592–600.		133.		 Gehler	S,	Baldassarre	M,	Lad	Y,	Leight	 JL,	Wozniak	MA,	Riching	KM,	et	al.	Filamin	A	–	␤	1	Integrin	Complex	Tunes	Epithelial	Cell	Response	to	Matrix	Tension.	2009;20:3224–38.		134.		 Ehrlicher	 	a	 J,	Nakamura	F,	Hartwig	 JH,	Weitz	D	a,	Stossel	TP.	Mechanical	strain	in	actin	networks	regulates	FilGAP	and	integrin	binding	to	filamin	A.	Nature.	2011	Oct	13;478(7368):260–3.		135.		 Eenjes	E,	Dragich	JM,	Kampinga	HH,	Yamamoto	A.	Distinguishing	aggregate	formation	 and	 aggregate	 clearance	 using	 cell	 based	 assays.	 J	 Cell	 Sci.	2016;129(6):1260–70.		136.		 Juo	L-Y,	Liao	W-C,	Shih	Y-L,	Yang	B-Y,	Liu	A-B,	Yan	Y-T.	HSPB7	interacts	with	dimerized	FLNC	and	its	absence	results	in	progressive	myopathy	in	skeletal	muscles.	J	Cell	Sci.	2016;1661–70.		137.		 Westerfield	 M.	 The	 Zebrafish	 Book;	 a	 laboratory	 guide	 for	 the	 use	 of	zebrafish	(Brachydanio	rerio).	University	of	Oregon;	1993.		138.		 Korzh	 S,	 Pan	 X,	 Garcia-Lecea	 M,	 Winata	 CL,	 Pan	 X,	 Wohland	 T,	 et	 al.	Requirement	of	vasculogenesis	and	blood	circulation	in	late	stages	of	liver	growth	in	zebrafish.	BMC	Dev	Biol.	2008;8:84.		139.		 Meijering	E,	Dzyubachyk	O,	Smal	 I.	Methods	 for	cell	and	particle	 tracking.	Methods	Enzymol.	2012;504(February):183–200.		140.		 Yang	 J,	 Xu	 X.	 Immunostaining	 of	 Dissected	 Zebrafish	 Embryonic	 Heart	 .	2012;(59):e3510.		141.		 Arnaout	R,	Ferrer	T,	Huisken	J,	Spitzer	K,	Stainier	DYR,	Tristani-firouzi	M,	et	al.	Zebrafish	model	for	human	long	QT	syndrome.	2007;104(27).		142.		 Doyle	E,	Booher	N.	TAL	Effector-Nucleotide	Targeter	(TALE-NT)	2.0:	tools	for	 TAL	 effector	 design	 and	 target	 prediction.	 Nucleic	 Acids	 ….	
	 	171	
2012;40(W117-22).		143.		 Cermak	T,	Doyle	EL,	Christian	M,	Wang	L,	Zhang	Y,	Schmidt	C,	et	al.	Efficient	design	 and	 assembly	 of	 custom	 TALEN	 and	 other	 TAL	 effector-based	constructs	for	DNA	targeting.	Nucleic	Acids	Res.	2011	Jul;39(12):e82.		144.		 Montague	 TG,	 Cruz	 JM,	 Gagnon	 JA,	 Church	 GM,	 Valen	 E.	 CHOPCHOP:	 A	CRISPR/Cas9	and	TALEN	web	tool	 for	genome	editing.	Nucleic	Acids	Res.	2014;42(W1):401–7.		145.		 Zhu	 Z,	 González	 F,	 Huangfu	 D.	 The	 iCRISPR	 Platform	 for	 Rapid	 Genome	Editing	in	Human	Pluripotent	Stem	Cells.	Vol.	546,	Methods	in	enzymology.	2014.	215-50	p.		146.		 Wilkinson	RN,	Elworthy	S,	Ingham	PW,	van	Eeden	FJM.	A	method	for	high-throughput	 PCR-based	 genotyping	 of	 larval	 zebrafish	 tail	 biopsies.	Biotechniques.	2013;55(6):314–6.		147.		 Ablain	J,	Durand	EM,	Yang	S,	Zhou	Y,	Zon	LI.	A	CRISPR/Cas9	Vector	System	for	Tissue-Specific	Gene	Disruption	in	Zebrafish.	Dev	Cell.	2015;32(6):756–64.		148.		 González	 F,	 Zhu	 Z,	 Shi	 Z-DD,	 Lelli	 K,	 Verma	 N,	 Li	 Q	 V.,	 et	 al.	 An	 iCRISPR	platform	for	rapid,	multiplexable,	and	inducible	genome	editing	 in	human	pluripotent	stem	cells.	Cell	Stem	Cell.	2014	Jun	11;15:215–26.		149.		 Lian	 X,	 Hsiao	 C,	Wilson	 G,	 Zhu	 K,	 Hazeltine	 LB,	 Azarin	 SM,	 et	 al.	 Robust	cardiomyocyte	 differentiation	 from	 human	 pluripotent	 stem	 cells	 via	temporal	 modulation	 of	 canonical	 Wnt	 signaling.	 Proc	 Natl	 Acad	 Sci.	2012;109(27):E1848–57.		150.		 Burridge	 PW,	 Holmström	 A,	 Wu	 JC.	 Chemically	 Defined	 Culture	 and	Cardiomyocyte	Differentiation	of	Human	Pluripotent	Stem	Cells.	Curr	Protoc	Hum	Genet.	2015;(October):21.3.1-21.3.15.		151.		 Arnaout	R,	Reischauer	S,	Stainier	DYR.	Recovery	of	Adult	Zebrafish	Hearts	for	High-throughput	Applications	Video	Link.	J	Vis	Exp.	2014;(94).		152.		 de	Bruijn	WC.	Glycogen,	 its	chemistry	and	morphologic	appearance	in	the	electron	microscope.	I.	A	modified	OsO4	fixative	which	selectively	contrasts	glycogen.	J	Ultrasructure	Res.	1973;42(1–2):29–50.		153.		 Dagda	 RK,	 Zhu	 J,	 Kulich	 SM,	 Chu	 CT.	 Mitochondrially	 localized	 ERK2	regulates	mitophagy	and	autophagic	cell	stress.	Autophagy.	2008;4(6):70–782.		154.		 Holtzinger	A,	Rosenfeld	GE,	Evans	T.	Gata4	directs	development	of	cardiac-inducing	endoderm	from	ES	cells.	Dev	Biol.	2010	Jan	1;337(1):63–73.		155.		 Nuriel	T,	Whitehouse	J,	Ma	Y,	Mercer	EJ,	Brown	N,	Gross	SS.	ANSID:	A	Solid-Phase	Proteomic	Approach	for	Identification	and	Relative	Quantification	of	Aromatic	Nitration	Sites.	Front	Chem.	2015;3(January):70.		156.		 Holtzinger	 	 a.	 Gata4	 regulates	 the	 formation	 of	 multiple	 organs.	Development.	2006	Jan	1;133(1):181–181.		
	 	172	
157.		 Cappola	TP,	Li	M,	He	J,	Ky	B,	Gilmore	J,	Qu	L,	et	al.	Common	variants	in	HSPB7	and	FRMD4B	associated	with	advanced	heart	failure.	Circ	Cardiovasc	Genet.	2010;3(2):147–54.		158.		 Stark	K,	Esslinger	UB,	Reinhard	W,	Petrov	G,	Winkler	T,	Komajda	M,	et	al.	Genetic	 association	 study	 identifies	 HSPB7	 as	 a	 risk	 gene	 for	 idiopathic	dilated	cardiomyopathy.	PLoS	Genet.	2010	Oct;6(10):e1001167.		159.		 Villard	 E,	 Perret	 C,	 Gary	 F,	 Proust	 C,	 Dilanian	G,	Hengstenberg	 C,	 et	 al.	 A	genome-wide	 association	 study	 identifies	 two	 loci	 associated	 with	 heart	failure	due	to	dilated	cardiomyopathy.	Eur	Heart	J.	2011	May;32(9):1065–76.		160.		 Garnier	S,	Hengstenberg	C,	Lamblin	N,	Dubourg	O,	De	Groote	P,	Fauchier	L,	et	al.	Involvement	of	BAG3	and	HSPB7	loci	in	various	etiologies	of	systolic	heart	 failure:	 Results	 of	 a	 European	 collaboration	 assembling	more	 than	2000	patients.	Int	J	Cardiol.	2015;189:105–7.		161.		 French	B,	Lumley	T,	Cappola	TP,	Mitra	N.	Non-iterative,	 regression-based	estimation	of	haplotype	associations	with	censored	survival	outcomes.	Stat	Appl	Genet	Mol	Biol.	2012	Jan;11(3):Article	4.		162.		 Lahvic	JL,	Ji	Y,	Marin	P,	Zuflacht	JP,	Springel	MW,	Wosen	JE,	et	al.	Small	heat	shock	 proteins	 are	 necessary	 for	 heart	 migration	 and	 laterality	determination	in	zebrafish.	Dev	Biol.	2013	Oct	17;384(2):1–15.		163.		 Miura	GI,	Yelon	D.	A	guide	to	analysis	of	cardiac	phenotypes	in	the	zebrafish	embryo.	Third	Edit.	 Vol.	 101,	Methods	 in	 cell	 biology.	 Elsevier	 Ltd;	 2011.	161-80	p.		164.		 Afzelius	BA,	Mossberg	B,	Bergström	SE.	Immotile	Cilia	Syndrome	(Primary	Ciliary	 Dyskinesia),	 Including	 Kartagener	 Syndrome.	 In:	 Beaudet	 AL,	Vogelstein	 B,	 Kinzler	 KW,	 Antonarakis	 SE,	 Ballabio	 A,	 Gibson	 KM,	 et	 al.,	editors.	The	Online	Metabolic	and	Molecular	Bases	of	Inherited	Disease.	New	York,	NY:	The	McGraw-Hill	Companies,	Inc.;	2014.		165.		 Wettstein	G,	Bellaye	PS,	Micheau	O,	Bonniaud	P.	Small	heat	shock	proteins	and	the	cytoskeleton:	an	essential	interplay	for	cell	integrity?	Int	J	Biochem	Cell	Biol.	2012	Oct;44(10):1680–6.		166.		 Kok	FO,	Shin	M,	Ni	CW,	Gupta	A,	Grosse	AS,	vanImpel	A,	et	al.	Reverse	genetic	screening	 reveals	 poor	 correlation	 between	 morpholino-induced	 and	mutant	phenotypes	in	zebrafish.	Dev	Cell.	2015;32(1):97–108.		167.		 Ata	 H,	 Clark	 KJ,	 Ekker	 SC.	 The	 zebrafish	 genome	 editing	 toolkit.	2016;135:149–70.		168.		 Palstra	AP,	Tudorache	C,	Rovira	M,	Brittijn	SA,	Burgerhout	E,	van	den	Thillart	GEEJM,	et	al.	Establishing	zebrafish	as	a	novel	exercise	model:	Swimming	economy,	 swimming-enhanced	 growth	 and	 muscle	 growth	 marker	 gene	expression.	PLoS	One.	2010;5(12):1–9.		169.		 Giallourakis	CC,	Rosenberg	PM,	Friedman	LS.	The	liver	in	heart	failure.	Clin	Liver	Dis.	2002;6(4):947–67,	viii–ix.		
	 	173	
170.		 Louie	CY,	Pham	MX,	Daugherty	TJ,	Kambham	N,	Higgins	JP.	The	liver	in	heart	failure:	 a	 biopsy	 and	explant	 series	 of	 the	histopathologic	 and	 laboratory	findings	 with	 a	 particular	 focus	 on	 pre-cardiac	 transplant	 evaluation.	ModPathol.	2015;28:932–43.		171.		 Jean	MJM,	Deverteuil	P,	Lopez	NH,	Tapia	 JD,	Schoffstall	B.	Adult	Zebrafish	Hearts	Efficiently	Compensate	for	Excessive	Forced	Overload	Cardiac	Stress	with	Hyperplastic	Cardiomegaly.	BioResearch	Open	….	2012;1(2):88–91.		172.		 Khan	R,	 Sheppard	R.	 Fibrosis	 in	 heart	 disease:	Understanding	 the	 role	 of	transforming	 growth	 factor-??1	 in	 cardiomyopathy,	 valvular	 disease	 and	arrhythmia.	Vol.	118,	Immunology.	2006.	p.	10–24.		173.		 Jonsson	MKB,	Hartman	RJG,	Ackers-Johnson	M,	Tan	WLW,	Lim	B,	van	Veen	TAB,	et	al.	A	Transcriptomic	and	Epigenomic	Comparison	of	Fetal	and	Adult	Human	 Cardiac	 Fibroblasts	 Reveals	 Novel	 Key	 Transcription	 Factors	 in	Adult	 Cardiac	 Fibroblasts	 [Internet].	 Vol.	 1,	 JACC:	 Basic	 to	 Translational	Science.	 2016.	 p.	 590–602.	 Available	 from:	http://linkinghub.elsevier.com/retrieve/pii/S2452302X16301140	174.		 Vos	MJ,	Kanon	B,	Kampinga	HH.	HSPB7	is	a	SC35	speckle	resident	small	heat	shock	protein.	Biochim	Biophys	Acta.	2009	Aug;1793(8):1343–53.		175.		 White	SM,	Constantin	PE,	Claycomb	WC.	Cardiac	physiology	at	the	cellular	level:	use	of	cultured	HL-1	cardiomyocytes	for	studies	of	cardiac	muscle	cell	structure	 and	 function.	 Am	 J	 Physiol	 Heart	 Circ	 Physiol.	 2004	Mar;286(3):H823-9.		176.		 Lewinter	MM,	Granzier	HL.	Titin	is	a	major	human	disease	gene.	Circulation.	2013;127(8):938–44.		177.		 van	der	Ven	PF,	Bartsch	 JW,	Gautel	M,	 Jockusch	H,	Fürst	DO.	A	 functional	knock-out	of	titin	results	in	defective	myofibril	assembly.	J	Cell	Sci.	2000;113	(	Pt	8:1405–14.		178.		 Dalkilic	 I,	 Schienda	 J,	 Thompson	TG,	Kunkel	 LM.	 Loss	 of	 FilaminC	 (FLNc)	results	in	severe	defects	in	myogenesis	and	myotube	structure.	Mol	Cell	Biol.	2006	Sep;26(17):6522–34.		179.		 Fujita	 M,	 Mitsuhashi	 H,	 Isogai	 S,	 Nakata	 T,	 Kawakami	 A,	 Nonaka	 I,	 et	 al.	Filamin	 C	 plays	 an	 essential	 role	 in	 the	 maintenance	 of	 the	 structural	integrity	of	 cardiac	and	skeletal	muscles,	 revealed	by	 the	medaka	mutant	zacro.	Dev	Biol.	2012;361(1):79–89.		180.		 Brodehl	A,	Ferrier	RA,	Hamilton	SJ,	Greenway	SC,	Brundler	MA,	Yu	W,	et	al.	Mutations	 in	 FLNC	 are	 Associated	 with	 Familial	 Restrictive	Cardiomyopathy.	Hum	Mutat.	2016;37(3):269–79.		181.		 Chevessier	 F,	 Schuld	 J,	 Orfanos	 Z,	 Plank	 A-C,	 Wolf	 L,	 Maerkens	 A,	 et	 al.	Myofibrillar	instability	exacerbated	by	acute	exercise	in	filaminopathy.	Hum	Mol	Genet.	2015;(October):ddv421.		182.		 Van	Der	Ven	PFM,	Obermann	WMJ,	Lemke	B,	Gautel	M,	Weber	K,	Fürst	DO.	Characterization	of	muscle	 filamin	 isoforms	suggests	a	possible	 role	of	γ-
	 	174	
Filamin/ABP-L	 in	 sarcomeric	 Z-disc	 formation.	 Cell	 Motil	 Cytoskeleton.	2000;45(2):149–62.		183.		 Vorgerd	M,	van	der	Ven	PFM,	Bruchertseifer	V,	Löwe	T,	Kley	R	a,	Schröder	R,	et	al.	A	mutation	in	the	dimerization	domain	of	filamin	c	causes	a	novel	type	of	 autosomal	 dominant	 myofibrillar	 myopathy.	 Am	 J	 Hum	 Genet.	2005;77(2):297–304.		184.		 Lee	E,	Koo	Y,	Ng	A,	Wei	Y,	Luby-Phelps	K,	 Juraszek	A,	 et	 al.	Autophagy	 is	essential	 for	 cardiac	 morphogenesis	 during	 vertebrate	 development.	Autophagy.	2014;10(4):572–87.		185.		 Levine	B,	Klionsky	DJ.	Development	by	Self-DigestionMolecular	Mechanisms	and	Biological	Functions	of	Autophagy.	Dev	Cell.	2004;6(4):463–77.		186.		 Maejima	Y,	Chen	Y,	Isobe	M,	Gustafsson	AB,	Kitsis	RN,	Sadoshima	J.	Recent	Progress	in	Research	on	Molecular	Mechanisms	of	Autophagy	in	the	Heart.	Am	J	Physiol	Heart	Circ	Physiol.	2014	Nov	14;308(4):H259-68.		187.		 Peterkin	T,	Gibson	A,	Loose	M,	Patient	R.	The	roles	of	GATA-4,	-5	and	-6	in	vertebrate	heart	development.	Semin	Cell	Dev	Biol.	2005	Feb;16(1):83–94.		188.		 Webster	LC,	Zhang	K,	Chance	B,	Ayene	I,	Culp	JS,	Huang	WJ,	et	al.	Conversion	of	 the	E1A	Cys4	 zinc	 finger	 to	 a	nonfunctional	His2,Cys2	 zinc	 finger	by	 a	single	point	mutation.	Proc	Natl	Acad	Sci	U	S	A.	1991;88(22):9989–93.		189.		 Xuan	S,	Sussel	L.	GATA4	and	GATA6	regulate	pancreatic	endoderm	identity	through	inhibition	of	hedgehog	signaling.	2016;780–6.		190.		 Rossi	A,	Kontarakis	Z,	Gerri	C,	Nolte	H,	Hölper	S,	Krüger	M,	 et	 al.	Genetic	compensation	induced	by	deleterious	mutations	but	not	gene	knockdowns.	Nature.	2015;Aug	13(524):230–3.		191.		 Bielinska	 M,	 Seehra	 A,	 Toppari	 J,	 Heikinheimo	 M,	Wilson	 DB.	 GATA-4	 Is	Required	 for	 Sex	 Steroidogenic	 Cell	 Development	 in	 the	 Fetal	 Mouse.	2007;(November	2006):203–13.		192.		 Kyrönlahti	A,	Euler	R,	Bielinska	M,	Schoeller	EL,	Moley	KH,	Toppari	J,	et	al.	Molecular	and	Cellular	Endocrinology	GATA4	regulates	Sertoli	cell	function	and	fertility	in	adult	male	mice	ଝ.	2011;333:85–95.		193.		 Siddiqui	M,	 Sheikh	H,	 Tran	 C,	 Bruce	 AEE.	 The	 Tight	 Junction	 Component	Claudin	E	is	Required	for	Zebrafish	Epiboly.	2010;(December	2009):715–22.		194.		 Gene	T,	Mix	H,	Bruce	AEE,	Howley	C,	 Fox	MD,	Ho	RK.	NIH	Public	Access.	2010;233(1):105–14.		195.		 Ogura	T.	Tbx5	Specifies	 the	Left/Right	Ventricles	and	Ventricular	Septum	Position	 During	 Cardiogenesis.	 In:	 Cardiovascular	 Development	 and	Congenital	Malformations:	Molecular	&	Genetic	Mechanisms.	2007.	p.	75–7.		196.		 Hirayama-Yamada	 K,	 Kamisago	 M,	 Akimoto	 K,	 Aotsuka	 H,	 Nakamura	 Y,	Tomita	H,	 et	 al.	 Phenotypes	with	GATA4	or	NKX2.5	mutations	 in	 familial	atrial	septal	defect.	Am	J	Med	Genet.	2005;135	A(1):47–52.		
	 	175	
197.		 Laforest	B,	Nemer	M.	GATA5	interacts	with	GATA4	and	GATA6	in	outflow	tract	development.	Dev	Biol.	2011;358(2):368–78.		198.		 Wang	J,	Panáková	D,	Kikuchi	K,	Holdway	JE,	Gemberling	M,	Burris	JS,	et	al.	The	 regenerative	 capacity	 of	 zebrafish	 reverses	 cardiac	 failure	 caused	by	genetic	 cardiomyocyte	 depletion.	 Development.	 2011	 Aug;138(16):3421–30.		199.		 Reiter	JF,	Alexander	J,	Rodaway	A,	Yelon	D,	Patient	R,	Holder	N,	et	al.	Gata5	is	 required	 for	 the	 development	 of	 the	 heart	 and	 endoderm	 in	 zebrafish.	1999;2983–95.		200.		 Du	S,	Draper	BW,	Mione	M,	Moens	CB,	Bruce	A.	Differential	 regulation	of	epiboly	initiation	and	progression	by	zebrafish	Eomesodermin	A.	Dev	Biol.	2012;362(1):11–23.			
